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The incidence of venous and arterial thromboembolic events (VTEs/ATEs) varies greatly 
by cancer type and age, with increased risk in the elderly. Very little research has been 
reported specific to elderly kidney cancer patients. Retrospective cohort analyses of 
Medicare patients, 11,463 with and 11,463 without kidney cancer, between 2003 and 
2010 were conducted to compare incidence rates of VTEs/ATEs in cancer patients with 
matched noncancer patients and to assess independent risk factors for VTEs in cancer 
patients. The advanced epidemiology triangle was the theoretical framework used to 
interpret the association between incident events and other factors. Using Cox 
proportional hazard regression, the first 2 research questions examined whether the 
incidence rates of VTEs/ATEs were higher in kidney cancer patients than noncancer 
patients; the third research question assessed which factors were associated with VTEs 
after kidney cancer diagnosis. In the year prior to index date, cancer patients had higher 
incidence rates of VTEs than noncancer patients; the incidence rate of myocardial 
infarction was higher in cancer patients than noncancer patients for patients with a history 
of cardiovascular disease. Elderly kidney cancer patients with transitional cell tumors had 
lower rates of pulmonary embolism and ischemic stroke compared to patients with clear 
cell tumors. Recent history of VTE and Charlson comorbidity score were strong 
predictors of VTE after cancer diagnosis. These results can lead to positive social change 
by helping healthcare providers to determine who may benefit from closer observation or 
prophylaxis to prevent or minimize morbidity from these thromboembolic events, thus 
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Chapter 1: Introduction to the Study 
Introduction 
Cancer patients are at increased risk of thromboembolic events, a group of serious 
conditions caused by a blockage of a vein or artery by a blood clot (Blom, Doggen, 
Osanto, & Rosendaal, 2005; Sallah, Wan, & Nguyen, 2002; Walker, Card, West, Crooks, 
& Grainge, 2013; White et al., 2005). Venous thromboembolic events (VTEs) and arterial 
thromboembolic events (ATEs) in cancer patients can cause serious complications and 
reduce survival (Agnelli et al., 2006; Chew, Wun, Harvey, Zhou, & White, 2006; 
Sørensen, Mellemkjaer, Olsen, & Baron, 2000; Svoboda, Poprach, Dobes, Kiss, & 
Vyzula, 2012; Yeh & Bickford, 2009; Zhang et al., 2007). Cancer cells and tumors 
increase the risk for thromboembolic events through effects on blood vessels and blood 
flow, tissue necrosis, and cellular changes which promote clotting (Kuderer, Ortel, & 
Francis, 2009; Previtali, Bucciarelli, Passamonti, & Martinelli, 2011). Cancer-directed 
surgery also increases the risk of thromboembolic events, however the risk appears to 
vary by surgery type and the risk may be decreased through prophylactic therapy (Agnelli 
et al., 2006; Blom et al., 2006; Hall et al., 2009; Khorana et al., 2008; National 
Comprehensive Cancer Network [NCCN], 2015; Previtali et al., 2011; Sallah, Wan, & 
Nguyen, 2002). Surgery increases the risk for thromboembolic events through increased 
tissue factor expression and increased coagulation from immobilization and inactivity 
(Previtali et al., 2011). Chemotherapy and targeted therapies increase the risk for 
thromboembolic events by increasing tissue factor expression and reducing natural 




Two of the factors which affect the incidence and risk of ATEs and VTEs in 
cancer patients are tumor type and patient age (Blom et al., 2006; Chew et al., 2006; 
Connelly-Frost, Shantakumar, Kobayashi, Li, & Li, 2013; Khorana & Connolly, 2009; 
NCCN, 2015; Piccirillo et al., 2008; Scappaticci et al., 2007; Walker et al., 2013). Age, 
gender, and calendar year adjusted incidence rates of VTEs per 1,000 person-years varied 
from 1.3 to 23 depending on the tumor site, with a rate of 4.7 for kidney cancer patients 
(Walker et al., 2013). Incidence rates of ATEs for kidney cancer patients were not 
identified in the literature, however an incidence proportion of 1.3% was reported based 
on clinical trial studies of patients treated with sunitinib or sorafenib chemotherapies for 
advanced or metastatic renal cell carcinoma (the most common type of kidney cancer) 
(Choueiri, Schutz, Je, Rosenberg, & Bellmunt, 2010). Kidney cancer is one of the 10 
most common newly diagnosed cancers in U.S. men and women, with more than 60,000 
new cases of kidney cancer diagnosed each year (American Cancer Society, 2015). In 
spite of the significant numbers of kidney cancer patients, information on VTEs and 
ATEs in kidney cancer patients is sparse. 
The risk of VTEs in cancer patients also varies by other factors including cancer 
stage, receipt of chemotherapy, cardiovascular surgeries, history of a VTE or 
cardiovascular disease, and placement of a central venous catheter (Alcalay et al., 2006; 
Blom et al., 2005; Chew, Wun, Harvey, Zhou, & White, 2007; Connelly-Frost et al., 
2013; Moore et al., 2011; Sallah, Wan, & Nguyen, 2002). Possible other risk factors are 
tumor histology and receipt of cancer-directed surgery (Alcalay et al., 2006; Blom, 




There is little published information about the incidence of ATEs and VTEs or the 
risk factors for VTEs in kidney cancer patients, even less so in elderly kidney cancer 
patients (Chew et al., 2006; Hall, Andersen, Krumholz, & Gross, 2009; Smith et al., 
2014). Information specific to kidney cancer may aid patients and healthcare providers in 
assessing the likelihood of VTEs and ATEs in this population. Accurate risk assessments 
are important for determining if close patient observation or prophylactic treatments are 
warranted (NCCN, 2015; Walker et al., 2013). 
Studies specific to elderly cancer patients are important because the elderly are a 
growing number of cancer patients and have age-related issues which impact care, 
morbidity and mortality (International Society of Geriatric Oncology, 2011; NCCN, 
2015; Repetto et al., 2003). The probability of developing cancer increases with 
increasing age (American Cancer Society, 2015). Age has also been identified as a risk 
factor for VTEs in some cancer patients, but not consistently (Agnelli et al., 2006; 
Alcalay et al., 2006; Chew et al., 2006, 2007; Moore et al., 2011). As the United States 
population age distribution shifts towards greater proportions of elderly persons and life 
expectancy increases, the number of elderly cancer patients continues to increase and 
remains as a significant public health and medical issue (International Society of 
Geriatric Oncology, 2011; Repetto et al., 2003). Elderly patients are affected by issues 
which may impact their outcomes more so than younger patients including less 
participation or eligibility for clinical trials (which hinders knowledge of optimal 
treatments), patient and provider beliefs, functional status, comorbidities and risk of drug 




NCCN, 2015; Repetto et al., 2003). A comprehensive study of the incidence of selected 
ATEs and VTEs and risk factors for these VTEs in elderly kidney cancer patients may 
improve understanding of the disease burden and risks in this at risk population. 
This chapter begins with an overview of kidney cancer, including its 
epidemiology, histology groups, staging, and treatment, followed by a summary of 
published literature on VTEs and ATEs in elderly kidney cancer patients. This chapter 
also contains a statement of the research problem, the purpose of the study, and a listing 
of the descriptive analyses, research questions and their corresponding hypotheses. A 
description of the theoretical framework of the study, the nature of the study, and terms 
used in this study are presented. The next section assesses the study assumptions, scope, 
delimitations, and limitations. This chapter ends with the study significance and a 
summary of the chapter. 
Background 
Epidemiology of Kidney Cancer 
It is estimated that over 60,000 people in the United States were newly diagnosed 
with kidney cancer in 2015 (American Cancer Society, 2015). Kidney cancer is the 
seventh most commonly diagnosed cancer in men and tenth most common in women 
(American Cancer Society, 2015). More than 90% of all kidney cancers in adults are 
renal cell carcinomas (RCC) (National Cancer Institute, 2010; Surveillance, 
Epidemiology, and End Results [SEER] Program, 2012). Renal cell carcinomas are 
malignant tumors that grow in the lining of kidney tubules (National Cancer Institute, 




which arise in the renal pelvis and have different histology, survival and staging than 
RCC (American Joint Committee on Cancer [AJCC], 2002; SEER, 2012). Established 
risk factors for kidney cancer include smoking tobacco, obesity, and hypertension 
(American Cancer Society, 2015; DeCastro & McKiernan, 2008; Ljungberg et al., 2011; 
National Cancer Institute, 2010; Weikert & Ljungberg, 2010). The risk of kidney cancer 
is also higher in patients with a family history of kidney cancer, end-stage renal disease 
(ESRD) or chronic renal failure, or mutations in the von Hippel-Lindau (VHL) gene (von 
Hippel Lindau syndrome), c-met proto-oncogene, fumarate hydratase gene, or folliculin 
tumor-suppressor gene (American Cancer Society, 2015; Ljungberg et al., 2011; National 
Cancer Institute, 2010; Weikert & Ljungberg, 2010). Evidence is inconsistent regarding 
an association between kidney cancer and occupational exposures to chemicals or 
carcinogenic metals (Ljungberg et al., 2011). 
Kidney cancer predominantly affects the elderly and men. The median age of U.S. 
kidney cancer patients diagnosed from 2007 to 2011 is 64 years old for all patients, 63 
years for men, 65 years for women, 64 for Whites, and 61 for Blacks (Howlader et al., 
2014). During that same period, kidney cancer incidence rates for patients diagnosed at 
65 years of age or older were 91.7 cases per 100,000 for men, 45.0 for women, 66.8 for 
Whites, and 73.8 for Blacks, respectively (Howlader et al., 2014). At each age group, the 
incidence rates for men were about two-fold the rate for women. 
The age-standardized incidence rates of kidney cancer in the United States 
increased 2% to 3% between 1975 to 2008, followed by an annual percent change of 




abdominal imaging over time is hypothesized to be part of the reason for the increase in 
incidence; however it does not fully explain the trend (American Cancer Society, 2013; 
Tyson et al., 2013). 
Kidney cancer is a public health burden, especially in the elderly population 
(American Cancer Society, 2015; Howlader et al., 2014). Within the kidney cancer 
patient population, there are differences in incidence and survival by age, race, gender, 
and stage. Better understanding of the risks of VTEs and ATEs within these 
subpopulations is a start to improving patient care and adding to geriatric oncology 
knowledge. 
Types of kidney cancer. The majority (90% or more) of kidney cancer tumors 
are RCC and the remainder are primarily transitional cell tumors of the renal pelvis (7% 
to 10%) (National Cancer Institute, 2010; SEER, 2012). Transitional cell tumors are a 
different histologic tumor type than RCC. Renal cell carcinoma is further divided into 
four main histology groups of clear cell, papillary, chromophobe, and other (Kovacs et 
al., 1997). In elderly kidney cancer patients, clear cell RCC is the most common group. 
Table 1 shows the definitions by ICD-O morphology code for each type of RCC and the 
proportions estimated in kidney cancer patients 60 years of age or older at diagnosis 





Proportion of RCC Histology Groups in Elderly Kidney Cancer Patients 
 ICD-O Histology Codes 
 
Proportion in Kidney Cancer 
Patients aged 60 or older 
Clear Cell 8310, 8312 79% - 82% 
Papillary 8260 9% - 13% 
Chromophobe 8317, 8270 4% - 5% 
Other All RCC codes except 8310, 
8312, 8317, 8260, and 8270 
3%- 5% 
Note. Proportions of each histology type were based on data in Keegan et al. (2012) and 
Olshan et al. (2012). 
 
Both studies of RCC patients used the SEER cancer registry data (Keegan et al., 
2012; Olshan et al., 2013) but used different populations, different time periods and 
reported different age groups. Keegan et al. (2012) analyzed patients diagnosed with 
RCC between 2000 and 2005 in the SEER registries who underwent nephrectomy during 
the first course of treatment. The study by Olshan et al. (2013) included patients with 
clear cell, papillary or chromophobe RCC diagnosed in the SEER registry areas between 
2000 and 2009. 
The majority of kidney cancers are RCC (National Cancer Institute, 2010; SEER, 
2012). Renal cell carcinoma can be further classified into four main histology groups 
(Kovacs et al., 1997). Histology group can impact patient prognosis (Keegan et al., 2012; 
Patard et al., 2005). As discussed further below, differences in incidence rates of VTEs 
by histology group has been noted in some tumors but not others (Alcalay et al., 2006; 
Blom et al., 2004; Chew et al., 2007, 2008). This study was the first known study to 




histology group. It also assessed whether histology type is a risk factor for VTEs in 
kidney cancer patients. 
Kidney cancer staging. Cancer staging is used to inform the healthcare provider 
about the extent of disease, as well as determine the type of treatment and patient 
prognosis (SEER, 2012). The main two staging systems used are the SEER summary 
stage and the staging system by the American Joint Committee on Cancer (AJCC) 
(SEER, 2012). Summary stage has five main groups which are (a) in situ, (b) localized, 
(c) regionalized, (d) distant, and (e) unknown (SEER, 2012). The main disadvantage of 
using the summary staging system is that the categories are very broad and may contain a 
wide variation of tumors (SEER, 2012). The AJCC staging system is a more detailed 
system defined by a combination of three components based on tumor size or 
invasiveness (T), whether tumor cells are present in regional lymph nodes (N), and 
whether the tumor has metastasized to distant sites (M) (AJCC, 2002; SEER, 2012). 
There are several editions of the AJCC cancer staging system, and the 6
th
 edition was 
designed to use with cancer cases diagnosed from 2003 to 2009. 
There are four stages for kidney cancer (excluding tumors of the renal pelvis) by 
the AJCC staging algorithm (a) Stage I, (b) Stage II, (c) Stage III, and (d) stage IV 
(AJCC, 2002). Stage I is defined by a tumor of 7 centimeters or less which is confined to 
the kidney, no regional lymph node metastases, and no distant metastases (AJCC, 2002). 
Stage II is defined by a tumor of greater than 7 centimeters which is confined to the 
kidney, no regional lymph node metastases, and no distant metastases (AJCC, 2002). 




the kidney into veins or fatty tissue around the kidney, or (b) had metastases in a single 
regional lymph node (AJCC, 2002). Stage IV is defined by extension of the tumor 
beyond the veins and fatty tissues around the kidney, metastases in more than one 
regional lymph node, or distant metastases (AJCC, 2002). 
The AJCC staging system (sixth edition) of renal pelvis tumors is defined as 
follows. Stage I, II, and III tumors do not have any regional lymph node metastasis or 
distant metastasis (AJCC, 2002). These stages are distinguished by tumor extension. 
Stage I tumors have extended into the subepithelial connective tissue; Stage II tumors 
have extended the muscularis; and Stage III tumors have extended beyond the muscularis 
into peripelvic fat or the renal parenchyma (AJCC, 2002, p. 330). Stage IV tumors are 
defined by either (a) tumor extension into adjacent organs or into the perinephric fat, (b) 
any regional lymph node metastasis, or (c) distant metastasis (AJCC, 2002). AJCC stage 
instead summary stage was used to define stage in this study as the AJCC staging system 
is more detailed and clinically relevant. 
VTEs and ATEs in elderly kidney cancer patients. The medical dictionary 
defines a thromboembolism as “the blocking of a blood vessel by a particle that has 
broken away from a blood clot at its site of formation” (MedlinePlus, 2014). According 
to the Centers for Disease Control and Prevention (CDC), the blockage or blood clot can 
occur in the vein (venous thromboembolism) or in an artery (arterial thromboembolism) 
(CDC, 2014). Two major types of VTEs are deep vein thrombosis (DVT) and pulmonary 
embolism (PE). Arterial thromboembolic events in arteries of the heart or brain include 




complications (CDC, 2014; MedlinePlus, 2014). Venous and arterial thromboembolic 
events may result in patient death, organ damage, or other serious health conditions 
(CDC, 2014; MedlinePlus, 2014). 
The risk factors for VTEs in cancer patients include age, cancer treatment (e.g., 
surgery, chemotherapy, immunotherapy), cancer site, history of VTE/ATE and 
cardiovascular conditions, comorbidities, cancer stage, histology group, major surgeries, 
hospitalizations, central venous catheter, and clinical factors (Blom et al., 2006; 
Connelly-Frost et al., 2013; Khorana & Connolly, 2009; NCCN, 2015). Comorbidities 
can be assessed individually or by a comorbidity index. The Charlson comorbidity index 
was originally developed to predict mortality in hospitalized patients due to comorbid 
conditions, and then adapted for predicting other adverse outcomes in hospitalized 
patients (Klabunde, Potosky, Legler, & Warren, 2000). The comorbidity index has been 
expanded and tested on inpatient and outpatient claims databases, and used for predicting 
other outcomes in patients including thromboembolic events (Doyle, et al., 2005; 
Klabunde, Legler, Warren, Baldwin, & Schrag, 2007; Smith et al., 2014). 
Incidence rates of VTEs in kidney cancer patients were found in two published 
articles, with other articles reporting cumulative incidence (Agnelli et al., 2006; Blom et 
al., 2006; Chew et al., 2006; Walker et al., 2013). Only one of the articles presented 
incidence rates by age group, and the incidence rate for VTEs for kidney cancer patients 
age 60 years or older at diagnosis was 14 per 1,000 person-years (95% CI 10 - 18) 
(Walker et al., 2013). The studies varied in incidence measure reported and duration of 




elderly RCC patients (Connelly-Frost et al., 2013). The study of RCC patients aged 65 
years or older at diagnosis and who had Medicare coverage reported incidence rates per 
1,000 person-years of 32.2 (95% CI 29.1-35.7) and 108.2 (95% CI 101.6-115.2) for DVT 
in the year prior and year after RCC diagnosis, respectively (Connelly-Frost et al., 2013). 
The incidence rates for pulmonary embolism were 8.0 (95% CI 6.5-9.8) and 30.0 (95% 
CI 26.6-33.7), for the same two respective periods relative to RCC diagnosis (Connelly-
Frost et al., 2013). The incidence rates for the grouping of other VTEs were 23.7 (95% CI 
21.1-26.7) and 49.0 (95% CI 44.6-53.7), in the year prior and year after RCC diagnosis 
respectively (Connelly-Frost et al., 2013). Incidence rates by RCC histology group were 
not reported by Connelly-Frost et al. (2013). 
Incidence rates of ATEs were not found in the published literature, but cumulative 
incidence was found in cancer patients treated with chemotherapy. The incidence for 
myocardial infarction ranged from 0.2% to 2.9% depending on the treatment and patient 
population (Bayer HealthCare Pharmaceuticals, 2013; GlaxoSmithKline, 2014; Moore et 
al., 2011). Other studies reported incidence of ATEs as a group and the results ranged 
from 1.3% to 3.8% for chemotherapy-treated patients of all ages, varying by treatment 
and study population (Choueiri et al. 2010; Scappaticci et al., 2007). A pooled analysis of 
clinical trial data reported an incidence of ATEs in patients age 65 years or older as 2.5% 
in control patients and 7.1% in bevacizumab-treated patients (Scappaticci et al., 2007). In 
the patients 65 years or older, the incidence of ATE was 2.6% and 4.4% in controls and 




history of ATE in the controls and bevacizumab-treated patients respectively (Scappaticci 
et al., 2007). 
Summary 
In summary, elderly kidney cancer patients are at increased risk of VTEs and 
ATEs which can increase mortality and cause other health problems (Blom et al., 2006; 
CDC, 2014; Connelly-Frost et al., 2013; Khorana & Connolly, 2009; MedlinePlus, 2014; 
NCCN, 2015). Incidence measures for VTEs in kidney cancer patients are available in 
the literature for VTEs but they are not consistent, and incidence of ATEs in kidney 
cancer patients is limited to clinical trial data from a specific subset of kidney cancer 
patients. The evidence of risk of VTEs and ATEs in elderly kidney patients is based 
mostly on studies of other tumor types and patients of all ages (Blom et al., 2005, 2006; 
Connelly-Frost et al., 2013; Sallah, Wan, & Nguyen, 2002; White et al., 2005). 
I sought to address this gap in the knowledge of VTE and ATE incidence rates 
and the risk factors for VTEs specific to a recent cohort of elderly kidney cancer patients 
with Medicare coverage using population-based data. Having the information for this 
specific population on the incidence and risk factors for thromboembolic events can aid 
healthcare providers and patients in making informed decisions about the patients’ risks 
for VTEs and ATEs, and thus improve both patient outcomes and patient care. 
Problem Statement 
Despite the risk of morbidity and mortality from VTEs and ATEs in cancer 
patients, in depth analyses of incidence rates and risk factors for these conditions have 




in cancer patients vary widely by type of cancer and patient age, however very little 
published information is available specifically about elderly kidney cancer patients 
(Connelly-Frost et al., 2013; Hall et al., 2009; Walker et al., 2013). 
Most studies of the risk factors for VTEs are based on studies of other cancers, 
multiple tumor types with small numbers of kidney cancer patients, or are not specific to 
the elderly (Chew et al., 2006; Hall et al., 2009). No studies were found for the risk 
factors for ATEs in elderly kidney cancer patients, with the only evidence reported from 
clinical trial data in a subset of patients on specific treatments (Choueiri et al., 2010). The 
problem is that incidence rates of VTEs and ATES for elderly kidney cancer patients 
(ages 65 years or older at diagnosis) are not readily available in the literature, much less 
incidence rates by histology group, patient, or other tumor characteristics. There is also a 
lack of evaluation of risk factors for VTEs in elderly kidney cancer patients. 
Understanding the incidence of VTEs and ATEs in elderly kidney cancer patients 
can help health care providers assess the need for prophylactic treatments or additional 
observation. Information on whether there are differences for subpopulations within these 
patients may be of assistance for patient care as well. 
Purpose of the Study 
This was a quantitative, retrospective cohort study. The entire cohort consisted of 
elderly patients with Medicare coverage who resided in the SEER registry areas. The 
outcomes of interest were VTEs and ATEs, and the exposure status was determined as 
follows: patients diagnosed with incident kidney cancer from 2004 to 2009 were exposed 




were unexposed. The study-specific aims were to (a) estimate the incidence rates of VTEs 
and ATEs that elderly kidney cancer patients with Medicare coverage have in the year 
prior to cancer diagnosis and in the year after diagnosis; (b) estimate the incidence 
proportions of VTEs and ATEs by discrete, mutually exclusive time periods after 
diagnosis; (c) compare the incidence rates of VTEs and ATEs occurring in the 12 months 
before diagnosis in cancer patients to a matched noncancer Medicare population during 
the same timeframe; (d) compare the incidence rates of VTEs and ATEs occurring in the 
follow-up period after diagnosis in cancer patients to a matched noncancer Medicare 
population during the same timeframe; and (e) assess the independent risk factors for 
each VTE and ATE in cancer patients after cancer diagnosis. The analyses for the first 
two aims and the last aim only used the exposed patients in the cohort (i.e., the kidney 
cancer patients). For the first aim, I estimated the incidence rates of VTEs and ATEs 
overall and according to factors including age group, gender, race, histology group, 
treatment, and year of diagnosis. For the third and fourth aims, I conducted a matched 
cohort study using all of the exposed patients and a random sample of the unexposed 
patients from the cohort. The unexposed patients (the noncancer patients) were matched 
to the exposed patients on age at index date, gender, race, SEER registry area, and 
duration of follow-up. The index dates for the exposed patients were the month and year 
of kidney cancer diagnosis. The index date for the unexposed patients was assigned the 




Descriptive Analyses, Research Questions, and Hypotheses 
There are two parts to this study, one descriptive and the other analytic. The 
descriptive part of the study calculated the incidence rates, overall and by patient and 
tumor characteristics, of VTEs and ATEs in elderly kidney cancer patients in the follow-
up period after index date. Also described was the timing of new events by presentation 
of the incidence proportions for VTEs and ATEs in discrete time intervals after index 
date. The analytic part of the study had two types of analyses. The first set of analyses 
used a matched cohort study to compare the incidence rates of VTEs and ATEs in the 
exposed patients (kidney cancer patients) to a matched noncancer comparison group in 
the year prior to the index date and compares the incidence rates in the follow-up period 
after the index date. The second analysis, conducted only in the exposed patients (elderly 
kidney cancer patients), was to quantify independent predictors of time to incident VTEs 
in this population. 
Descriptive Analysis 1 
The first descriptive analysis involved the calculation of the incidence rates of 
individual VTEs and of ATEs in elderly kidney cancer patients over the 12 months before 
index date (kidney cancer diagnosis) and in the follow-up period after index date. For 
each of the prespecified patient and tumor characteristics, the incidence rates of VTEs 
and ATEs are also presented by age group, race, gender, history of VTE/ATE, history of 
cardiovascular disease, AJCC stage, treatment by immunotherapy, treatment by 
nephrectomy, treatment by chemotherapy or targeted therapy, histology group, Charlson 




Descriptive Analysis 2 
For this analysis, the proportion of elderly kidney cancer patients who 
experienced incident VTEs and incident ATEs in discrete, mutually exclusive time 
periods during follow-up (0 to 90 days, 91 to 180 days, 181 to 270 days, and 271 to 365 
days) after index date were calculated. The incidence proportions were calculated for 
each VTE and ATE of interest. 
Research Question 1 
Research Question 1: How do the incidence rates of VTEs and ATEs in elderly 
exposed (kidney cancer) patients 12 months before index date compare to a matched 
unexposed (noncancer) Medicare population during the same 12-month timeframe? 
HA1: In the year prior to index date, the incidence rates of VTEs or of ATEs are 
statistically significantly greater in the exposed patients than in the unexposed patients. 
H01: There is no statistically significant difference in the incidence rates of VTEs 
or ATEs in the year prior to the index date in the exposed patients and in the matched 
unexposed patients. 
Research Question 2 
Research Question 2: How do the incidence rates of VTEs and rates of ATEs in 
elderly exposed (kidney cancer) patients after index date compare to a matched 
unexposed (noncancer) Medicare population during the same timeframe? 
HA2: In the follow-up period after the index date, the incidence rates of VTEs or 





H02: There is no statistically significant difference in the incidence rates of VTEs 
or ATEs in the period after index date in the exposed patients and in the matched 
unexposed patients. 
Research Question 3 
Research Question 3: In the follow-up period after kidney cancer diagnosis, what 
are the risk factors associated with time to newly diagnosed, individual VTE (DVT, PE, 
or OTE)? 
HA3: No factors are statistically significantly associated with the time to newly 
diagnosed VTEs in the period after kidney cancer diagnosis. 
H03: Tumor histology and other factors are statistically significantly associated 
with the time to newly diagnosed VTEs after kidney cancer diagnosis. 
For each question, a Cox proportional hazard model was used to identify 
independent predictors for each outcome. The outcome was time to the occurrence of the 
first VTE or ATE after kidney cancer diagnosis or duration of follow-up. The potential 
predictors included in the initial (full) model were age at diagnosis, race, gender, 
diabetes, atherosclerosis, varicose veins, cardiovascular surgery, central venous catheter, 
kidney disease, history of VTE, history of cardiovascular disease, AJCC stage, treatment 
type (immunotherapy, nephrectomy, chemotherapy), histology group, SEER registry 
region, and year of diagnosis. Independent variables which were statistically significant 
at the 0.05 level were retained in the final model. The final model included any variables 




expected to be rarer than incident VTEs, assessment of independent risk factors for ATEs 
in elderly kidney cancer patients was not included in this research question.  
Theoretical Framework 
A visual representation of the proposed theoretical framework is presented in 
Figure 1. This theoretical framework used the advanced epidemiology triangle to 
interpret the association between incident VTEs and ATEs with causative factors, 
environment and lifestyle factors, and population characteristics (Merrill, 2009). While 
the traditional epidemiology triangle is primarily used for modeling infectious disease 
transmission, the advanced epidemiology triangle is adapted for use with chronic 
diseases, injuries, and other conditions (Merrill, 2009). The factors which make up the 
traditional epidemiology triangle are host, agent, and environment, whereas the factors in 
the advanced triangle are population, causative factors, and environmental factors 
(Merrill, 2009). In the advanced model, environmental factors include behavioral, 
cultural, physiological and ecological elements (Merrill, 2009). The interaction of time 
with these factors is also taken into account. 
The dependent variable, the outcomes, were incident ATEs and VTEs. The 
potentially confounding and effect measure modifying variables were identified from the 
literature and only variables which were included in this study were presented on the 
framework (Earp & Ennett, 1991). Patient factors and cancer-specific factors can directly 
impact the likelihood of a patient having a VTE, and indirectly through effects on which 
RCC treatments (e.g., chemotherapy and targeted therapies, nephrectomy, and 




venous catheter. The patient factors (age, gender, SEER registry region of 
diagnosis/residence, and comorbidities) and cancer-specific factors (year of diagnosis, 
cancer stage, tumor histology, and cancer treatments) were selected based on previous 
studies of risk factors for VTEs and ATEs (Blom et al., 2006; Chew et al., 2006; 
Connelly-Frost et al., 2013; Geraci, Escalante, Freeman, & Goodwin, 2005; Khorana & 
Connolly, 2009; NCCN, 2015). Placement of a central venous catheter and 
cardiovascular surgery were selected based on studies that found them to be predictive 
factors for VTEs in cancer patients (Connelly-Frost et al., 2013; Khorana & Connolly, 






Figure 1. Theoretical model of the association between population, causative, and 
environmental factors related to thromboembolic events.  
 
Nature of the Study 
This study was a quantitative, retrospective cohort study. The cohort consisted of 
Medicare beneficiaries. The exposure was kidney cancer while the outcome was the 
occurrence of a venous or arterial thromboembolic event. The data source utilized was 
the linked SEER-Medicare database. The study population was patients diagnosed with 
kidney cancer between 2004 and 2009 (exposed) and, for Research Questions 1 and 2, a 
noncancer comparison group (unexposed) matched to the kidney cancer patients on 
gender, age, race, SEER registry region, and duration of follow-up after the index date. 
Each matched unexposed patient was assigned an index date of the month and year of the 
corresponding kidney cancer patient’s diagnosis. The kidney cancer patients were 
restricted to patients 65 years of age or older, diagnosed between the years of 2004 and 
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months was the effective minimum age as the patients in the cohort were be required to 
have two years of Medicare Part A and B coverage and no Medicare managed care plan 
participation prior to and including the month and year of the index date. Duration of 
follow-up was calculated as the number of months from index date until patient does not 
have both Parts A and B coverage, participates in a managed care plan, dies, or December 
31, 2010. Follow-up time for the unexposed patient was truncated to the same amount of 
time as the corresponding kidney cancer patient. 
In order to describe the risk of VTEs and ATEs in kidney cancer patients and in a 
noncancer comparison group, incidence rates and incidence proportions were calculated. 
Tables of the incidence rates overall and stratified by patient and tumor characteristics 
were generated. Cox proportional hazards regression analyses were used to model 
whether the incidence of VTEs and the incidence of ATEs are more likely in kidney 
cancer patients than the matched comparison group for each time period. Modeling the 
risk factors for each VTE in kidney cancer patients and estimating the relative risk of 
VTE after kidney cancer diagnosis used Cox proportional hazards regression analyses. 
Unadjusted Kaplan-Meier curves of time to VTE or ATE were generated overall and 
stratified by patient and tumor characteristics. Log rank tests were used to determine 
whether differences in the time-to-event curves are statistically significant. All analyses 
were conducted using SAS 9.3 software (SAS Institute Inc., Cary, NC, USA). 
This methodology is consistent with that used by Connelly-Frost et al. (2013) to 
estimate incidence of VTEs and ATEs in RCC patients, calculate relative risk estimates 




noncancer comparison group. The incidence rate calculation is also consistent with 
Walker et al. (2013). Additionally models of relative risk and risk factors for VTEs and 
ATEs were assessed as an overall group and also using the CCI and histology group as 
potential risk factors, which provided results more easily comparable with other studies 
in other cancer types (Alcalay et al., 2006; Chew et al., 2007). 
Definitions 
Arterial thromboembolism: A thromboembolism which occurs in an artery (CDC, 
2014; MedlinePlus, 2014). For this study, the ATEs to be examined are acute myocardial 
infarction and ischemic stroke. 
Cancer-directed treatment: Treatment given with the purpose of destroying, 
removing, or controlling malignant or metastatic tumor cells. Palliative care and 
diagnostic tests are excluded (SEER, 2012). 
Chemotherapy: Pharmaceutical drugs which kill cancer cells (National Cancer 
Institute, 2013). 
Comorbidity: Any condition, acute or chronic, other than the disease of interest 
(Klabunde, Warren, & Legler, 2002). 
Elderly: The elderly are defined as persons 65 years of age or older, as 65 has 
been considered the retirement age in the United States and it is the earliest age U.S. 
residents without ESRD or certain disabilities are eligible for the Medicare program 





Exposed: The exposed population in the cohort consisted of patients with an 
incident diagnosis of kidney cancer between 2004 and 2009. 
History of cardiovascular disease: A diagnosis code for a myocardial infarction, 
ischemic stroke, new onset congestive heart failure, angina or transient ischemic attack in 
the 12 months before the period of interest (Connelly-Frost et al., 2013). 
Immunotherapy: A type of biologic therapy which affects the immune system in 
order to treat diseases (National Cancer Institute, 2013). Types of immunotherapies 
include cytokines and monoclonal antibodies (National Cancer Institute, 2013). 
Localized tumors: Tumors which are confined to the tissue or organ from which it 
originated (National Cancer Institute, 2013). 
Metastasis: Cancer cells have spread to parts of the body outside the tissue or 
organ from which it originated (National Cancer Institute, 2013). 
Nephrectomy: Surgery which removes part or the entire kidney (National Cancer 
Institute, 2010). 
Palliative care: Treatments given to treat symptoms, treatment-related side 
effects, or otherwise improve patient quality of life (National Cancer Institute, 2013; 
SEER, 2012). 
Pediatric: Related to children (National Cancer Institute, 2013). Children are 
considered any person of age 18 years or younger. 





Stage (cancer): Cancer grouping based on the extent to which the cancer has 
spread from the tissue or organ from which it originated (SEER, 2012). Factors which go 
into staging include the primary tumor site, tumor size or thickness, extension or 
metastases beyond the primary site, and presence of metastases in regional lymph nodes 
(SEER, 2012). 
Systemic therapy: Drugs which travel through the blood stream to affect cells in 
various parts of the body (National Cancer Institute, 2013). 
Targeted therapy: Anticancer drugs which interrupt cancer cell growth and tumor 
spread. Different types of targeted therapies attack cells with different characteristics by 
targeting specific cellular molecules. (National Cancer Institute, 2013). 
Thromboembolism: A blood vessel blockage caused by a portion of a blood clot 
which originated in another site (MedlinePlus, 2014). 
Tumor: A mass caused by abnormal cell growth. Tumors are also known as 
neoplasms. (National Cancer Institute, 2013). 
Unexposed: The exposed population in the cohort consisted of patients who did 
not have a cancer diagnosis in the SEER registry data at any time. 
Venous thromboembolism: A thromboembolism which occurs in a vein (CDC, 
2014; MedlinePlus, 2014). The VTEs to be examined in this study are deep venous 
thrombosis, pulmonary embolism, and other thromboembolic events. 
Assumptions 
The following assumptions were made for this study: (a) all clinically relevant 




directed treatments were processed by Medicare and thus captured in the data, (c) the 
date of cancer diagnosis was accurate, and (d) date of death was correctly identified. The 
first assumption is a limitation of administrative claims data (Klabunde, Warren, & 
Legler, 2002) which is discussed further in the limitations section below. The diagnoses 
of interest to this study (i.e., VTEs and ATEs) are serious conditions which should meet 
the criteria of being clinically relevant. The second assumption is specific to the SEER-
Medicare database, as only claims processed by Medicare are included in the database 
(Applied Research Program, 2013). Nephrectomy, and intravenous immunotherapy and 
chemotherapy administered inpatient or outpatient settings which are covered by 
Medicare for kidney cancer patients should be captured. Studies have validated the 
SEER-Medicare data for assessing receipt of chemotherapy (Lund et al., 2013; Warren et 
al., 2002b). However, many of the targeted chemotherapy drugs for RCC approved in the 
past decade are given orally, do not have an IV equivalent, and thus may not be captured 
as they would be billed as prescription drugs. With the passage of the Medicare 
Modernization Act of 2003, prescription drug coverage (hereafter referred to as Part D) 
was an available option for Medicare participants beginning January 1, 2006 (CMS, 
2013). Oral chemotherapy drugs may be captured in the HCPCS codes or in the 
prescription drug event file containing Part D data using National Drug Code (NDC) 
codes (Applied Research Program, 2013). The Part D data released with the SEER-
Medicare data released in 2013 covers years 2007 to 2010 (Applied Research Program, 
2013), which overlaps with half (2007 to 2009) of my study period. Part D is optional, so 




therapies are the primary therapy for Stage IV or advanced RCC (NCCN, 2015). 
Restricting to 2010 kidney cancer patients, 12% or less of Stage III patients age 60 years 
of age or older had chemotherapy in the first course of treatment (National Cancer Data 
Base, 2013). For Stage IV patients, 52% of patients age 60 to 69 years of age at diagnosis 
had chemotherapy in the first course of treatment and the proportion declined to 29% of 
patients 80 to 89 years of age, and 8% for patients 90 years of age or older (National 
Cancer Data Base, 2013). It was not possible to determine how many patients received 
oral drugs as part of the chemotherapy treatments. Treatments which are paid for by the 
patient during a prescription plan coverage gap are also not captured (CMS, n.d.). 
SEER data is considered a high-quality cancer data source and there was 
approximately 90% agreement on the date of cancer diagnosis whether using the SEER 
data or Medicare claims data (Applied Research Program, 2013; SEER, 2013). The 
fourth assumption is necessary for correctly calculating duration of follow-up, and 96% 
of the dates of death have been validated in the Medicare enrollment file (Asper, 2012). 
Scope and Delimitations 
The population included elderly kidney cancer patients with Medicare (both parts 
A and B) coverage, who had no participation in Medicare Managed care plans in the two 
years prior to kidney cancer diagnosis or during follow-up, whose kidney cancer was 
their first diagnosed cancer, and who were 65 years of age or older at diagnosis. 
Continuous Medicare coverage with parts A and B and exclusion of patients in Managed 
Medicare plans prior to index date and during patient follow-up are required to reduce the 




the study patients (Asper & Mann, 2011). The proportion of Medicare enrollees 
participating in a managed care plan ranged from 13% to 25% between 1998 and 2010 
(Asper & Mann, 2011). Although people may be eligible for Medicare coverage starting 
at age 65 (excluding people with coverage at earlier ages due to disability or end-stage 
renal disease), so that there are two years of data including the month of index date for 
each patient prior to kidney cancer diagnosis (index date) the study population needs to 
be at least 66 years and 11 months of age to be eligible. Patients at risk for a VTE or ATE 
during each period (the year prior to diagnosis/ index date or the year after 
diagnosis/index date) were defined as patients who did not have a diagnosis for the VTE 
or ATE in the year prior to the period of interest. Thus, a second year prior to the 
diagnosis/index date was necessary for identifying incident events in the first year prior 
to that date. 
Duration of follow-up was calculated from the month after the index date until 
loss of Parts A and B of Medicare coverage, participation in a Medicare managed care 
plan, death, or December 31, 2010. Patients who died or were lost to follow-up in the 
same month of index date (i.e., duration of follow-up is zero full months) were excluded. 
Thus, the study population had at least 1 month of follow-up. No other minimum amount 
of follow-up was required so as not to introduce survival bias into the study. 
Additionally, follow-up for matched unexposed patients were truncated at the same 
duration as the corresponding kidney cancer patient. 
Patients with other cancers diagnosed in the same month as or prior to the kidney 




therapies captured were for treatment of the kidney cancer and not another cancer type. 
Additionally, restricting to patients without other cancers helped ensure that the study 
findings in the exposed patients were due to the exposure (kidney cancer) and not other 
exposures. Thus, the results of this study are generalizable to elderly Medicare patients 
newly diagnosed with kidney cancer, which have both parts A and B of Medicare 
coverage, and who do not participate in a managed care plan. 
Limitations 
Some potential limitations arise from the use of SEER-Medicare, an 
administrative claim database. Administrative claims are designed for billing and 
reimbursement purposes, thus reimbursement rates may influence which diagnoses and 
procedures are listed and how they are listed (Klabunde, Warren, & Legler, 2002). 
Another limitation is that the claims file may not contain all of the diagnosis or procedure 
codes from a health care interaction. Only claims processed through Medicare are 
captured. Care which took place at Veterans Administration, was billed to an insurance 
program other than Medicare, or was paid for out-of-pocket are being captured in the 
database (Applied Research Program, 2013). The Medicare claims databases have a 
predefined number of variables to capture the diagnosis or procedure codes; for example 
the outpatient claims dataset had 10 diagnosis codes variables prior to 2010, but 25 
variables for 2010 and later (Applied Research Program, 2013). As such, some conditions 
may be underreported because there are not enough positions for them to be included in 




listed as a diagnosis code (Klabunde et al., 2002). This is a limitation with any 
administrative claim database. 
Another limitation of using administrative claims is that severity of comorbidity is 
difficult or impossible to measure (Geraci et al., 2005). Lab data are not contained in the 
database, thus serum levels of bilirubin (high levels are a contraindication for 
temsirolimus) cannot be ascertained. Severity of condition could not be assessed in this 
study, and presence or absence of VTE, comorbidity and procedures were reported based 
on ICD-9-CM diagnosis codes, ICD-9-CM procedure codes, or HCPCS procedure codes. 
However, SEER-Medicare database also has advantages over use of other data 
sources. One such benefit is the generalizability of the database because the source 
population is large and population-based. In addition, several validation studies have 
been conducted using the database to assess its usefulness and appropriateness for various 
purposes including identification of chemotherapy (Lund et al., 2013; Warren et al., 
2002b) and comorbidities (Klabunde et al., 2000; Klabunde et al., 2002). 
Significance 
This project was significant for several reasons. First, it quantified the rates of 
VTEs and ATEs and the risk of VTEs in a group of kidney cancer patients for whom 
there is not a lot of information (elderly patients with Medicare coverage) and assessed 
whether the incidence rates of thromboembolic events differed from the rates in a 
matched, noncancer comparison group. Information on incident conditions post-diagnosis 
can aid in interpreting clinical trial or post-marketing drug safety profiles and identify 




Secondly, the assessment of the association between time to incident VTEs and 
ATEs and potential independent risk factors can aid in the understanding of patient risk 
for VTEs and ATEs among elderly kidney cancer patients with Medicare coverage. New 
contributions of this study are the assessment of histology group as a potential risk factor 
and use of AJCC stage instead of summary stage. Histology group had not been assessed 
as a risk factor for VTEs or ATEs in kidney cancer patients, however it was found as a 
risk factor for VTEs in patients with other tumor types (Blom et al., 2004; Chew et al., 
2007, 2008). The results of this study contributed to positive social change by quantifying 
the incidence and risk of VTEs and ATEs for this population. Increased understanding of 
the patient risk for VTEs and ATEs may improve patient care and prognosis. The 
understanding may help inform healthcare providers as to which patients may benefit 
from additional observation or prophylactic treatments to prevent thromboembolic 
events. 
Summary 
VTEs and ATEs are serious conditions for which elderly cancer patients are at 
higher risk than the general population (Connelly-Frost et al., 2013; Khorana & 
Connolly, 2009; NCCN, 2015). Although the risk of VTE and ATE varies by cancer type, 
information on the risk and risk factors in elderly kidney cancer patients is sparse (Blom 
et al., 2006; Connelly-Frost et al., 2013). Therefore, tumor type-specific assessment of 
the risks and outcomes in the patient population can help health-care providers and 
patients make treatment decisions and understand potential outcomes. This retrospective 




elderly kidney cancer population, comparing incidence rates in kidney cancer patients to 
a matched, noncancer comparison group, and assessing risk factors for incident VTEs and 
ATEs in elderly kidney cancer patients. Chapter 2 presents the literature search 
methodology and a review of the literature for incidence rates of VTEs and ATEs and 
risk factors for VTEs in elderly kidney cancer patients. The chapter concludes with a 




Chapter 2: Literature Review 
Introduction 
This review of the literature provides background information on the incidence 
and risk of ATEs and VTEs in elderly kidney cancer patients. Most of the publications 
citing the increased risk for thromboembolism events in cancer patients are based on 
multiple cancers (which included approximately 0% to 3% kidney cancers), assessed 
outcomes as a grouping instead of individual thromboembolic events, and included adult 
patients of all ages without results presented stratified by elderly and nonelderly (Agnelli 
et al., 2006; Blom et al., 2006; Hall et al., 2009; Khorana et al., 2008; Sallah et al., 2002). 
Other studies which included kidney cancer patients included patients diagnosed more 
than a decade ago (e.g., 2003 or earlier) or focused on specific groups of patients such as 
clinical trial participants who received a specific treatments (Connelly-Frost et al., 2013; 
Hurwitz et al., 2011; Svoboda, Poprach, Dobes, Kiss, & Vyzula, 2012). The problem is 
that evidence on ATEs and VTEs in elderly kidney cancer patients is not available from a 
recent population-based data source which reflects the incidence rates of ATEs and VTEs 
in this population or assesses the risk factors for the conditions in this population 
(Connelly-Frost et al., 2013; Khorana, Kuderer, Culakova, Lyman, & Francis, 2008). 
Thus this quantitative study analyzed kidney cancer patients diagnosed between 2004 and 
2009 and a matched, noncancer cohort during the same period in order to ascertain the 
incidence of ATEs and VTEs before and after kidney cancer diagnosis, compare the 
incidence rates in kidney cancer patients to a comparable group of noncancer patients, 




Only one study was found which published incidence rates of VTEs and assessed 
risk factors for VTEs in elderly RCC cancer patients diagnosed between 1991 and 2003 
(Connelly-Frost et al., 2013). Other studies reported incidence rates or cumulative 
incidence of VTEs in kidney cancer patients of all ages (Blom et al., 2006; Chew et al., 
2006; Walker et al., 2013). No similar study of ATEs in kidney cancer patients was 
identified in the published literature. 
This chapter details the strategy utilized in search engines to identify the current 
literature reviewed for this study. The next section discusses in depth the theoretical 
framework of this study that was introduced in chapter one. The published literature on 
ATEs and VTEs in elderly kidney cancer patients was exhaustively reviewed in regards 
to study methodology and variables. The chapter ends with a summary of the published 
literature and transition to the methods chapter. 
Literature Search Strategy 
Searches for peer-reviewed literature were conducted in the Scopus electronic 
multidisciplinary database. The Scopus database contains abstracts and citations from 
more than 20,000 peer-reviewed journals, 6 million conference papers, and articles-in-
press from almost 4,000 journals (Elsevier, 2014). The search criteria and numbers of 
articles found during the search on September 29, 2015 are found in Table 2. The asterisk 
directs Scopus to search for words containing the characters prior to asterisk plus any 
variation of characters which appear in place of the asterisk. The Scopus search was 
restricted to results in journal articles, English language, and published between January 




articles. Reviews were included in the initial search and the reference lists of all studies 
pulled were searched for additional relevant articles, including those with information on 
other cancer types. In addition, the title and abstracts of publications which cited the 
articles selected for review in this chapter were also examined for locating additional 
relevant articles. Searches of the primary authors’ other publications also yielded articles 
including in this literature review. Case studies and studies focusing on pediatric 
populations were excluded. 
Table 2 
Scopus Search Criteria and Results 




Row 1 (“kidney cancer” or “renal cell carcinoma”) and ("pulmonary 
embolism" or "deep venous thrombosis" or “venous 
thromboemb*” or "thromboemb*") 
279 
Row 2 (“kidney cancer” or “renal cell carcinoma”) and 
("myocardial infarction" or “stroke” ) 
92 
Row 3 #1 or #2 355 
Row 4 Articles included in the literature review 58 
 
Theoretical Framework 
The theoretical framework for the study of factors related to ATEs and VTEs in 
elderly kidney cancer patients was the advanced epidemiologic triangle, which is 
applicable to diseases and conditions other than infectious diseases (Merrill, 2009). This 
epidemiologic triangle consists of three components –population, causative factors, and 




epidemiologic triangle does not assume a single cause or etiology, and allows for the 
modeling the complex nature of conditions (Merrill, 2009). 
The outcome, ATE or VTE, in elderly kidney cancer patients is influenced by 
several factors, some directly and others indirectly. The population factors are increasing 
age, gender, marital status, region of residence or diagnosis, number of comorbidities, 
and history of cardiovascular or thromboembolic events. These characteristics have been 
shown to be risk factors for VTEs (Alcalay et al., 2006; Chew et al., 2007; Connelly-
Frost et al., 2013; Hall et al., 2009; Walker et al., 2013). The causative factor or exposure 
of interest in this study is kidney cancer. The factors which may affect development of a 
VTE or ATE are year of diagnosis, cancer stage, and cancer treatment. Cancer treatments 
include receipt of chemotherapy or immunotherapy, receipt of targeted therapies, or 
undergoing a cancer-directed surgery (e.g., nephrectomy). Whether tumor histology 
group is a risk factor for thromboembolic events in kidney cancer patients has not been 
assessed. However, in some cancer types, histology has been an independent risk factor 
for thromboembolic events (Alcalay et al., 2006; Chew et al., 2007). Major cardiac or 
vascular surgery and placement of a central venous catheter are grouped with the 
environmental risk factors for thromboembolic events (Alcalay et al., 2006; Khorana & 
Connolly, 2009; NCCN, 2015). 
Thus the framework for this study was constructed from patient and tumor 
characteristics, kidney cancer treatments, and whether the patient had the insertion of a 
central venous catheter or underwent a major cardiac or vascular surgery. Studies of risk 




included these factors in their initial or final multivariate models (Connelly-Frost et al., 
2013; Doyle et al., 2005; Hall et al., 2009). The Connelly-Frost et al. (2013) article, the 
only one which analyzed any kidney cancer patients, found that atherosclerosis, presence 
of a central venous catheter, diabetes, high-risk surgery, history of CVD, and kidney 
disease were effect measure modifiers of the risk of VTEs in RCC patients compared to 
the matched, noncancer cohort. Male gender; diagnoses of atherosclerosis, diabetes, 
hypercholesterolemia, kidney disease, varicose veins, history of cancer diagnosis, history 
of VTE; receipt of chemotherapy or immunotherapy treatment; placement of a central 
venous catheter; undergoing high-risk surgery; and cancer stage were statistically 
significant predictors of new VTEs (DVT, pulmonary embolism or other thromboembolic 
events) in the 12 months after RCC diagnosis (Connelly-Frost et al., 2013). Other studies 
which examined risk factors of VTEs using other data sources found some of these 
factors as independent predictors in multivariate models (Agnelli et al., 2006; Alcalay et 
al., 2006; Blom et al., 2004; Chew et al., 2008; Khorana et al., 2008; Moore et al., 2011; 
Scappaticci et al., 2007). Where available they also included clinical data, which was not 
available in the SEER-Medicare data (Agnelli et al., 2006; Blom et al., 2004; Khorana et 
al., 2008; Moore et al., 2011). 
Smith et al. (2014) used a subset of these factors to estimate the risk of VTEs in a 
kidney cancer population compared to a noncancer population matched on age, sex, and 
comorbidity score. After adjusting for the matching and year of cancer diagnosis, they 
found that the risk of VTEs after cancer diagnosis was higher than the risk in a noncancer 




The increased risk persisted even after stratifying by comorbidity score, time since cancer 
diagnosis, whether or not the cancer was metastatic, and presence of surgery within 3 
months of VTE (Smith et al., 2014). These factors, measureable in the SEER-Medicare 
database, are discussed in further detail below. 
The advantage of this framework was that it is comprehensive yet flexible enough 
to assess risk factors for VTEs in the population of interest. The weakness of the 
framework was that it can only include measurable information available in the study 
data and therefore does not include clinical information or other variables which were 
identified as risk factors in other studies. 
Incidence of Venous Thromboembolic Events 
Methods 
The studies of incidence rates of VTEs for kidney cancer have analyzed different 
populations with some variations of methods (Agnelli et al., 2006; Blom et al., 2006; 
Chew et al., 2006; Connelly-Frost et al., 2013; Walker et al., 2013). The Walker et al. 
(2013) study analyzed patients registered with a general practitioner in the United 
Kingdom, diagnosed with a cancer in the national cancer registry database between 1997 
and 2006, were 18 or older at time of cancer diagnosis, were included in the UK Clinical 
Practice Research Datalink (CPRD) database linked to the Hospital Episode Statistics 
data, had no history of VTE prior to the first cancer diagnosis, and the cancer diagnosis 
occurred during a registration period but after the first year of registration at a practice (p. 
1405). Cancer diagnoses were based on cancer registry data and only the first cancer was 




was calculated as time from cancer diagnosis until diagnosis of a VTE, death, exit from a 
practice which was linked to CPRD, or December 31, 2010. The median follow-up time 
was 2 years with an interquartile range of 0.3 to 5.7 years for all cancer patients (Walker 
et al., 2013). Statistics on follow-up time were not presented separately by cancer type, so 
the corresponding information for the kidney cancer patients was not reported. Chew et 
al. (2006) also analyzed cancer registry data; however it was linked to state hospital 
discharge data. Connelly-Frost et al. (2013) reported incidence rates of VTEs in a subset 
of kidney cancer patients using the SEER-Medicare database which is cancer registry 
data linked to the Medicare claims database. The Medicare claims database includes 
patient information from inpatient, outpatient, long-term, short-term, hospice and other 
stays (Applied Research Program, 2013). Similarly, Blom et al. (2006) analyzed cancer 
registry data linked to another data source, anticoagulation clinic data. However, the 
study population for the Agnelli et al. (2006) study was selected prospectively from 
patients undergoing cancer-directed surgery in Italian surgical departments. The main 
strength of using cancer registry data is that it is a population-based data source. Linkages 
with data sources where patients with VTEs are likely to be treated (e.g., hospitalization 
data, anticoagulation clinics) increase the likelihood of capturing VTEs, however some 
incidents may not be captured if the patient died prior to hospitalization or 
anticoagulation treatment (Blom et al., 2006). 
Unlike Walker et al. (2013), other studies restricted the maximum amount of 
follow-up post cancer diagnosis. Chew et al. (2006) presented incidence rates and 




Chavez-MacGregor et al. (2011), Connelly-Frost et al. (2013) and Shantakumar, 
Connelly-Frost, Kobayashi, Allis, and Li (2015) restricted to a maximum of one year. 
Studies reporting cumulative incidence of VTEs in kidney cancer patients used follow-up 
of six months or less with follow-up starting at time of cancer diagnosis or date of cancer-
directed surgery (Agnelli et al., 2006; Blom et al., 2006). Researchers have consistently 
shown that VTEs after cancer diagnosis more frequently occur closer to the date of the 
cancer diagnosis and are less common as time increases (Chavez-MacGregor et al., 2011; 
Chew et al., 2006; Connelly-Frost et al., 2013; Walker et al., 2013). Thus, while 
restriction of the duration of follow-up is reasonable, variations in reported incidence 
measures may be due to differences in duration of follow-up time used. Another 
difference in reported incidence measures may be due to the exclusion of patients with 
prior VTEs. Walker et al. (2013) and Chew et al. (2006) excluded patients with prior 
VTEs from analyses. Agnelli et al., (2006), Blom et al. (2006), and Connelly-Frost et al. 
(2013) did not exclude patients with prior VTEs allowing for estimation of incidence 
measures or risk by history of VTE. As history of VTE was shown to increase the risk of 
a future VTE, the incidence measures from these studies are expected to be higher than 
those from studies where patients with a prior VTE were excluded (Agnelli et al., 2006; 
Blom et al., 2006; Connelly-Frost et al., 2013). 
Three studies examined the incidence of VTEs in cancer patients in the period 
prior to cancer diagnosis (Connelly-Frost et al., 2013; Shantakumar et al., 2015; White et 
al., 2005). White et al. (2005) presented the number of VTE events in the 12 months prior 




counts to the expected counts in the general California population. The study population 
consisted of all patients age 18 or older with a cancer diagnosed between 1993 and 1995 
or 1997 and 1999 which was recorded in the California Cancer Registry (White et al., 
2005). Connelly-Frost et al. (2013) presented incidence rates in the 12 months prior to 
RCC diagnosis for DVT, pulmonary embolism and OTE separately. Shantakumar et al. 
(2015) presented incidence rates in the 12 months prior to soft tissue sarcoma diagnosis 
for DVT, pulmonary embolism and OTE separately. Both Connelly-Frost et al. (2013) 
and Shantakumar et al. (2015) used SEER-Medicare database and included patients 65 
years of age or older at cancer diagnosis who had continuous coverage by Medicare Parts 
A and B without participation in a managed care plan for at least 24 months prior to the 
cancer diagnosis. Only the White et al. (2005) study excluded patients with a VTE 
diagnosed more than 1 year prior to cancer diagnosis from the incidence calculations. 
For this study, incidence rates were calculated prior to and after cancer diagnosis. 
Incidence rates were calculated using 12 months in the period prior to cancer diagnosis 
for kidney cancer patients and index date for the matched noncancer patients. For the 
period after cancer diagnosis/index date, incidence rates were presented for the entire 
follow-up period. 
Incidence 
Table 3 summarizes the incidence rates by cancer type, patient age, and stage for 
several solid tumor types. Few studies contributed information for the same cell (e.g., 
reporting 60 years and older versus reporting 65 years and older) and one study 




(DVT, pulmonary embolism, and OTE) for elderly patients diagnosed with RCC, a subset 
of kidney cancer. Connelly-Frost et al. (2013) did not report an overall incidence rate for 
any type of VTE, while most other articles reported overall incidence rates without 
separating the rates by type of VTE. 
Of the four studies which reported the incidence of VTEs in kidney cancer 
patients, only one provided incidence rates for older patients (Agnelli et al., 2006; Blom 
et al., 2006; Chew et al., 2006; Walker et al., 2013). The incidence rate for patients 
diagnosed at age 60 or older at diagnosis was 14 per 1,000 person-years (95% CI 10 – 18) 
(Walker et al., 2013). Although other studies of multiple cancer types have reported 
differences in the incidence of VTEs for younger and older patients, Walker et al. (2013) 
found that the incidence rate for kidney cancer patients diagnosed at ages 18 to 60 (12 per 
1,000 person-years, 95% CI 8.1-19) was similar to the rate for the older patients (Chew, 
Wun, Harvey, Zhou, & White, 2007; Hall et al., 2009). Walker et al. (2013) reported that 
although the overall incidence rate for VTEs in all cancer patients 60 or older was higher 
than the rate for younger cancer patients, that pattern did not hold for all individual 
cancer types and for some types the pattern was reversed (Walker et al., 2013).  
Timing relative to cancer diagnosis, stage at diagnosis, and time since cancer 
diagnosis appeared to effect differences in incidence rates. Chew et al. (2006) reported 
first and second year incidence rates for VTEs after a kidney cancer diagnosis by 
summary staging. The first year incidence rates were higher than the second year, and 
incidence rates increased with later stage (Chew et al., 2006). The incidence rates for 




for localized, regional, and distant metastatic stage, respectively (Chew et al., 2006). The 
rates in the second year were approximately a quarter of the rates for the first year for 
each stage (Chew et al., 2006). Other studies also consistently found that the incidence 
rates or proportions of VTEs in kidney cancer patients or cancer patients with other tumor 
types were highest in the periods directly after the date of cancer diagnosis, then 
decreased for later periods from the date of cancer diagnosis (Chew et al., 2008; 
Connelly-Frost et al., 2013; Moore et al., 2011; Walker et al., 2013). Studies of other 
tumor types also reported higher incidence rates in patients diagnosed with later stages of 
cancer (Alcalay et al., 2006; Chew et al., 2007, 2008; Connelly-Frost et al., 2013; Moore 
et al., 2011). 
Studies of breast, lung, and colorectal cancer patients have been inconsistent as to 
whether incidence rates of VTEs differ by histology group (Alcalay et al., 2006; Blom et 
al., 2004; Chew et al., 2007, 2008). A study of colorectal cancer patients found 
statistically significant differences in the 2-year cumulative incidence of VTEs by 
histology group (Alcalay et al., 2006). Incidence rates also appear to vary by histology 
group in lung cancer patients as well. The incidence rates in patients with squamous cell 
carcinoma was 21.2 per 1,000 person-years (95% CI 10.1-36.2) as compared to 66.7 per 
1,000 person-years (95% CI 36.2-106.2) in patients with adenocarcinoma lung cancers 
(Blom et al., 2004). The increased risk persisted even after adjusting for age, gender, and 
cancer treatment. The incidence rates of VTEs also appeared to differ by histology group 
in lung cancer patients in a study by Chew et al. (2008), however no statistical testing 




for the incidence rates reported. However, a study of breast cancer patients reported little 
difference between incidence rates by histology group (Chew et al., 2007). No studies 






























Pancreatic 98 127 89 - - - Walker et al., 2013 
 - - - 42 200 - Chew et al., 2006 
 - - - - - 174 Hall et al., 2009 
        
Lung 44 48 42 - - - Walker et al., 2013 
 44 - - - - - Blom et al., 2004 
 - - - 11 50 - Chew et al., 2006 
 - - - - - 60 Hall et al., 2009 
        
Breast 9 5 12 - - - Walker et al., 2013 
 12 - - 8 68 - Chew et al., 2007 
 - - - 5 28 - Chew et al., 2006 
 - - - - - 50 Hall et al., 2009 
        
Colorectal 17 16 17 - - - Walker et al., 2013 
 - - - 9 43 - Chew et al., 2006  
 - - - - - 50 Hall et al., 2009 
        
Prostate 9 7 9 - - - Walker et al., 2013 
 - - - 8 9 - Chew et al., 2006  
 - - - - - 14 Hall et al., 2009 
        
Kidney  13 12 14 - - - Walker et al., 2013 
 13 - - - - - Blom et al., 2006 
 25 - - - - - Agnelli et al., 2006  
 - - - 12 60 - Chew et al., 2006 
        
RCC - - 108 - - 229 Connelly-Frost et 
al., 2013 
        
Noncancer 
cohort 
3.0 1.0 4.3 - - - Walker et al., 2013 
Note. Rates are per 1,000 person-years and based on the first year after cancer diagnosis, except for rates 
from Blom et al. (2006) and Chew et al. (2007) which are based on the first six months after cancer 
diagnosis. 
 
Of the studies identified which contained incidence of VTEs in kidney cancer 




others reported cumulative incidence. Differing patient populations and methods makes 
comparison across studies challenging. The increased incidence of VTEs in the period 
just after kidney cancer diagnosis is consistent with findings in other cancer types, 
however the incidence of VTEs may not follow the pattern of higher incidence in older 
patients and whether there are any differences by histology group has not been assessed. 
Risk Factors for Venous Thromboembolic Events 
Methods 
Most studies used the Cox proportional hazards model to analyze the time to the 
first VTE after cancer diagnosis and generate hazard ratios for risk factors (Alcalay et al., 
2006; Blom et al., 2004; Chew et al., 2006, 2007, 2008; Connelly-Frost et al., 2013; Hall 
et al., 2009; Walker et al., 2013). The hazard ratio estimates the incidence rate ratio as 
long as the Cox proportional hazards assumption holds true (Hoffman et al., 2008; 
Spruance, Reid, Grace, & Samore, 2004). Less commonly, odds ratios from multivariate 
logistic regression analyses were presented based on an outcome of occurrence of a VTE 
during follow-up (Agnelli et al., 2006; Blom et al., 2005; Khorana et al., 2008; Moore et 
al., 2011). One study used logistic regression and generated odds ratios for identifying 
risk factors (Chavez-MacGregor et al., 2011). 
The main strength of using the hazard ratio over using the odds ratio as the 
epidemiologic measure includes the ability to account for varying patient follow-up time. 
This is important as survival time differs greatly by one potential risk factor, stage, and 




including only the patients with lower stage or who are healthier (American Cancer 
Society, 2014). 
Cox proportional hazards model were used to compare the incidence rates of 
VTEs during the 12 months prior to the index date between exposed patients and matched 
unexposed patients (Research Question 1) and for the period after index date (Research 
Question 2). 
Tumor Type 
Several studies have reported differences in the risk of VTEs in cancer patients by 
tumor type (Blom et al., 2005; Hall et al., 2009; Walker et al., 2013; White et al., 2005). 
A study comparing the incidence of VTEs in California cancer patients diagnosed 
between 1993 and 1995 or 1997 and 1999 to the incidence rates in the total California 
population reported standardized incidence ratios (SIRs) ranging from 0.6 to 4.2 
depending on tumor type (White et al., 2005). The standardized incidence ratio for VTE 
in kidney cancer patients was 2.5 (95% CI 1.5-3.9), the standardized incidence ratio for 
acute myelogenous leukemia patients was 4.2 (95% CI 2.4-6.8), and for melanoma the 
standardized incidence ratio was 0.6 (95% CI 0.2-1.1) (White et al., 2005). Similarly, a 
study of cancer patients in the Netherlands reported adjusted odds ratios of 1.6 to 28.0 for 
VTEs depending on the type of cancer (Blom et al., 2005). The adjusted odds ratio for 
VTE in kidney cancer patients was 6.2 (95% CI 0.8-46.5), but patients with a 
hematologic cancer had an adjusted odds ratio of 28.0 (95% CI 4.0-199.7) (Blom et al., 
2005). Venous thromboembolic events occurred at a higher rate in breast cancer patients 




12.21-38.09), and male pancreatic cancer patients (HR = 17.68, 95% CI 9.48-32.95) 
compared to prostate cancer patients (Hall et al., 2009). Cancer is comprised of several 
heterogeneous diseases which vary in presentation, characteristics, risk factors, and 
treatments (National Cancer Institute, 2013). Differences in the risks of VTE by tumor 
type indicate that findings based on one tumor type may not necessarily hold true in other 
tumor types. Thus, there is a need for assessment of the risk factors for VTEs by specific 
tumor type. My goal in conducting this study is to add to the evidence for or against the 
association between previously identified risk factors and the occurrence of VTEs in 
kidney cancer patients. 
Age at Diagnosis 
Similar to the inconsistent findings regarding differences in incidence rates by age 
group, study results have not been consistent as to whether age is an independent risk 
factor for VTEs in cancer patients after adjusting for other factors. Additionally, the 
majority of evidence was based on studies of multiple tumor types combined or 
individual tumor types other than kidney cancer. 
One study which assessed the association between age and incidence of VTE in 
the year after kidney cancer diagnosis found no significant risk with increasing age after 
adjusting for race, gender, and stage (HR = 1.0, 95% CI 0.8-1.1) (Chew et al., 2006). 
Chew et al. (2006) analyzed patients diagnosed between 1993 and 1995 in California and 
excluded any patient with a hospitalization for VTE between 1991 and the cancer 
diagnosis. In a study of elderly RCC patients Connelly-Frost et al. (2013) similarly found 




Some studies of combined tumor types reported that the risk of VTEs in cancer 
patients increases with age. In one study, the risk increased 19% (OR = 1.19, 95% CI 
1.02-1.39) for each 10-year increase in age at diagnosis after adjusting for gender, race, 
presence of a CVC, stage and performance status (Moore et al., 2011). A study of cancer 
patients of all ages and multiple types undergoing cancer-directed surgery found a 2.6-
fold risk of VTEs in patients age 60 or older compared to patients under 60 (OR = 2.6, 
95% CI 1.2-5.7) (Agnelli et al., 2006). 
Studies of the association between age and risk of VTE within specific tumor 
types have shown inconsistent results. Researchers focusing on breast cancer and 
colorectal cancer patients reported increasing risk of VTE in older age groups compared 
to patients less than 45 years old or 50 years old or younger at diagnosis (Alcalay et al., 
2006; Chew et al., 2007). In a study of breast cancer patients 66 years or older at 
diagnosis, researchers also reported increasing risk of VTEs with increasing age at 
diagnosis (Chavez-MacGregor et al., 2011). Another study of patients with ovarian 
serous or clear cell carcinoma reported that age of 60 years or older increased the risk 
compared to patients less than 60 years of age (Matsuo et al., 2015). In contrast, a study 
of lung cancer patients found that age at diagnosis after age 44 was protective against the 
development of VTE after cancer diagnosis in non-small cell lung cancer (Chew et al., 
2008). The adjusted hazard ratios for increasing age groups in patients diagnosed with 
small cell lung cancer were also less than 1.0; however they did not reach statistical 
significance (Chew et al., 2008). Age was also not associated with development of VTE 




late stage breast, lung, colon, prostate and pancreatic cancer patients (Hall et al., 2009). A 
study of chemotherapy-associated VTE in cancer patients of multiple tumor types also 
did not find an association with age after adjusting for other risk factors (Khorana, 
Kuderer, Culakova, Lyman, & Francis, 2008). Other studies in multiple tumor types 
adjusted for age in the multivariate models assessing risk factors for VTEs without 
indicating whether age was evaluated as an independent risk factor (Blom et al., 2004, 
2005, 2006). 
Given the inconsistent results in the literature, there is a need to assess whether 
there are differences in the risk of VTE by age group within the elderly kidney cancer 
population independent of other risk factors. The prevalence of comorbidities varies by 
age group and patterns of other risk factors, such as receipt of cancer treatment, are 
different in elderly patients as compared to younger cancer patients (NCCN, 2015; 
Piccirillo et al., 2008). Thus the identification of risk factors in elderly kidney cancer 
patients as the risk factors may be different than those in younger kidney cancer patients 
was a focus of this study. 
Tumor Stage of Disease 
Most studies reported that tumors with distant metastases have higher risks of 
VTEs than patients with tumors without distant metastases. The risk in one study of 
patients in the Netherlands reported an adjusted odds ratio of 58.0 (95% CI 9.7-346.7) for 
patients with metastatic tumors compared to noncancer patients, and adjusted odds ratio 
of 19.8 (95% CI 2.6-149.1) compared to patients with nonmetastatic tumors (Blom et al., 




advanced and metastatic tumors compared to early stage tumors (OR = 2.7, 95% CI 1.4-
5.2) (Agnelli et al., 2006). In elderly Medicare enrollees with breast cancer, patients 
diagnosed with Stage IV cancer were at 1.5 to two-fold risk of venous thromboembolic 
events compared to patients with Stage I tumors at diagnosis (Chavez-MacGregor et al., 
2011). A study of advanced and metastatic breast, colon, lung, and pancreatic cancers 
reported that the risk of VTEs was higher in metastatic (Stage IV) tumors compared to 
advanced (Stage III) tumors (HR = 1.75, 95% CI 1.44-2.12) (Hall et al., 2009). These 
studies included none or few (less than 4%) of kidney cancer patients (Agnelli et al., 
2006; Blom et al., 2005; Hall et al., 2009). However, a study of elderly RCC patients also 
reported higher rates of VTEs in patients with regional or distant summary stage 
compared to localized stage (Connelly-Frost et al., 2013). 
Tumor stage at diagnosis was assessed as a potential risk factor for development 
of VTEs in elderly kidney cancer patients. Tumor stage in this study was defined by 
AJCC staging which is more clinically relevant for treatment and prognosis than stage 
defined by summary staging. 
Histology 
Two studies of lung cancer patients reported statistically significant increases in 
the risk for VTEs in patients with adenocarcinoma compared to patients with squamous 
cell carcinoma (Blom et al., 2004; Chew et al., 2008). Chew et al. (2008) also reported 
increased risk for patients with carcinoma not otherwise specified compared to squamous 
cell carcinoma lung cancer. Conversely studies of breast cancer patients and colorectal 




histologic subtype (Alcalay et al., 2006; Chew et al., 2007). A study of ovarian cancer 
patients, reported that risk for VTEs was increased in patients with advanced stage 
ovarian clear cell carcinoma compared to advanced serous ovarian carcinoma (Matsuo et 
al., 2015). Neither early stage serous ovarian carcinoma nor early stage ovarian clear cell 
carcinoma increased the risk compared to advanced serious ovarian carcinoma (Matsuo et 
al., 2015). No study was found comparing the risk of VTEs in kidney cancer patients by 
histology group. Kidney cancer histology groups differ from the groups in other tumor 
types, thus it cannot be inferred from the findings of other tumor types as to whether 
there is any difference in risk by kidney cancer histology group. This study was the first 
study (known to date) in which incidence rates of VTEs by histology group in elderly 
kidney cancer patients were calculated. The risk of developing incident VTEs by 
histology groups was also assessed. The histology analyses were unique contributions of 
this study to the literature and further informed healthcare providers regarding the risks of 
VTEs in kidney cancer patients. 
History of VTE 
Previous VTE (OR = 6.0, 95% CI 2.1-16.8), was a significant risk factor for VTEs 
in cancer patients undergoing cancer-directed surgical treatment (Agnelli et al., 2006). 
Similarly, in a study of elderly RCC patients, previous VTE prior to cancer diagnosis 
increased the risk for DVT (HR = 5.4, 95% CI 4.4-6.4), pulmonary embolism (HR = 20.1, 
95% CI 13.8-29.2), and OTE (HR = 7.6, 95% CI 5.9-9.9) (Connelly-Frost et al., 2013). 
Some researchers have chosen to exclude patients with a prior VTE from the analysis 




of the patients at highest risk of developing VTEs after cancer diagnosis (Connelly-Frost 
et al., 2013). Therefore, information about the history of VTE as a potential risk factor for 
development of a subsequent VTE after cancer diagnosis was needed. 
Cancer Treatments 
The main treatments for RCC are nephrectomy, chemotherapy, and 
immunotherapy (Kirkali, 2009; NCCN, 2015). All three of these treatments may be risk 
factors for VTEs to varying levels. The evidence for increased risk after cancer-directed 
surgery is mostly based on studies which included few to no kidney cancers and did not 
analyze specific surgical types (Agnelli et al., 2006; Blom et al., 2006; Hall et al., 2009).  
Nephrectomy. Connelly-Frost et al. (2013) reported incidence rates of VTEs 
among RCC patients for DVT, pulmonary embolism and OTE by nephrectomy. Radical 
and partial nephrectomies were not distinguished, and the incidence rates for each VTE 
were higher in the patients who did not undergo nephrectomy (Connelly-Frost et al., 
2013). The unadjusted incidence rates per 1,000 person years for DVT, pulmonary 
embolism and OTE were 95.5, 28.1, and 47.6 for patients who had a nephrectomy, 
respectively (Connelly-Frost et al., 2013). For the patients who did not have a 
nephrectomy, the incidence rates for the three VTEs were 148.6, 35.9, and 53.3, 
respectively (Connelly-Frost et al., 2013). Nephrectomy was not an independent predictor 
of individual VTEs in the study; however high risk cardiac or vascular surgeries in the 
year after RCC diagnosis appeared to reduce the risk of VTE after adjusting for age and 
race (Connelly-Frost et al., 2013). The authors hypothesize that the decreased risk may 




guidelines recommend risk assessment for VTE among cancer patients (Connelly-Frost et 
al., 2013; NCCN, 2015). Similarly, if patients who underwent a nephrectomy received 
thromboembolism prophylaxis, this may have accounted for the lowered incidence rates 
and finding that nephrectomy did not have a statistically significant impact on risk of 
VTE. Additionally, the patients who were at higher risk of VTE may have been poor 
candidates for surgical treatment. 
Hall et al. (2009) reported higher risk of VTE associated with cancer-directed 
surgery in the year after a diagnosis of advanced lung, breast, colon, prostate or pancreas 
cancer in elderly patients (RR = 4.0, 95% CI 3.49-4.57). However, receipt of surgery was 
not a significant risk factor in the multivariate cox proportional hazards model (Hall et 
al., 2009). A study of Dutch cancer patients also reported no significant increase in risk of 
VTE in patients with cancer-directed surgery as the first course of treatment (adjusted RR 
= 1.0; 95% CI 0.8–1.2) (Blom et al., 2006). This study included patients of multiple 
tumor types and ages, and the risk of VTE by specific tumor type or surgery type was not 
reported (Blom et al., 2006).  
Agnelli et al. (2006) studied 2,373 cancer patients undergoing cancer-directed 
surgeries in Italy, of which 79 (3.3%) had kidney cancer. It was reported that 71% to 87% 
of the patients received in-patient antithrombotic prophylaxis and approximately 30% of 
patients received prophylaxis treatments at discharge (Agnelli et al., 2006). The incidence 
of VTE (DVT or pulmonary embolism) was higher in general surgery and gynecologic 




(Agnelli et al., 2006). Because all of the patients had surgery, incidence of VTEs could 
not be compared to the incidence in patients without surgery. 
Nephrectomy was defined dichotomously (i.e., receipt of nephrectomy or lack 
thereof) instead of being defined by type of nephrectomy (e.g., no nephrectomy, partial 
nephrectomy, or radical nephrectomy). Prophylaxis therapy for VTEs was not well 
captured in the SEER-Medicare data and so was not assessed. 
Chemotherapy. The approved chemotherapy treatments for kidney cancer are 
targeted therapies, specifically the following tyrosine kinase inhibitors (TKIs): 
bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, temsirolimus, axitinib, and 
erlotinib (Monsuez et al., 2010; NCCN, 2015). Bevacizumab is also a monoclonal 
antibody, while the other medications listed above are small molecule TKIs (Monsuez et 
al., 2010). A meta-analyses and pooled studies of the association of treatment with 
bevacizumab and the risk of VTEs in cancer patients reported conflicting results. One, 
which included a study of RCC patients, reported an increased risk of VTE in patients 
treated with bevacizumab plus chemotherapy (RR = 1.29, 95% CI 1.03-1.63) compared to 
patients treated with chemotherapy without bevacizumab (Nalluri, Chu, Keresztes, Zhu, 
& Wu, 2008). Two pooled studies found no statistically significant increase in the risk of 
VTE in patients who were treated with chemotherapy plus bevacizumab, however neither 
of those studies included RCC patients (Hurwitz et al., 2011; Scappaticci et al., 2007). Of 
note, of the 15 studies included in the meta-analyses, the largest relative risk in a single 
study was the analysis of RCC patients and that study was only one of two studies which 




estimation of risk for VTEs from chemotherapy for RCC patients as well as transitional 
cell kidney cancer patients and risk for each histology group in all kidney cancer patients. 
Evidence for an association between one of these newer treatments, bevacizumab, 
and risk of VTE from meta-analyses or pooled studies is inconsistent (Hurwitz et al., 
2011; Nalluri, Chu, Keresztes, Zhu, & Wu, 2008; Scappaticci et al., 2007). The 
cardiovascular risks of small molecule TKIs are primarily associated with ATEs, and no 
associations were found with VTEs (Qi et al., 2013; Sonpavde et al., 2013; Svoboda, 
Poprach, Dobes, Kiss, & Vyzula, 2012; Yeh & Bickford, 2009). However, similar to 
bevacizumab, the meta-analyses evidence for VTEs was based on trial data, included 
many tumor types, and patients of all ages. 
Receipt of chemotherapy increased the risk of VTEs in one study of elderly breast 
cancer patients (Chavez-MacGregor et al., 2011). A different study of specific 
chemotherapies (cyclophosphamide, methotrexate, fluorouracil, doxorubicin, and any 
chemotherapy not otherwise specified) in elderly breast cancer patients reported that none 
of the chemotherapy types nor receipt of any chemotherapy were statistically significant 
with an increase in myocardial infarction and had wide confidence intervals, after 
adjusting for age, race, stage, year of breast cancer diagnosis, preexisting heart disease, 
and comorbidity score (Doyle et al., 2005). The study had 31,748 women in the study, 
5,575 of which received any chemotherapy, however the authors did not report the 
number of patients with myocardial infarction (Doyle et al., 2005). Thus, it is difficult to 
know whether the lack of association between myocardial infarction and chemotherapy 




A study of Dutch patients diagnosed with any cancer type reported a two-fold 
relative risk of VTE in patients treated with chemotherapy for patients without metastases 
(RR = 2.0, 95% CI 1.6-2.7) and for patients with metastatic tumors (RR = 2.3, 95% CI 
1.7-3.1) (Blom et al., 2006). A study of VTEs in lung cancer patients also reported two-
fold elevated risks in patients with chemotherapy (OR = 2.9, 95% CI 1.8-4.0) (Blom et 
al., 2004). Similarly, a study of advanced or metastatic breast, colon, lung and pancreatic 
cancer reported higher risk of VTEs in patients treated with chemotherapy (HR = 1.31, 
95% CI 1.10-1.57) (Hall et al., 2009). 
Although there are several types of immunotherapy used to treat cancers, the main 
immunotherapies used to treat RCC are two cytokines, interleukin-2 (IL-2) and interferon 
alfa (NCCN, 2015). Neither IL-2 nor interferon alfa are listed as risk factors in the 
clinical guidelines for VTE in cancer patients (NCCN, 2015). However, there is some 
evidence for cardiovascular toxicity for both drugs. Cardiovascular disorders due to 
treatment with interferon alfa are rare, however the evidence is based on studies limited 
by small sample sizes, were not in RCC or kidney cancer patients, or were conducted 
more than a decade ago (Sleijfer, Bannink, Van Gool, Kruit, & Stoter, 2005). 
Cardiovascular toxicity is more common with IL-2, possibly due in part to its adverse 
effect of vascular leak syndrome (Clark et al., 2013; Siegel & Puri, 1991). Based on the 
toxicity profile of IL-2, it has not been widely used in elderly cancer patients (Clark et al., 
2013). However, a recent study of 22 elderly metastatic cancer patients reported less 
toxicity for most adverse events compared to patients under age 65 years (Clark et al., 




addition, it was not possible to assess the impact of bias introduced if the older patients 
treated with IL-2 were healthier than the treated younger patients. 
This study assessed receipt of chemotherapy and receipt of immunotherapy 
dichotomously, without attempting to identify individual chemotherapy and 
immunotherapy drugs or drug classes, as that level of detail was outside the scope of this 
study. 
Other Factors 
The study of elderly RCC patients by Connelly-Frost et al. (2013) reported that 
CVC and cardiac or vascular surgeries which occurred more than 30 days before the 
event were independent risk factors protective for DVT, pulmonary embolism, and OTE 
in RCC patients after the cancer diagnosis. The authors hypothesize that the decreased 
risk observed may have been due to prophylactic treatment given to these patients 
because of the association between surgery and CVC and VTE risk (Connelly-Frost et al., 
2013; NCCN, 2015). Additionally, the reduced risk from cardiovascular surgeries and 
CVD may have also been due to selection bias as elderly patients undergo geriatric 
assessments as an additional screening when determining how to treat the patient’s cancer 
(NCCN, 2015). The study by Alcalay et al. (2006) of colorectal cancer patients also 
reported lower incidence of VTEs in patients who undergone a major abdominal surgery 
compared to those who never had (HR = 0.4, 95% CI 0.3-0.4). This study also was unable 
to assess use of prophylactic therapy (Alcalay et al., 2006). Similarly, a study of breast 
cancer patients age 18 or older reported lower incidence risk of VTE in patients who 




Conversely, the study by Chavez-MacGregor et al. (2011) in breast cancer patients 
reported placement of a CVC within the first year after the cancer diagnosis increased the 
risk of VTEs. CVC was not assessed as a potential risk factor in the Alcalay et al. (2006) 
or Chew et al. (2007) studies. 
A study of cancer patients aged 19 or older at diagnosis and treated with cisplatin 
at the Memorial Sloan-Kettering Cancer Center in 2008 reported that a central venous 
catheter increased the risk of a thromboembolic event, even after adjusting for age, 
gender, race, Karnofsky performance status, cancer stage, and risk group (OR = 1.61, 
95% CI 1.10-2.36) (Moore et al., 2011). Surgery was also assessed as a risk factor, but 
was not statistically significant in univariate analyses. However, the timing of the surgery 
variable was within two months of starting cisplatin treatment and the types of surgery 
included in the variable were not described (Moore et al., 2011). This study included 932 
cancer patients of multiple cancer types. Ten percent of the study population was 
classified as “other” cancer types, which may have included kidney cancer (Moore et al., 
2011). The number and proportion of kidney cancer patients could not be determined 
from the publication. 
A study of elderly breast, colon, lung, prostate, and pancreas cancer patients with 
Stage III or IV cancers found an increased incidence of VTEs in patients who had cancer-
directed surgeries (p < 0.01), however the risk was not statistically significant in the 
multivariate analysis (Hall et al., 2009). The risk of VTE varied widely by cancer type, 
was increased in Stage IV cancers (HR = 1.75, 95% CI 1.44-2.12) compared to Stage III 




A study of the risk of heart diseases, including myocardial infarction, in elderly breast 
cancer patients reported that neither breast cancer surgery nor histologic subtype were 
associated with the broad category of heart disease in this population after adjusting for 
other factors (Doyle et al., 2005). CVC and other surgical procedures were not assessed 
in the Doyle et al. (2005) study. This study included binary variables indicating insertion 
of a CVC and receipt of a high risk surgery as potential risk factors for development of 
VTEs. 
Incidence of Arterial Thromboembolic Events 
Incidence rates of ATEs in kidney cancer patients were not found in the published 
literature, but cumulative incidence was found in RCC patients treated with 
chemotherapy. According to prescribing information, the incidence of myocardial 
infarction in clinical trials of Nexavar-treated patients with late-stage RCC was 2.9% 
(Bayer HealthCare Pharmaceuticals, 2013). Similarly, clinical trials of Votrient-treated 
patients with late-stage RCC reported 2% incidence of myocardial infarction or ischemia 
(GlaxoSmithKline, 2014). However this information is from clinical trial data, may not 
have been published, is not population-based, and is often limited by small sample size. 
A meta-analysis of clinical trials which reported on the incidence of ATEs 
(defined as myocardial infarction, arterial thrombosis, cerebral infarct, cerebral ischemia, 
cerebrovascular accident, or myocardial ischemia) in RCC patients was restricted to 
advanced or metastatic patients who received specific targeted therapies as treatment 
(Choueiri et al., 2010). The incidence of ATEs in these RCC patients was 1.8% (Choueiri 




RCC patients of 2.0% (95% CI = 1.5–2.7%) (Qi et al., 2014). There was some overlap in 
the studies used by Choueiri et al. (2010) and Qi et al. (2014). 
A pooled analysis of clinical trial data, but which included no kidney cancer 
patients, reported an incidence of ATEs as 2.5% in control patients and 7.1% in 
bevacizumab-treated patients 65 years of age or older (Scappaticci et al., 2007). In the 
patients 65 years of age or older, the incidence of ATE was 2.6% and 4.4% in patients 
without a history of ATE and 2.2% and 17.9% with a history of ATE, in the controls and 
bevacizumab-treated patients respectively (Scappaticci et al., 2007). The definition of 
ATEs used by Scappaticci et al. (2007) included the same events as Choueiri et al. (2010) 
but also included angina pectoris. Neither Scappaticci et al. (2007), Choueiri et al. (2010), 
nor Qi et al. (2014) reported incidence for individual ATE events.  
A meta-analysis of patients with various cancers who participated in randomized 
clinical trials of anti-EGFR agents reported an incidence of arterial thromboembolic 
events of 4.5% in the patients the cituximab or erlotinib versus 3.4% in the comparison 
group (Petrelli, Cabiddu, Borgonovo, & Barni, 2012). One of the studies was of RCC 
patients, however the sample size was only 104 patients total with only 1 ATE event. 
Myocardial infarction was included in the definition of ATEs, but ischemic stroke was 
not.  
One study of cancer patients treated with cisplatin-based chemotherapy reported 
incidence of 0.2% for myocardial infarction and 2% for any arterial events (Moore et al., 
2011). This study analyzed 932 cancer patients aged 19 to 87 years of age treated in 




A study reported an incidence rate for ischemic stroke of 21.80 per 1,000 p-y in 
the lung cancer group and 15.10 per 1,000 p-y in the noncancer comparison group (Chen, 
Muo, Lee, Yu, & Sung, 2011). The patients were 20 or older at lung cancer diagnosis, 
diagnosed between 1999 and 2007, and matched by age, sex, and month of lung cancer 
diagnosis to a noncancer comparison group (Chen et al., 2011). All patients were 
beneficiaries of the Taiwan National Health Insurance. 
A study of Dutch lung cancer patients of all ages reported incidence rates of 4.5 
and 3.8 per 1,000 p-y for myocardial infarction and ischemic stroke in the first six 
months after cancer diagnosis (van Herk-Sukel et al., 2013). For 6 months after lung 
cancer diagnosis until the end of follow-up, the incidence rate for myocardial infarction 
and ischemic stroke were 1.9 and 1.8, respectively (van Herk-Sukel et al., 2013). There 
were no statistically significant differences in incidence rates for the lung cancer patients 
compared to a noncancer comparison group for myocardial infarction or ischemic stroke. 
However because there were less than 15 of either myocardial infarction or ischemic 
stroke events in those periods, there may not have been sufficient power to distinguish 
any differences. 
The 1-year cumulative incidence of ischemic stroke in cohorts of elderly cancer 
patients and matched cohorts of noncancer patients vary by cancer type. The cumulative 
incidence for breast cancer patients and the noncancer cohort were 3.6% and 3.6% 
respectively (Navi et al., 2015). The incidences for prostate cancer and its comparison 




incidence rates were higher for colorectal cancer, 5.8% and 4.3%, and for lung cancer, 
7.3% and 4.1% (Navi et al., 2015).  
A study of Dutch patients of all ages who had been hospitalized for breast cancer 
reported incidence rates of 1.6, 1.6, and 1.8 per 1,000 p-y for myocardial infarction in the 
first six months after breast cancer hospitalization, 6 to 12 months after, and 12 months to 
end of follow-up (van Herk-Sukel et al., 2011). For ischemic stroke, the incidence rates 
for the same periods were 1.5, 1.8, and 1.6 (van Herk-Sukel et al., 2011). The number of 
events was small (less than 10) in each period in the first 12 months after the breast 
cancer hospitalization, but increased in the rest of the follow-up period. Similar to the 
lung cancer study, after adjusting the incidence rates were not statistically significantly 
different from a noncancer comparison group (van Herk-Sukel et al., 2011). 
No report of incidence (rates or cumulative) of ATEs myocardial infarction, or 
ischemic stroke in the broader kidney cancer population was identified. This study was 
the first (known to date) to calculate incidence rates for ATEs in elderly kidney cancer 
patients utilizing a large, population-based data source, and which presented the 
incidence rates stratified by patient and tumor characteristics. Incidence rates for ATEs 
were presented overall as well as for individual ATEs (myocardial infarction and 
ischemic stroke). Although ATEs were rarer than VTEs, the incidence and risk of ATEs 
were of interest particularly for understanding the background rate of these conditions 




Risk Factors for Myocardial Infarction and Ischemic Stroke 
Myocardial infarction and ischemic stroke may be higher in cancer patients than 
noncancer patients, although the risk may vary by cancer type. The standardized 
incidence ratio for ischemic stroke in Swedish kidney cancer patients was 1.1 (95% CI 
1.1 – 1.2) (Zoller, Ji, Sundquist, & Sundquist, 2012). The standardized incidence ratios 
for other cancers in this population ranged from 0.7 to 1.6, with an overall standardized 
incidence ratio of 1.2 (95% CI 1.2 – 1.2) (Zoller et al., 2012). Another study of Swedish 
breast cancer patients reported an increased risk of ischemic stroke in breast cancer 
patients aged 55 to 69 (RR = 1.1, 95% CI 1.0–1.3) and breast cancer patients 70 years or 
older (RR = 1.1, 95% CI 1.0–1.2) compared to the expected numbers of events in the 
general population of those age groups (Nilsson et al., 2005). 
A study of Taiwanese cervical cancer patients who underwent radiotherapy had 
higher risks of myocardial infarction and ischemic stroke than a comparison group of 
appendectomy patients. The adjusted hazard ratios for myocardial infarction and 
ischemic stroke in cancer patients compared to the comparison group were 1.58 and 1.52, 
both with p-values of 0.01 or less (Tsai et al., 2013). A study of Taiwanese head and neck 
cancer patients reported higher risk of stroke compared to noncancer patients (adjusted 
HR = 1.5, 95% CI 1.4 – 1.7) (Chu et al., 2011). 
Two articles were identified which assessed risk factors for myocardial infarction 
or ischemic stroke in lung and breast cancer patients (van Herk-Sukel et al., 2011, 2013). 
Both studies were conducted in Dutch cancer patients of all ages. The risk factors for 




compared to 49 and younger, prior use of antihypertensive drugs, and a hospitalization of 
11 or more days within the first six months after breast cancer hospitalization (van Herk-
Sukel et al., 2011). The risk factors for ischemic stroke was age of 70 or older compared 
with patients 49 or younger at diagnosis, prior use of platelet aggregation inhibitor drugs, 
prior use of antihypertensive drugs, and prior use of antidiabetic drugs (van Herk-Sukel et 
al., 2011). 
The risk factors for myocardial infarction or ischemic stroke in lung cancer 
patients in the period starting sex months after the cancer diagnosis to the end of the 
follow-up period were age of 65 years or older, prior hospitalization for the condition, 
prior drug use of antithrombotic drugs, cardiovascular drugs, or antidiabetic drugs (van 
Herk-Sukel et al., 2013). Female gender was protective for both conditions (van Herk-
Sukel et al., 2013).  
In a study of lung cancer patients in Taiwan, the risk factors for any type of stroke 
(other than traumatic stroke) were age, male gender, blue collar or other work compared 
to white collar work, history of hypertension, history of diabetes, history of coronary 
heart disease, history of atrial fibrillation, and history of coronary obstructive pulmonary 
disorder (Chen et al., 2011). Decreasing urbanization was identified as protective against 
stroke (Chen et al., 2011). These findings were based on the unadjusted hazard ratios as 
adjusted model results were not presented.  
Studies of risk factors for ischemic stroke comparing cancer patients and 
noncancer patients have reported similar prevalence of several risk factors in the two 




had a stroke than in noncancer stroke patients (Karlinska, Gromadzka, Karlinski, & 
Czlonkowska, 2015; Kim & Lee, 2014). No differences in the prevalence of diabetes or 
smoking status were found (Karlinska et al., 2015; Kim & Lee, 2014). The Karlinska et 
al. (2015) article found a lower prevalence of previous stroke in cancer patients, but no 
difference in the prevalence of hypertension, or congestive heart failure. Kim and Lee 
(2015) reported lower prevalence of hypertension, ischemic heart disease, 
hyperlipidemia, and family history of stroke in cancer patients compared to the noncancer 
patients. There was no difference in the prevalence of previous stroke in the cancer and 
noncancer patients (Kim & Lee, 2014). Although both studies included patients with 
various kinds of cancers, neither Karlinska et al. (2015) nor Kim and Lee (2014) had 
more than five kidney cancer patients in their studies. 
The published literature regarding risk factors for myocardial infarction or 
ischemic stroke in cancer patients was limited to a couple of tumor types. Age, co-
medications, and comorbidities increased the risk of the outcomes. In comparison with 
noncancer patients, the prevalence of risk factors for ATEs was similar for smoking and 
diabetes, but lower for atrial fibrillation. Whether the prevalence of other risk factors 
differed between cancer and noncancer patients depended on the study population and 
methodology. Research on the risk factors for ATEs in kidney cancer patients was not 
found, and so this study will make a contribution to the literature by providing 




Summary and Conclusions 
This literature review summarized what was known about the incidence of VTEs 
and ATEs in kidney cancer patients and the assessed risk factors for VTEs. Incidence 
rates for VTEs in kidney cancer patients are approximately 13 – 14 per 1,000 person-
years overall, but are higher for more distant stage (Chew et al., 2006; Walker et al., 
2013). No significant differences in the rates of VTEs in kidney cancer were observed for 
older patients compared to younger patients (Chew et al., 2006; Walker et al., 2013). 
Studies of other tumor types have been inconsistent as to whether there are differences in 
rates or risk of VTEs by age at cancer diagnosis (Alcalay et al., 2006; Chew et al., 2007, 
2008; Hall et al., 2009; Khorana et al., 2008). While studies have consistently shown that 
the risk of VTE varies significantly by tumor type, there are very few studies conducted 
specifically in kidney cancer patients (Blom et al., 2005; Hall et al., 2009; Walker et al., 
2013; White et al., 2005). Thus, it is unclear whether VTE risk factors identified in other 
tumor types are risk factors for VTEs in kidney cancer patients as well. In addition, 
incidence and risk of VTEs and ATEs is noticeably absent for kidney cancer histology 
groups. Venous thromboembolic events in cancer patients have been more studied than 
ATEs for all tumor types including kidney cancer. This study provided incidence rates for 
VTEs and ATEs in elderly kidney cancer patients, described incidence rates by histology 
group, and assessed independent risk factors for VTEs in this population including 
histology group. 
Chapter 3 provides more detail on the study population criteria, calculation of 




descriptive analyses and to answer the research questions. Each variable and how it was 
constructed are provided. Threats to validity and ethical concerns are discussed as related 




Chapter 3: Research Method 
Introduction 
The previous chapters described the importance of VTEs and ATEs in elderly 
cancer patients, summarized the literature, and highlighted the gaps in knowledge. The 
problem was that incidence rates of VTEs and ATES for elderly kidney cancer patients 
(ages 65 years or older at diagnosis) are not readily available in the literature, much less 
incidence rates by histology group, and other patient and tumor characteristics. Analysis 
of risk factors for VTEs in elderly kidney cancer patients was also needed. 
This chapter described the rationale and methodology for using a quantitative, 
retrospective cohort study design. The study population, inclusion and exclusion criteria, 
the data set characteristics and procedures for accessing the data set, operational 
constructs, the data analysis plan, threats to validity, and ethical procedures were 
thoroughly discussed. 
Research Design and Rationale 
The dependent variables were diagnoses of VTE or ATE, depending on the 
analysis or research question. For Research Question 1, the outcome was the calculation 
of incidence rates for diagnosis of the first incident VTE/ATE in the year prior to kidney 
cancer diagnosis or index date. Hazard ratios were calculated to estimate the incidence 
rate ratios of VTE/ATEs comparing the exposed to unexposed groups. For Research 
Question 2, the dependent variable was the calculated hazard ratio approximating the 




rate of VTE/ATE in the unexposed. Only the first incident event was counted for all 
analyses. 
The exposed and unexposed patients were matched on age (in years) at kidney 
cancer diagnosis (exposed) or index date (unexposed), gender, race, SEER registry area, 
and duration of follow-up. For matching, duration of follow-up for the unexposed was 
required to be equal to or greater than the duration of follow-up for the exposed. 
However, for the analyses, the duration of follow-up for the unexposed was truncated to 
the same value as the corresponding kidney cancer patient. Patients from the exposed and 
unexposed cohorts were matched in order to reduce the likelihood that the differences in 
the incidence rate ratios are due to age, gender, or any of the other matching factors, as 
estimating any difference in rate ratios due to exposure status is the objective. 
The analysis for Research Question 3 included kidney cancer patients only. The 
dependent variable was the time in years from kidney cancer diagnosis to occurrence of 
the first VTE or duration of follow-up. Individual dependent variables were created for 
each VTE and for any VTE. The potential predictors included in the initial (full) model 
were age at diagnosis, race, gender, diabetes, atherosclerosis, varicose veins, 
cardiovascular surgery, central venous catheter, kidney disease, history of VTE, history 
of cardiovascular disease, AJCC stage, treatment type (immunotherapy, nephrectomy, 
chemotherapy), histology group, SEER registry region, Charlson comorbidity score, and 
year of diagnosis. 
This study was a quantitative, retrospective cohort study. A cohort study was the 




descriptive analyses and research questions (Aschengrau & Seage, 2008; Rothman, 
1986). The resource constraint from the use of a retrospective cohort design using 
secondary data for this research study was that only the data on outcomes and 
independent variables included in the dataset were available. Thus measurement of some 
risk factors for incident VTEs and ATEs were not in the dataset, and were not included in 
this study. The use of the study design was consistent with other studies which add to the 
understanding of incident VTEs and ATEs in cancer patients (Connelly-Frost et al., 2013; 
Walker et al., 2013). 
Data Source 
The SEER-Medicare database is a linkage of the SEER cancer registry data with 
Medicare claims data, creating a population-based resource for cancer-related analyses 
(Warren et al., 2002a). Also available with the SEER-Medicare database is Medicare 
enrollment and claims data for a sample of noncancer patients. The noncancer patients 
are selected from a 5% random sample of Medicare beneficiaries who reside in the same 
SEER registry areas and who are not in the SEER cancer registry database (Applied 
Research Program, 2013; Warren et al., 2002a). The noncancer patient cohort was used in 
this research study as the unexposed comparison group.  
The SEER data contains newly diagnosed cancers in the SEER registry areas, 
some of which began collecting data in 1973. As of 2013, there were 18 registry areas 
which covered approximately 27% of the entire U.S. population (SEER, 2013). The 
SEER data are of high quality and annually meet quality criteria of the North American 




Medicare is a government program to insure the elderly in the United States, 
although persons with disabilities or end-stage renal disease may qualify for Medicare 
coverage before 65 years of age. The Medicare data include claims plus demographic and 
entitlement information from the Medicare master enrollment file (Applied Research 
Program, 2013; Warren et al., 2002a). 
The two databases were first linked in 1991 and updated in subsequent years, with 
current plans to update the linkage every two years (Applied Research Program, 2013; 
Warren et al., 2002a). Social security number, sex, name, and date of birth are used to 
link the databases (Warren et al., 2002a), however personal identifiers such as social 
security number and name are not included in the final database for release to 
researchers. Generalizability of the database has been assessed as well. On characteristics 
such as age and sex, the database population is similar to the U.S. elderly population 
(Warren et al., 2002a). However, the database differs from the U.S. elderly population in 
race, residence in an urban (versus rural) location, participation in a Medicare managed 
care plan, and cancer mortality rate (Warren et al., 2002a). 
Although the linked SEER-Medicare database is a high-quality, population based 
resource for researchers, it has several limitations. Limitations identified include no 
information about services which are not covered by Medicare or which are paid for out 
of pocket, incomplete claims for persons enrolled in Medicare managed care plans, and 
the general limitations which affect any administrative claims databases (Warren et al., 
2002a). However, the database can be used for various types of studies along the entire 




published include cancer screening, treatment patterns and outcomes, hospice and other 
resource utilization, health economic studies, healthcare disparities, and survival analyses 
(Applied Research Program, 2013; Warren et al., 2002a). 
Study Population 
The exposed cohort consisted of patients in the SEER-Medicare database 
diagnosed with kidney cancer at age 65 years or older, diagnosed between the years of 
2004 and 2009, and whose kidney cancer was their first primary cancer. Patient follow-
up was from the month of kidney cancer diagnosis until death, participation in a managed 
care plan, coverage by only Part A or B of Medicare, or December 31, 2010. For this 
study, the estimated number of kidney cancer patients was 12,240. This estimate was 
calculated by summing the number of kidney cancer patients in the SEER-Medicare 
database between 2004 and 2009 (Applied Research Program, 2013) and multiplying by 
69% to estimate the number of patients remaining after applying the study inclusion and 
exclusion criteria. The percentage remaining after applying inclusion and exclusion 
criteria was based on the proportion remaining after applying the same criteria for the 
Connelly-Frost et al. (2013) study. 
The patient criteria applied for the counts from the Applied Research Program 
(2013) were: (a) patients 65 years of age or older at diagnosis, (b) kidney cancer was the 
first diagnosed cancer (sequence number 00 or 01), and (c) patients had Medicare Part A 
and B coverage and were not participating in a Medicare managed care program during 




A comparison cohort of noncancer patients were individually matched, without 
replacement, to the kidney cancer patients by age at index date, sex, SEER registry 
region, and duration of follow-up. The index date of the matched noncancer patient was 
assigned as the month and year of diagnosis of its corresponding kidney cancer patient. 
The unexposed patients were also required to have two years of continuous enrollment in 
Medicare parts A and B prior to the index date with no participation in a managed care 
program during that time. Each unexposed patient were required to have at least as much 
follow-up as their corresponding exposed patient, however the follow-up for the 
unexposed was truncated to the same month as the corresponding cancer patient. With 
659,639 noncancer patients in the potential comparison group, the majority of exposed 
patients were matched to an unexposed patient. 
Sampling Strategy 
The sampling strategy for the exposed cohort was to include all kidney cancer 
patients who met the inclusion and exclusion criteria and were matched to a 
corresponding unexposed patient. Cancer patients who developed multiple primary 
cancers before or at the time of the initial kidney cancer diagnosis were excluded. 
Inclusion criteria required all patients to have at least two years of continuous enrollment 
in Medicare parts A and B prior to the index date and at least one month of survival after 
the index date. Patients who participated in a managed Medicare plan in the two years 
prior to the index date were excluded. The same inclusion and exclusion criteria were 




Power calculations were not generated for the descriptive analyses. For Research 
Question 1, the required sample size to achieve power of 0.8 ranged from 848 to 3594, 
depending on the unknown true values of the overall response probability, covariate 
standard deviation, and odds ratios for specific VTE or ATE. The assumptions used were 
alpha level 0.05, covariate odds ratio of 1.2, and odds ratio for test predictor of 1.5 to 
1.75. The ranges for the covariate odds ratio and test predictors were based on the values 
reported by Connelly-Frost (2013). 
For the second and third research questions, power calculations were generated to 
compare two survival curves using the log-rank test. Using the assumptions that both 
survival curves are exponential, a year (12 months) of follow-up time, and a two-sided 
test at alpha level 0.05, a sample size of 1,044 per group is needed to achieve power of 
0.8 and a sample size of 1,194 per group is needed to achieve power of 0.85. All power 
calculations were generated using SAS 9.3 software. 
Variable Definitions and Operationalization 
Variables to identify the kidney cancer patients, variables related to the kidney 
cancer diagnosis, patient characteristics and Medicare coverage or managed Medicare 
plans were contained in or constructed from information in the SEER-Medicare Patient 
Entitlement and Diagnosis Summary File. The Patient Entitlement and Diagnosis 
Summary File contains cancer information at diagnosis and during first course of 
treatment from the SEER program. The Medicare claims files were used to identify 
cancer treatments, diagnoses of venous and arterial thromboembolic events, and the 




The Medicare Entitlement files contain monthly indicators of participation in Part 
A, Part B, or managed care plans. To determine eligibility, a patient must have had 
coverage by Parts A and B of Medicare for 24 months prior to index date and no 
participation in HMO during that time. Thus, each of the 24 variables for the period prior 
to index date indicating Medicare coverage must have a value of 3, Parts A and B 
coverage. Each of the 24 variables for the period prior to index date indicating managed 
care participation must have a value of 0 indicating no participation to be eligible. 
Duration of follow-up was calculated as the number of months after the index date until 
the variable indicating coverage does not have a value of 3, the variable indicating 
managed care participation has a value other than 0, the patient dies (using month and 
year of death), or December 2010. 
The index date for patients was defined as follows. For kidney cancer patients, the 
index date was first day of the month and year of the first kidney cancer diagnosis. For 
the matched, noncancer comparison group, the index date was the same as the index date 
of the corresponding kidney cancer patient it is matched to. One of the matching criteria 
was the comparator patient must meet the same Medicare coverage and managed care 
criteria in the month of the index date. 
Age at index date was calculated as the number of years between year of birth and 
year of index date. Age was grouped into the following categories: 65-69, 70-74, 75-79, 




Race was provided by the Medicare Entitlement information and was categorized 
as White, Black and other race. Because there were less than 10 patients in each cohort 
with unknown race, those patients were included with the other race group. 
Gender was categorized as male or female, and was provided in the Medicare 
Entitlement file. 
SEER registry area of diagnosis or residence was categorized using the United 
States Census Region groupings for analysis of geographic region. The regions were 
Northeast, Midwest, South and West. The states which make up each region are listed in 
Appendix B. 
For analyses of Research Questions 1 and 2, the unexposed patients (the 
noncancer patients) were matched to the exposed patients on age at index date, gender, 
race, SEER registry area, and duration of follow-up. The matched, unexposed patients 
were assigned the same index date as the corresponding exposed patient, and thus were 
required to meet the same criteria of Part A and B Medicare coverage with no managed 
care participation prior to the same index date. 
Kidney cancer was defined using International Classification of Diseases for 
Oncology, 3rd edition (ICD-O-3) coding site for the kidney (C64.9), excluding histology 
codes 9590-9989. Only malignant tumors were included. 
The types of kidney cancer, transitional cell and RCC, were defined by ICD-O-3 
codes as well. Transitional cell kidney cancer was defined as kidney cancers with 
histology codes 8050-8130 (inclusive). RCC was defined as kidney cancers excluding 




(ICD-O-3 histology codes 8310 or 8312); Papillary (ICD-O-3 histology code 8260); 
Chromophobe (ICD-O-3 histology codes 8317, 8270) and Other RCC (ICD-O-3 
histology codes excluding 8050-8130 inclusive, 8310, 8312, 8317, 8260, and 8270). 
For VTEs, each condition (deep vein thrombosis, pulmonary embolism, or other 
thromboembolic events) were coded dichotomously, indicating whether or not a 
diagnosis of the condition was recorded. The codes used to define these conditions are 
located in Appendix B. A derived variable for any VTE was coded dichotomously. 
Similarly, for ATEs, each condition (myocardial infarction or ischemic stroke) 
were coded dichotomously, indicating whether or not a diagnosis of the condition was 
recorded. For ischemic stroke, diagnoses were only included if they occurred during a 
hospitalization. This is because outpatient claims with a diagnosis of ischemic stroke may 
be for rehabilitation or other follow-up care and not actually indicate the incident stroke 
event. The codes used to define these conditions are located in Appendix B. A derived 
variable for any ATE was coded dichotomously. 
Cancer treatments were coded as follows. Any chemotherapy was coded 
dichotomously, indicating whether or not a cancer patient received chemotherapy. The 
procedure and NDC codes used to identify chemotherapy are located in Appendix B. Any 
immunotherapy was coded dichotomously, indicating whether or not a cancer patient 
received immunotherapy. The procedure and NDC codes used to identify immunotherapy 
are located in Appendix B. Nephrectomy was coded dichotomously, indicating whether 
or not a procedure code for nephrectomy was coded. The procedure codes to identify 




The following conditions were defined dichotomously, with a value of 1 
indicating whether or not the condition was reported in the claims data: diabetes, 
atherosclerosis, varicose veins, high risk cardiovascular surgeries, placement of a CVC, 
and kidney disease. The diagnosis and procedure codes to define each of these conditions 
are located in Appendix B. High risk surgeries and placement of a CVC events were 
restricted to those events which occurred more than 30 days prior to the outcome.  
A weighted score was calculated from the conditions in the adapted Charlson 
comorbidity index. The score was analyzed as 0, 1, 2, and 3 or greater. See Appendix C 
for the index conditions and the ICD-9-CM diagnosis and procedure codes used to define 
the score. See Appendix D for the program to calculate the score. 
Data Analysis Plan 
SAS 9.3 was used to perform all analyses. Analyses for each research question 
and hypotheses are described below. Univariate and bivariate frequencies and descriptive 
statistics were generated for variables to identify outliers and unusual values. 
Descriptive Analysis 1 
The first analysis involved the calculation of the incidence rates of individual 
VTEs and of ATEs in elderly kidney cancer patients over the 12 months before and in the 
follow-up period after cancer diagnosis. Incidence rates were calculated as the number of 
incident events in the study period divided by the sum total of person-time at risk during 
the period. No statistical tests were performed. For each of the prespecified patient and 
tumor characteristics, the incidence rates of VTEs and ATEs were presented by age 




treatment by immunotherapy, treatment by nephrectomy, treatment by chemotherapy or 
targeted therapy, histology group, Charlson Comorbidity Index, SEER registry region, 
and year of diagnosis. 
Descriptive Analysis 2 
For this analysis, the proportion of elderly kidney cancer patients who 
experienced incident VTEs and incident ATEs in discrete, mutually exclusive time 
periods during follow-up (0 to 90 days, 91 to 180 days, 181 to 270 days, and 271 to 365 
days) after cancer diagnosis were calculated. Incidence proportions were calculated as the 
number of incident events in the time period divided by the number of patients still at risk 
for an incident VTE or ATE during the period. No statistical tests were performed. 
Research Question 1 
Research Question 1: How do the incidence rates of VTEs and ATEs in elderly 
exposed (kidney cancer) patients 12 months before index date compare to a matched 
unexposed (noncancer) Medicare population during the same 12-month timeframe? 
HA1: In the year prior to index date, the incidence rates of VTEs or of ATEs are 
statistically significantly greater in the exposed patients than in the unexposed patients. 
H01: There is no statistically significant difference in the incidence rates of VTEs 
or ATEs in the year prior to the index date in the exposed patients and in the matched 
unexposed patients. 
Hazard ratios were calculated to compare the incidence rates of VTEs and ATEs 




date). Adjustment was made for the matching of the cohorts using the STRATA 
statement in the PHREG procedure of SAS. 
Research Question 2 
Research Question 2: How do the incidence rates of VTEs and rates of ATEs in 
elderly exposed (kidney cancer) patients after index date compare to a matched 
unexposed (noncancer) Medicare population during the same timeframe? 
HA2: In the follow-up period after the index date, the incidence rates of VTEs or 
of ATEs are statistically significantly greater in the exposed patients than in the 
unexposed patients. 
H02: There is no statistically significant difference in the incidence rates of VTEs 
or ATEs in the period after index date in the exposed patients and in the matched 
unexposed patients. 
Hazard ratios were calculated to compare the incidence rates of VTEs and ATEs 
in cancer patients to the matched noncancer cohort in the period after diagnosis (index 
date). Adjustment was made for the matching of the cohorts using the STRATA 
statement in the PHREG procedure of SAS. 
Research Question 3 
Research Question 3: In the follow-up period after kidney cancer diagnosis, what 
are the risk factors associated with time to newly diagnosed, individual VTE (DVT, PE, 
or OTE)? 
HA3: No factors are statistically significantly associated with the time to newly 




H03: Tumor histology and other factors are statistically significantly associated 
with the time to newly diagnosed VTEs after kidney cancer diagnosis. 
For each question, a Cox proportional hazard model was used to identify 
independent predictors for each outcome. The outcome was time to the occurrence of the 
first VTE or ATE after kidney cancer diagnosis or duration of follow-up. The potential 
predictors to be included in the initial (full) model were age at diagnosis, race, gender, 
diabetes, atherosclerosis, varicose veins, cardiovascular surgery, central venous catheter, 
kidney disease, history of VTE, history of cardiovascular disease, AJCC stage, treatment 
type (immunotherapy, nephrectomy, chemotherapy), histology group, SEER registry 
region, and year of diagnosis. Exploration of the data and these variables prior to 
modeling included production of a correlation matrix to identify any highly correlated 
variables. Highly correlated variables were those with an absolute value of the correlation 
coefficient greater than or equal to 0.7 (Taylor, 1990). If two variables were highly 
correlated, then only one variable of the pair were included in the model to avoid 
redundancy. 
Potential effect measure modifiers were identified by testing the equality of 
survivorship over strata for each variable. If a variable had a p-value for the log rank test 
less than 0.05, then this variable were characterized as a potential effect measure modifier 
(Szklo & Nieto, 2006). Potential confounders were identified as those variables which 
were a) associated with exposure and b) associated with outcome among the unexposed. 
Mediating variables are variables which are on the causal pathway between the 




model were considered mediating variables. The initial full model contained all potential 
effect measure modifiers and confounders. The proportional hazards assumption was 
tested for each variable. If the proportional hazards assumption did not hold true for any 
variable, stratification of the model by this variable was used to account for the violation. 
For those variables for which the proportional hazards assumption held, the final test for 
effect measure modifiers were conducted by determining whether the p-value for 
interaction term was less than 0.05 in the full model. Next the final confounders for the 
model were identified as those variables for which there is a 15% change in the hazard 
ratio estimate for the adjusted versus unadjusted model. 
Alternative models were run using a Deyo-Romano adaptation of the Charlson 
Comorbidity Index (CCI) instead of the individual variables (diabetes, cardiovascular 
surgery, kidney disease, and history of cardiovascular disease), as the CCI includes these 
procedures and diagnoses in addition to others (see Appendix C). 
Survival curves were generated for incidence of VTEs and ATEs stratified by 
patient and tumor characteristics, using the log-rank test to distinguish statistically 
significant differences in curves at the 0.05 level. 
Threats to Validity 
The main threat to validity was unmeasured factors, such as smoking and patient 
platelet counts, which may impact the incidence or risk of VTEs or ATEs. Other threats 
to validity were minimized by the use of previously defined constructs for comorbidity 
classification, exposure and independent variable definitions. Bias may also have been 




mediator variables in the model will introduce bias if (a) confounders of the mediator-
outcome relationship are not adjusted for in the model, (b) the mediator-outcome 
confounders are affected by exposure, or (c) there is an interaction effect between the 
exposure and the mediator variables (Richiardi, Bellocco, & Zugna, 2013). None of the 
variables in this study were considered mediator variables but were adjusted for as 
confounders or effect measure modifiers.  
Ethical Procedures 
Accessing the Data 
In order to access the SEER-Medicare database, several steps were completed. 
The first step was to submit an application for review. The application contained the 
completed application form which included a description of the study project and a 
signed data use agreement (Applied Research Program, 2013). The data was only 
available for purchase after the application has been approved. The proposal for the 
original study using SEER-Medicare data was submitted and approved in 2006. The 
request to update the study with additional cancer sites, years of data, and outcomes was 
approved January 2013. As this project does not require restricted variables which may 
compromise patient or provider confidentiality, the request form for these variables was 
not necessary. 
The data was accessed through a pharmaceutical company. The SEER-Medicare 
account manager at the company was listed as the Principal Investigator and signatory on 
the data use agreement, although the use of the data was restricted to my analysis as the 




Program, 2013). The study proposal for the research questions and hypotheses were 
approved prior to purchase of the data. Note that IRB approval was not required as the 
original proposal was approved prior to the inclusion of IRB approval as an application 
component. However, IRB approval of this study was requested through Walden 
University prior to start of any data analysis. The Walden University IRB approval 
number for this study is 07-23-15-0083161. 
The National Cancer Institute has taken multiple steps to protect patient and 
provider confidentiality in the SEER-Medicare database and it is considered a limited-
data set per the Health Insurance Portability and Accountability Act (HIPAA) regulations 
(Applied Research Program, 2013). The database uses encrypted identifiers for patients, 
providers and hospitals; and does not provide variables such as patient zip code unless 
justification is provided that the data are absolutely necessary for the research project. 
Additional conditions to protect the data confidentiality and usage are required as part of 
the data use agreement, including suppression of cell sizes less than 11 in tables. 
The data was uploaded to a departmental LINUX server and stored securely and 
centrally. No duplications were made. Access to this server was restricted solely to 
qualified data analysts via a secure connection on a validated environment. Access to 
source data directories and files were further protected by means of an electronic gateway 
system which ensured that the data were accessible only to authorized users who 
understood and agreed to comply with contractual obligations specific to the data source. 
All work with the dataset was carried out by authorized personnel of the Worldwide 




computer hard drives at any time. I was required to comply with existing policies and 
procedures to ensure proper computer security and appropriate data access, storage, use, 
and confidentiality. The data will be destroyed after five years, unless other arrangements 
are made, as stipulated in the data use agreement. 
Summary 
This study aimed to address deficiencies in the published literature regarding the 
incidence of VTEs and ATEs and the risk factors for VTEs in elderly kidney cancer 
patients with Medicare coverage. Overall and stratified incidence rates and incidence 
proportions were calculated for descriptive analyses 1 and 2. Rate ratios and 95% 
confidence intervals were calculated for each VTE and ATE for the three research 
questions, accounting for matching (for Research Questions 1 and 2) and differing 
duration of follow-up for study population in the year after index date (Research 
Questions 2 and 3). Cox proportional hazard models were used to identify statistically 
significant predictors for each VTE to answer Research Question 3. The study used the 
SEER-Medicare database which is a large, population-based data source consisting of 
cancer registry data linked with Medicare claims data. Strengths of this study included 
use of a large study population size (11,463 cancer patients and 11,463 matched 
noncancer patients). Limitations included lack of lab data and limitations inherent in the 
use of administrative claims databases. The contribution of this study was to improve the 
knowledge surrounding the risks associated with these potentially serious events in 




The following chapter presents the data analyses conducted to address the 
descriptive analyses and research questions. Baseline descriptive and demographic 
characteristics of the study population are presented in tabular form. The results for the 
descriptive analyses and Research Questions 1 and 2 were reported and interpreted. For 
Research Question 3, each step of testing and decision making for the potential 
confounders and effect measure modifiers were presented along with the rationale for 
including or excluding each variable from the final model. The chapter concludes with a 




Chapter 4: Results 
Introduction and Purpose of the Study 
The purpose of this retrospective cohort study was to describe the incidence rates 
of venous and arterial thromboembolic events in elderly kidney cancer patients and 
compare the incidence rates in cancer patients with matched noncancer elderly patients. 
In addition, the risk factors for venous thromboembolic events in elderly kidney cancer 
patients were assessed. The three research questions and associated hypotheses are listed 
below. 
Research Question 1 
Research Question 1: How do the incidence rates of VTEs and ATEs in elderly 
exposed (kidney cancer) patients 12 months before index date compare to a matched 
unexposed (noncancer) Medicare population during the same 12-month timeframe? 
HA1: In the year prior to index date, the incidence rates of VTEs or of ATEs are 
statistically significantly greater in the exposed patients than in the unexposed patients. 
H01: There is no statistically significant difference in the incidence rates of VTEs 
or ATEs in the year prior to the index date in the exposed patients and in the matched 
unexposed patients. 
Research Question 2 
Research Question 2: How do the incidence rates of VTEs and rates of ATEs in 
elderly exposed (kidney cancer) patients after index date compare to a matched 




HA2: In the follow-up period after the index date, the incidence rates of VTEs or 
of ATEs are statistically significantly greater in the exposed patients than in the 
unexposed patients. 
H02: There is no statistically significant difference in the incidence rates of VTEs 
or ATEs in the period after index date in the exposed patients and in the matched 
unexposed patients. 
Research Question 3 
Research Question 3: In the follow-up period after kidney cancer diagnosis, what 
are the risk factors associated with time to newly diagnosed, individual VTE (DVT, PE, 
or OTE)? 
HA3: No factors are statistically significantly associated with the time to newly 
diagnosed VTEs in the period after kidney cancer diagnosis. 
H03: Tumor histology and other factors are statistically significantly associated 
with the time to newly diagnosed VTEs after kidney cancer diagnosis. 
This chapter describes the process of identifying the data eligible for the study, 
the data analyses processes including variable selection and modeling, and the analyses 
results. The study results for each of the descriptive analyses and research questions are 
thoroughly discussed. 
Data Collection 
All kidney cancer tumors diagnosed 1973 to 2009 were identified in the SEER-
Medicare database. Kidney cancer was defined by ICD-O-3 coding with malignant 




patients. After restricting to the first kidney cancer for each patient, 43,784 patients had a 
kidney cancer diagnosed between 2004 and 2009. The number of kidney cancer patients 
excluded for each criteria are listed in Table 4. The distinct number of cancer patients 
excluded for having any of the exclusion criteria was 32,319. The number in the exposed 
cohort eligible for this study was 11,465. After matching the exposed cohort to the 
unexposed, noncancer patients on age, sex, race, SEER registry region and duration of 
follow-up; the final numbers of eligible patients for this study were 11,463 in the exposed 
cohort and 11,463 in the unexposed cohort. The two exposed cohort members who were 
not matched were male; one was 66 to 69 years of age and one was 85 or older at 
diagnosis; and both were of unknown or other (neither White nor Black) race. 
The excluded patients were much more likely to be younger (median age of 67 
years with a range of 18 to 107 years) compared to the patients eligible for the study 
(median age of 76 years with a range of 66 to 108 years). This was not unexpected as the 
age, minimum duration of Medicare coverage, and reason for initial Medicare entitlement 
criteria in effect excludes patients less than 66 years and 11 months old. The excluded 
patients were more likely to be diagnosed in the later years of the study period, be male, 





Exposed Cohort Exclusion Criteria and Patient Counts 
Exclusion Criteria Number of 
Patients 
Excluded 
Prior cancer in the SEER research data 10,254 
Invalid date of death 21 
Age less than 65 at date of kidney cancer diagnosis 12,569 
Original reason for Medicare entitlement was disability or ESRD 10,313 
Less than 24 months of Medicare coverage (A & B) before index date 14,820 
Medicare managed care plan participation within 24 months before 
index date 
8,093 
Less than 1 month follow-up after index date  19,623 
Note. Exclusion criteria were not mutually exclusive. 
 
After matching by gender, age, region, race, and minimum duration of follow-up, 
there were 11,463 patients in each cohort. Because the age-matching was done by 
matching the year of birth and year of index date, not including month of birth, the 
proportions in each age group differ slightly in spite of the matching. For example, a 
patient in the unexposed cohort had the same year of birth and year of index date as 
his/her corresponding exposed cohort member, but was born in a different month. Thus, 
when I calculated age at index date using month of birth, year of birth, month of index 
date and year of index date, the matched patient had an age which was 1 year greater or 
younger than the corresponding exposed patient.  
The kidney cancers in the exposed cohort were mostly renal cell carcinoma 
(97.6%). The histology types were clear cell carcinoma (75.7%), with 8.5% papillary 
tumors, 3.6% chromophobe, 9.7% other RCC types, and 2.4% Transitional cell tumors. 




III, 18.1% Stage IV, and 10.3% unstaged or stage unknown. The majority of the cancer 
patients were treated with a nephrectomy (66.8%), however less than 11 of the unexposed 
cohort had nephrectomies as well. This was not surprising in the cancer patients as 
nephrectomy is a primary treatment especially for patients with Stage I, II, and III kidney 
cancer (NCCN, 2015). Nephrectomies in these noncancer patients were most likely due 
to other conditions. Chemotherapy was used to treat 20.6% of the cancer patients and 












Total study participants 11,463 (100) 11,463 (100) 
Age at index date   
66-69 1,932 (16.85) 1,939 (16.92) 
70-74 3,131 (27.31) 3,139 (27.38) 
75-79 2,885 (25.17) 2,867 (25.01) 
80-84 2,042 (17.81) 2,073 (18.08) 
85+ 1,473 (12.85) 1,445 (12.61) 
Gender   
Male 6,331 (55.23) 6,331 (55.23) 
Female 5,132 (44.77) 5,132 (44.77) 
Race   
White 9,788 (85.39) 9,788 (85.39) 
Black 892 (7.78) 892 (7.78 
Other or unknown 783 (6.83) 783 (6.83) 
Year of Index   
2004 1,845 (16.10) 1,845 (16.10) 
2005 1,956 (17.06) 1,956 (17.06) 
2006 1,940 (16.92) 1,940 (16.92) 
2007 2,002 (17.46) 2,002 (17.46) 
2008 1,896 (16.54) 1,896 (16.54) 
2009 1,824 (15.91) 1,824 (15.91) 
Geographic Region   
Midwest 1,451 (12.66) 1,451 (12.66) 
Northeast 2,388 (20.83) 2,388 (20.83) 
South 3,102 (27.06) 3,102 (27.06) 
West 4,522 (39.45) 4,522 (39.45) 
Cancer Stage   
Stage I - 5,700 (49.73) 
Stage II - 848 (7.40) 
Stage III - 1,658 (14.46) 
Stage IV - 2,078 (18.13) 
Stage Unknown - 1,179 (10.29) 












Cancer Histology Group   
Chromophobe - 413 (3.60) 
Clear Cell - 8,678 (75.70) 
Other RCC - 1,117 (9.74) 
Papillary - 977 (8.52) 
Transitional cell tumor - 278 (2.43) 
Cancer treated with chemotherapy   
No - 9,102 (79.40) 
Yes - 2,361 (20.60) 
Cancer treated with immunotherapy   
No - 10,986 (95.84) 
Yes - 477 (4.16) 
Nephrectomy after index date   
No  - (> 99.9) 3,810 (33.24) 
Yes < 11 (< 0.1) 7,653 (66.76) 
Note. Numbers less than 11 have been suppressed. 
Note. RCC = renal cell carcinoma. 
 
For each outcome, the number of patients with the outcome was higher in the 
exposed cohort than in the unexposed cohort (Table 6). For each outcome and cohort, the 
number of patients with the outcome was higher in the period after index date as 







Frequency of Outcomes Within Study Population 
 Year prior to index date Follow-up period after index date 










Any VTE     
No 11,192 (97.64) 11,069 (96.56) 11,022 (96.15) 10,061 (87.77) 
Yes 271 (2.36) 394 (3.44) 441 (3.85) 1,402 (12.23) 
DVT     
No 11,316 (98.72) 11,217 (97.85) 11,174 (97.48) 10,491 (91.52) 
Yes 147 (1.28) 246 (2.15) 289 (2.52) 972 (8.48) 
PE     
No 11,408 (99.52)  11,373 (99.21) 11,363 (99.13) 11,077 (96.63) 
Yes 55 (0.48) 90 (0.79) 100 (0.87) 386 (3.37) 
Other VTE     
No 11,365 (99.15) 11,334 (98.87) 11,336 (98.89) 11,085 (96.70) 
Yes 98 (0.85) 129 (1.13) 127 (1.11) 378 (3.30) 
Any ATE     
No 11,172 (97.46) 11,109 (96.91) 10,838 (94.55)  10,380 (90.55) 
Yes 291 (2.54) 354 (3.09)  625 (5.45)  1,083 (9.45) 
MI     
No 11,310 (98.67) 11,271 (98.33) 11,172 (97.46) 10,848 (94.63) 
Yes 153 (1.33) 192 (1.67) 291 (2.54) 615 (5.37) 
IS     
No 11,318 (98.74) 11,290 (98.49) 11,093 (96.77)  10,915 (95.22) 
Yes 145 (1.26) 173 (1.51)  370 (3.23)  548 (4.78) 
Note. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = 
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = 
pulmonary embolism; VTE = venous thromboembolic event. 
 
The following table presents the frequency of each covariate in both cohorts for 





Frequency of Covariates Within Study Population 
 Year prior to index date Follow-up period after index date 










Charlson Score     
0 5,688 (49.62) 4,446 (38.79) 4,754 (41.47) 2,373 (20.70) 
1 2,843 (24.80) 3,037 (26.49) 2,732 (23.83) 2,098 (18.30) 
2 to 3 2,182 (19.04) 2,794 (24.37) 2,700 (23.55) 3,849 (33.58) 
4+ 750 (6.54) 1,186 (10.35) 1,277 (11.14) 3,143 (27.42) 
Type 1 Diabetes     
No 10,964 (95.65) 10,711 (93.44) 10,776 (94.01) 10,307 (89.92) 
Yes 499 (4.35) 752 (6.56) 687 (5.99) 1,156 (10.08) 
Type 2 Diabetes     
No 8,702 (75.91) 7,839 (68.39) 8,230 (71.80) 7,008 (61.14) 
Yes 2,761 (24.09) 3,624 (31.61) 3,233 (28.20) 4,455 (38.86) 
Atherosclerosis     
No 10,539 (91.94) 10,147 (88.52) 10,094 (88.06) 9,225 (80.48) 
Yes 924 (8.06) 1,316 (11.48) 1,369 (11.94) 2,238 (19.52) 
Varicose Veins     
No 11,349 (99.01) 11,353 (99.04) 11,264 (98.26) 11,256 (98.19) 
Yes 114 (0.99) 110 (0.96) 199 (1.74) 207 (1.81) 
Kidney Disease     
No 10,736 (93.66) 9,813 (85.61) 10,063 (87.79) 6,200 (54.09) 
Yes 727 (6.34) 1,650 (14.39) 1,400 (12.21) 5,263 (45.91) 
History of CVD a     
No 9,799 (85.48) 9,526 (83.10) 9,521 (83.06) 8,914 (77.76) 
Yes 1,664 (14.52) 1,937 (16.90) 1,942 (16.94) 2,549 (22.24) 
History of VTE a     
No 11,247 (98.12) 11,225 (97.92) 11,192 (97.64) 11,069 (96.56) 
Yes 216 (1.88) 238 (2.08) 271 (2.36) 394 (3.44) 
History of DVT a     
No 11,358 (99.08) 11,324 (98.79) 11,316 (98.72) 11,217 (97.85) 
Yes 105 (0.92) 139 (1.21) 147 (1.28) 246 (2.15) 
History of PE a     
No 11,419 (99.62) 11,429 (99.70) 11,408 (99.52) 11,373 (99.21) 
Yes 44 (0.38) 34 (0.30) 55 (0.48) 90 (0.79) 
History of Other 
VTE a     
No 11,374 (99.22) 11,368 (99.17) 11,365 (99.15) 11,334 (98.87) 
Yes 89 (0.78) 95 (0.83) 98 (0.85) 129 (1.13) 
History of Any 
ATE a     
No 11,213 (97.82) 11,228 (97.95) 11,172 (98.74) 11,109 (96.91) 







 Year prior to index date Follow-up period after index date 










History of MI a     
No 11,340 (98.93) 11,335 (98.88) 11,310 (98.67) 11,271 (98.33) 
Yes 123 (1.07) 128 (1.12) 153 (1.33) 192 (1.67) 
History of IS a     
No 11,326 (98.80) 11,349 (99.01) 11,318 (98.74) 11,290 (98.49) 




     
No  - (> 97.0) 378 (95.94) 416 (94.33) 1,264 (90.16) 
Yes < 11 (< 3.0) 16 (4.06) 25 (5.67) 138 (9.84) 
CVC prior to 
VTE
b
     
No  - (> 97.0) 383 (97.21) 425 (96.37) 1,229 (87.66) 




     
No  - (> 96.0) 230 (93.50) 271 (93.77) 856 (88.07) 
Yes < 11 (< 4.0) 16 (6.50) 18 (6.23) 116 (11.93) 
CVC prior to 
DVT
b
     
No  - (> 96.0) 235 (95.53) 277 (95.85) 826 (84.98) 




     
No  - (> 80.0)  - (> 88.0)  - (> 89.0) 339 (87.82) 
Yes < 11 (< 20.0) < 11 (< 12.0) < 11 (< 11.0) 47 (12.18) 
CVC prior to PE
b
     
No  - (> 80.0)  - (> 88.0)  - (> 89.0) 329 (85.23) 
Yes < 11 (< 20.0) < 11 (< 12.0) < 11 (< 11.0) 57 (14.77) 
High-risk Surgery 
prior to Other 
VTE
b
     
No  - (> 88.0)  - (> 91.0)  - (> 91.0) 333 (88.10) 
Yes < 11 (< 12.0) < 11 (< 9.0) < 11 (< 9.0) 45 (11.90) 
CVC prior to 
Other VTE
b
     
No  - (> 88.0)  - (> 91.0)  - (> 91.0) 331 (87.57) 
Yes < 11 (< 12.0) < 11 (< 9.0) < 11 (< 9.0) 47 (12.43) 
High-risk Surgery 
prior to Any ATE
b
     
No 279 (95.88) 339 (95.76) 565 (90.40) 936 (86.43) 
Yes 12 (4.12) 15 (4.24) 60 (9.60) 147 (13.57) 
CVC prior to Any 
ATE
b
     
No  - (> 96.0)  - (> 96.0) 607 (97.12) 936 (86.43) 






 Year prior to index date Follow-up period after index date 













     
No  - (> 92.0)  - (> 94.0) 264 (90.72) 514 (83.58) 
Yes < 11 (< 8.0) < 11 (< 6.0) 27 (9.28) 101 (16.42) 
CVC prior to MI
b
     
No  - (> 92.0)  - (> 94.0)  - (> 96.0) 513 (83.41) 




     
No  - (> 92.0)  - (> 92.0) 325 (87.84) 459 (83.76) 
Yes < 11 (< 8.0) < 11 (< 8.0) 45 (12.16) 89 (16.24) 
CVC prior to IS
b
     
No  - (> 92.0)  - (> 92.0) 358 (96.76) 473 (86.31) 
Yes < 11 (< 8.0) < 11 (< 8.0) 12 (3.24) 75 (13.69) 
Note. Any ATE = any arterial thromboembolic event (MI or IS); CVC = central venous catheter; CVD = 
cardiovascular disease (myocardial infarction, ischemic stroke, new onset congestive heart failure, angina 
or transient ischemic attack); DVT = deep vein thrombosis; IS = ischemic stroke; MI = myocardial 
infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE = venous 
thromboembolic event. 
a
 History is within the 12 months prior to the start of the period of interest. 
b
 High-risk surgery and central venous catheter were more than 30 days before outcome. Proportion is out 
of patients with the outcome. 
 
Results 
Descriptive Analysis 1 
The purpose of descriptive analysis 1 was to describe the incidence rates of 
thromboembolic events in the kidney cancer cohort in the year prior to kidney cancer 
diagnosis (Tables 8 to 14) and in the follow-up period after cancer diagnosis (Tables 15 
to 21). The incidence rates were described overall and stratified by demographic, cancer, 
and other patient characteristics. 
The year prior to kidney cancer diagnosis. The incidence rate for any VTE in 
the year prior to kidney cancer diagnosis was 35.05 per 1,000 person-years for all patients 




age at kidney cancer diagnosis, with the highest rate in the patients 85 or older. Incidence 
rates also varied by race with Black patients having incidence rates almost twice that of 
the White patients. Females had a higher incidence rate than males, 39.88 as compared to 
31.16 per 1,000 p-y, respectively. The incidence rates for any VTE were similar across 
geographic regions and year of diagnosis. Within RCC, the incidence rates were similar 
and lower than the incidence rate for transitional cell tumors. However, the incidence rate 
or 52.30 for transitional cell tumors was based on a small number of events (n = 14) and 
had a wide confidence interval (95% CI 28.60-87.76). The incidence rate ranged from 
30.04 to 36.54 for patients with Stage I to IV tumors, but was 56.11 for patients with 
unstaged or unknown stage tumors (Table 8). A history of any VTE was a major 
characteristic driving up the incidence rates overall, with a rate of 1,481 per 1,000 p-y 
compared to a rate of 20.67 per 1,000 p-y in patients without a history of any VTE in the 





Incidence Rates per 1,000 p-y for Any VTE in the Year Prior to Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 394 11,239.8 35.05 31.68-38.69 
Age at Diagnosis 66-69 54 1,911.92 28.24 21.22-36.85 
 70-74 98 3,087.67 31.74 25.77-38.68 
 75-79 101 2,806.75 35.98 29.31-43.72 
 80-84 69 2,031.17 33.97 26.43-42.99 
 85+ 72 1,402.25 51.35 40.18-64.66 
Race Black 53 862.25 61.47 46.04-80.40 
 Other/Unknown 22 769.50 28.59 17.92-43.29 
 White 319 9,608.00 33.20 29.66-37.05 
Gender Female 200 5,014.75 39.88 34.55-45.81 
 Male 194 6,225.00 31.16 26.93-35.87 
Geographic Region Midwest 51 1,424.25 35.81 26.66-47.08 
 Northeast 92 2,335.83 39.39 31.75-48.30 
 South 104 3,041.67 34.19 27.94-41.43 
 West 147 4,438.00 33.12 27.99-38.93 
Year of Diagnosis 2004 67 1,812.17 36.97 28.65-46.95 
 2005 64 1,918.92 33.35 25.69-42.59 
 2006 59 1,910.00 30.89 23.51-39.85 
 2007 76 1,956.42 38.85 30.61-48.62 
 2008 60 1,859.17 32.27 24.63-41.54 
 2009 68 1,783.08 38.14 29.61-48.35 
Histology Group Chromophobe 12 406.92 29.49 15.24-51.51 
 Clear Cell 296 8,512.58 34.77 30.92-38.97 
 Other RCC 41 1,092.58 37.53 26.93-50.91 
 Papillary 31 960.00 32.29 21.94-45.84 
 Transitional cell 
tumor 
14 267.67 52.30 28.60-87.76 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 182 5,589.17 32.56 28.00-37.65 
 Stage II 25 832.25 30.04 19.44-44.34 
 Stage III 58 1,631.75 35.54 26.99-45.95 
 Stage IV 65 2,046.00 31.77 24.52-40.49 
 Stage Unknown 64 1,140.58 56.11 43.21-71.65 
History of Condition No 230 11,129.1 20.67 18.08-23.52 
 Yes 164 110.67 1,481.93 1,263.80-1,726.89 
History of CVD No 282 9,374.50 30.08 26.67-33.81 
 Yes 112 1,865.25 60.05 49.44-72.25 
CVCa No 383 11,232.6 34.10 30.77 - 37.69 
 Yes 11 7.17 1,534.88 766.21 – 2,746.33 
High-risk Surgerya No 378 11,230.0 33.66 30.35 - 37.23 
 Yes 16 9.75 1,641.03 937.99 – 2,664.92 
Charlson Score 0 95 4,396.75 21.61 17.48-26.41 
 1 77 2,993.67 25.72 20.30-32.15 
 2 to 3 139 2,708.67 51.32 43.14-60.59 
 4+ 83 1,140.67 72.76 57.96-90.20 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); RCC = renal cell 
carcinoma; VTE = venous thromboembolic event. 
a More than 30 days before the outcome. 
 
The incidence rate for DVT in the year prior to kidney cancer diagnosis was 21.71 
per 1,000 p-y (Table 9). The pattern of rates was similar to the pattern in Table 8 for race, 
geographic region, year of diagnosis, stage, history of condition, history of CVD, and 
Charlson score. The incidence rates were similar for females 23.10 (95% CI 19.10-27.68) 
and males, 20.59 (95% CI 17.19-24.47). There were very small numbers with DVT in the 
Chromophobe and transitional cell tumors, leading to very wide confidence intervals 





Incidence Rates per 1,000 p-y for DVT in the Year Prior to Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 246 11,329.6 21.71 19.08-24.60 
Age at Diagnosis 66-69 35 1,920.92 18.22 12.69-25.34 
 70-74 62 3,108.58 19.94 15.29-25.57 
 75-79 59 2,835.58 20.81 15.84-26.84 
 80-84 39 2,049.00 19.03 13.53-26.02 
 85+ 51 1,415.50 36.03 26.83-47.37 
Race Black 38 870.67 43.64 30.89-59.91 
 Other/Unknown 14 774.25 18.08 9.89-30.34 
 White 194 9,684.67 20.03 17.31-23.06 
Gender Female 117 5,065.42 23.10 19.10-27.68 
 Male 129 6,264.17 20.59 17.19-24.47 
Geographic Region Midwest 34 1,434.67 23.70 16.41-33.12 
 Northeast 58 2,357.25 24.60 18.68-31.81 
 South 68 3,062.00 22.21 17.25-28.15 
 West 86 4,475.67 19.22 15.37-23.73 
Year of Diagnosis 2004 40 1,825.50 21.91 15.65-29.84 
 2005 47 1,930.08 24.35 17.89-32.38 
 2006 31 1,924.67 16.11 10.94-22.86 
 2007 44 1,974.58 22.28 16.19-29.91 
 2008 37 1,877.83 19.70 13.87-27.16 
 2009 47 1,796.92 26.16 19.22-34.78 
Histology Group Chromophobe < 11 - 14.61 5.36-31.79 
 Clear Cell 191 8,575.33 22.27 19.23-25.67 
 Other RCC 24 1,102.42 21.77 13.95-32.39 
 Papillary 17 969.00 17.54 10.22-28.09 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 120 5,630.50 21.31 17.67-25.48 
 Stage II 17 839.00 20.26 11.80-32.44 
 Stage III 33 1,643.00 20.09 13.83-28.21 
 Stage IV 41 2,056.17 19.94 14.31-27.05 
 Stage Unknown 35 1,160.92 30.15 21.00-41.93 
History of Condition No 159 11,259.5 14.12 12.01-16.49 
 Yes 87 70.08 1,241.38 994.29-1,531.24 
History of CVD No 168 9,440.50 17.80 15.21-20.70 
 Yes 78 1,889.08 41.29 32.64-51.53 
CVCa No 235 11,322.4 20.76 18.19 - 23.59 
 Yes 11 7.17 1,534.88 766.21 – 2,746.33 
High-risk Surgerya No 230 11,318.9 20.32 17.78 - 23.12 
 Yes 16 10.67 1,500.00 857.38 – 2,435.91 
Charlson Score 0 53 4,420.50 11.99 8.98-15.68 
 1 37 3,016.00 12.27 8.64-16.91 
 2 to 3 90 2,742.17 32.82 26.39-40.34 
 4+ 66 1,150.92 57.35 44.35-72.96 
Note. Numbers less than 11 and the associated person-years have been suppressed. 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); DVT = deep vein 
thrombosis; RCC = renal cell carcinoma. 
a More than 30 days before the outcome. 
The incidence rate for pulmonary embolism in the year prior to kidney cancer 
diagnosis was 7.88 per 1,000 p-y (Table 10). There were a small number of patients with 
the outcome in many categories making patterns and differences between groups difficult 
to distinguish. Blacks and females had incidence rates approximately twice that of their 
reference groups. In the two histology groups with 11 or more patients with pulmonary 
embolism, clear cell carcinoma and other RCC, the incidence rates were similar - 7.98 
(95% CI 6.21 – 10.10) and 9.91 (95% CI 4.95 – 17.73), respectively. Incidence rates were 





Incidence Rates per 1,000 p-y for PE in the Year Prior to Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 90 11,417.2 7.88 6.34-9.69 
Age at Diagnosis 66-69 19 1,931.17 9.84 5.92-15.36 
 70-74 17 3,130.33 5.43 3.16-8.70 
 75-79 22 2,854.58 7.71 4.83-11.67 
 80-84 16 2,063.58 7.75 4.43-12.59 
 85+ 16 1,437.50 11.13 6.36-18.08 
Race Black - - 15.85 8.67-26.60 
 Other/Unknown < 11 - 5.12 1.40-13.11 
 White 72 9,752.92 7.38 5.78-9.30 
Gender Female 56 5,102.00 10.98 8.29-14.25 
 Male 34 6,315.17 5.38 3.73-7.52 
Geographic Region Midwest < 11 - 4.84 1.94-9.96 
 Northeast - - 8.84 5.47-13.52 
 South - - 7.11 4.46-10.77 
 West 40 4,502.33 8.88 6.35-12.10 
Year of Diagnosis 2004 14 1,838.67 7.61 4.16-12.78 
 2005 - - 5.64 2.82-10.10 
 2006 < 11 - 5.16 2.48-9.49 
 2007 17 1,994.25 8.52 4.97-13.65 
 2008 19 1,884.67 10.08 6.07-15.74 
 2009 19 1,813.75 10.48 6.31-16.36 
Histology Group Chromophobe < 11 - 4.85 0.59-17.51 
 Clear Cell 69 8,644.75 7.98 6.21-10.10 
 Other RCC 11 1,109.83 9.91 4.95-17.73 
 Papillary < 11 - 7.19 2.89-14.82 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 53 5,668.50 9.35 7.00-12.23 
 Stage II < 11 - 5.92 1.92-13.81 
 Stage III < 11 - 5.43 2.48-10.31 
 Stage IV < 11 - 4.34 1.98-8.23 
 Stage Unknown 14 1,171.33 11.95 6.53-20.05 
History of Condition No 63 11,402.4 5.53 4.25-7.07 
 Yes 27 14.75 1,830.51 1,206.32-2,663.29 
History of CVD No 66 9,494.75 6.95 5.38-8.84 
 Yes 24 1,922.42 12.48 8.00-18.58 
CVCa No - - 7.71 6.18 - 9.50 
 Yes < 11 - 1,500.00 181.66 – 5,418.52 
High-risk Surgerya No - - 7.62 6.10 - 9.40 
 Yes < 11 - 1,440.00 296.96 – 4,208.29 
Charlson Score 0 18 4,437.58 4.06 2.40-6.41 
 1 23 3,024.00 7.61 4.82-11.41 
 2 to 3 32 2,778.25 11.52 7.88-16.26 
 4+ 17 1,177.33 14.44 8.41-23.12 
Note. Numbers less than 11 and the associated person-years have been suppressed. 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); PE = pulmonary embolism; 
RCC = renal cell carcinoma. 
a More than 30 days before the outcome. 
 
More kidney cancer patients had a diagnosis of other VTE than pulmonary 
embolism, still some of the subgroups had very small counts (Table 11). The incidence 
rate of other VTE was 11.33 per 1,000 p-y. The incidence rate for patients 66 to 69 at 
diagnosis was 7.25, with higher rates for older patients at diagnosis, but there was no 
apparent trend at the older ages. There were small numbers in nonwhite patients but the 
rates appear similar for each group. Similarly, there were small numbers of patients with 
the outcome for the chromophobe and transitional cell tumor patients. The incidence rates 




males, patients with history of other VTE or history of CVD, and increased with 










n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 129 11,385.9 11.33 9.46-13.46 
Age at Diagnosis 66-69 14 1,930.92 7.25 3.96-12.17 
 70-74 39 3,118.33 12.51 8.89-17.10 
 75-79 37 2,841.83 13.02 9.17-17.95 
 80-84 22 2,060.58 10.68 6.69-16.16 
 85+ 17 1,434.25 11.85 6.90-18.98 
Race Black < 11 - 10.14 4.63-19.24 
 Other/Unknown < 11 - 9.00 3.62-18.53 
 White 113 9,719.83 11.63 9.58-13.98 
Gender Female 69 5,090.67 13.55 10.55-17.15 
 Male 60 6,295.25 9.53 7.27-12.27 
Geographic Region Midwest 16 1,440.58 11.11 6.35-18.04 
 Northeast 35 2,369.00 14.77 10.29-20.55 
 South 31 3,084.50 10.05 6.83-14.27 
 West 47 4,491.83 10.46 7.69-13.91 
Year of Diagnosis 2004 27 1,832.33 14.74 9.71-21.44 
 2005 19 1,944.50 9.77 5.88-15.26 
 2006 24 1,925.17 12.47 7.99-18.55 
 2007 27 1,985.25 13.60 8.96-19.79 
 2008 18 1,884.08 9.55 5.66-15.10 
 2009 14 1,814.58 7.72 4.22-12.94 
Histology Group Chromophobe < 11 - 14.66 5.38-31.91 
 Clear Cell 91 8,623.50 10.55 8.50-12.96 
 Other RCC 14 1,108.50 12.63 6.90-21.19 
 Papillary 11 970.92 11.33 5.66-20.27 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 50 5,668.92 8.82 6.55-11.63 
 Stage II < 11 - 8.31 3.34-17.12 
 Stage III 24 1,645.25 14.59 9.35-21.70 
 Stage IV 25 2,066.25 12.10 7.83-17.86 
 Stage Unknown -  - 19.78 12.54-29.68 
History of Condition No 61 11,339.7 5.38 4.11-6.91 
 Yes 68 46.25 1,470.27 1,141.72-1,863.92 
History of CVD No 100 9,467.25 10.56 8.59-12.85 
 Yes 29 1,918.67 15.11 10.12-21.71 
CVCa No - - 11.16 9.30 - 13.27 
 Yes < 11 - 1,263.16 152.97 – 4,562.96 
High-risk Surgerya No - - 10.81 8.98 - 12.89 
 Yes < 11 - 1,674.42 614.48 – 3,644.50 
Charlson Score 0 35 4,425.25 7.91 5.51-11.00 
 1 30 3,019.92 9.93 6.70-14.18 
 2 to 3 47 2,762.42 17.01 12.50-22.63 
 4+ 17 1,178.33 14.43 8.40-23.10 
Note. Numbers less than 11 and the associated person-years have been suppressed. Cells with numbers 
greater than 11 are also suppressed so that the counts for other cells cannot be derived. 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); Other VTE = other venous 
thromboembolic event; RCC = renal cell carcinoma. 
a More than 30 days before the outcome. 
 
The incidence rate for any ATE (myocardial infarction or ischemic stroke) in the 
year prior to kidney cancer diagnosis was 31.32 per 1,000 person-years (Table 12). With 
wide confidence intervals, there was no clear trend due to age, year of diagnosis, or stage. 
However, patients with unknown stage appeared to have higher incidence rates of any 
ATE than patients whose tumors were staged at diagnosis. The incidence rates were 
similar for Black and White patients, but lower for those with other or unknown race. The 
rate for males was higher than the incidence rate for females. Incidence rates were lowest 




increased with increasing Charlson score, with history of any ATE, history of CVD, 
recent placement of a CVC, and recent high-risk surgery. The incidence rates for the four 
RCC histology groups (range 25.92 to 41.02) and these rates were not different than the 
rate for transitional cell tumors, 29.15. However, the confidence intervals for the 





Incidence Rates per 1,000 p-y for Any ATE in the Year Prior to Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 354 11,303.5 31.32 28.14 - 34.76 
Age at Diagnosis 66-69 40 1,921.25 20.82 14.87 - 28.35  
 70-74 83 3,104.33 26.74 21.30 - 33.14 
 75-79 104 2,818.75 36.90 30.15 - 44.71 
 80-84 68 2,041.08 33.32 25.87 - 42.24  
 85+ 59 1,418.08 41.61 31.67 - 53.67  
Race Black 31 879.33 35.25 23.95 - 50.04 
 Other/Unknown 19 775.83 24.49 14.74 - 38.24 
 White 304 9,648.33 31.51 28.07 - 35.26 
Gender Female 141 5,066.42 27.83 23.43 - 32.82 
 Male 213 6,237.08 34.15 29.72 - 39.06 
Geographic Region Midwest 60 1,425.83 42.08 32.11 - 54.17 
 Northeast 83 2,351.00 35.30 28.12 - 43.76 
 South 99 3,056.75 32.39 26.32 - 39.43 
 West 112 4,469.92 25.06 20.63 - 30.15 
Year of Diagnosis 2004 54 1,819.17 29.68 22.30 - 38.73 
 2005 61 1,925.58 31.68 24.23 - 40.69 
 2006 61 1,912.75 31.89 24.39 - 40.97 
 2007 53 1,975.83 26.82 20.09 - 35.09 
 2008 63 1,871.50 33.66 25.87 - 43.07 
 2009 62 1,798.67 34.47 26.43 - 44.19 
Histology Group Chromophobe -  - 26.96 13.46 - 48.23 
 Clear Cell 265 8,559.67 30.96 27.34 - 34.92 
 Other RCC 45 1,097.00 41.02 29.92 - 54.89 
 Papillary 25 964.33 25.92 16.78 - 38.27 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 178 5,624.42 31.65 27.17 - 36.65 
 Stage II 23 836.92 27.48 17.42 - 41.24 
 Stage III 42 1,639.17 25.62 18.47 - 34.63 
 Stage IV 55 2,052.00 26.80 20.19 - 34.89 
 Stage Unknown 56 1,151.00 48.65 36.75 - 63.18  
History of Condition No 309 1,1097.4 27.84 24.83 - 31.13 
 Yes 45 206.08 218.36 159.27 - 292.18 
History of CVD No 249 9,791.08 25.43 22.37 - 28.79 
 Yes 105 1,512.42 69.43 56.78 - 84.04 
CVCa No - - 30.54 27.40 - 33.94 
 Yes  < 11  - 1,421.05 649.80 -2,697.60  
High-risk Surgerya No 339 11,293.9 30.02 26.91 - 33.39 
 Yes 15 9.58 1,565.22 876.04 – 2,581.59  
Charlson Score 0 57 5,246.42 10.86 8.23 - 14.08 
 1 85 3,147.00 27.01 21.57 - 33.40 
 2 to 3 141 2,268.42 62.16 52.32 - 73.31 
 4+ 71 641.67 110.65 86.42 - 139.57 
Note. Numbers less than 11 and the associated person-years have been suppressed. Cells with numbers 
greater than 11 are also suppressed so that the counts for other cells cannot be derived. 
Note. Any ATE = any arterial thromboembolic event (MI or IS); CVC = central venous catheter; CVD = 
cardiovascular disease (myocardial infarction, ischemic stroke, new onset congestive heart failure, angina 
or transient ischemic attack); IS = ischemic stroke; MI = myocardial infarction; RCC = renal cell 
carcinoma. 
a More than 30 days before the outcome. 
 
The incidence rate for myocardial infarction in the year prior to kidney cancer 
diagnosis was 16.88 per 1,000 person-years (Table 13). The incidence rates were higher 
for patients 70 years or older at diagnosis than patients 66 to 69 years of age. The 
incidence rates were similar for Black and White patients, but less for those with other or 
unknown race. The incidence rates were higher for males than females. There was no 
clear trend in rates for geographic region, year of diagnosis, or histology group. The 




infarction and with history of CVD. The rates were similar for the RCC histology groups, 
but the confidence intervals were very wide. The numbers of patients with myocardial 





Incidence Rates per 1,000 p-y for MI in the Year Prior to Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 192 11,373.8 16.88 14.58-19.44 
Age at Diagnosis 66-69 18 1,931.08 9.32 5.52-14.73 
 70-74 52 3,117.92 16.68 12.46-21.87 
 75-79 50 2,842.83 17.59 13.05-23.19 
 80-84 40 2,052.42 19.49 13.92-26.54 
 85+ 32 1,429.58 22.38 15.31-31.60 
Race Black - - 15.79 8.63-26.49 
 Other/Unknown < 11 - 12.83 6.15-23.60 
 White 168 9,707.83 17.31 14.79-20.13 
Gender Female 72 5,095.58 14.13 11.06-17.79 
 Male 120 6,278.25 19.11 15.85-22.86 
Geographic Region Midwest 24 1,441.67 16.65 10.67-24.77 
 Northeast 48 2,364.67 20.30 14.97-26.91 
 South 53 3,078.25 17.22 12.90-22.52 
 West 67 4,489.25 14.92 11.57-18.95 
Year of Diagnosis 2004 33 1,827.42 18.06 12.43-25.36 
 2005 28 1,940.25 14.43 9.59-20.86 
 2006 33 1,923.75 17.15 11.81-24.09 
 2007 27 1,988.50 13.58 8.95-19.76 
 2008 36 1,883.58 19.11 13.39-26.46 
 2009 35 1,810.33 19.33 13.47-26.89 
Histology Group Chromophobe < 11 - 19.53 8.43-38.49 
 Clear Cell 144 8,614.33 16.72 14.10-19.68 
 Other RCC 20 1,105.25 18.10 11.05-27.95 
 Papillary 14 969.67 14.44 7.89-24.22 
 Transitional cell 
tumor 








n Person-Years Incidence 
Rate  
95% CI 
Stage at Diagnosis Stage I 101 5,656.33 17.86 14.54-21.70 
 Stage II 13 840.17 15.47 8.24-26.46 
 Stage III 19 1,649.58 11.52 6.93-17.99 
 Stage IV 23 2,067.92 11.12 7.05-16.69 
 Stage Unknown 36 1,159.83 31.04 21.74-42.97 
History of Condition No 159 11,267.5 14.11 12.00-16.48 
 Yes 33 106.33 310.34 213.63-435.84 
History of CVD No 110 9,478.75 11.60 9.54-13.99 
 Yes 82 1,895.08 43.27 34.41-53.71 
CVCa No - - 75.32 70.28 - 80.64 
 Yes < 11 - 1,523.81 657.87 – 3,002.51 
High-risk Surgerya No 809 10,970.1 73.75 68.75 - 79.01 
 Yes 26 14.42 1,803.47 1,178.09 – 2,642.50 
Charlson Score 0 12 4,439.75 2.70 1.40-4.72 
 1 35 3,018.92 11.59 8.08-16.12 
 2 to 3 75 2,762.17 27.15 21.36-34.04 
 4+ 70 1,153.00 60.71 47.33-76.70 
Note. Numbers less than 11 and the associated person-years have been suppressed. Cells with numbers 
greater than 11 are also suppressed so that the counts for other cells cannot be derived. 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); MI = myocardial infarction; 
RCC = renal cell carcinoma. 
a More than 30 days before the outcome. 
 
The incidence rate for ischemic stroke in the year prior to kidney cancer diagnosis 
was 15.19per 1,000 person-years (Table 14). There was no clear trend in incidence rates 
for age at diagnosis, gender, year of diagnosis, or stage at diagnosis. The incidence rates 
increased with increasing Charlson comorbidity score and were higher in patients with 
history of ischemic stroke, history of CVD, recent placement of CVC, and recent high-
risk surgery. Incidence rates appeared higher for regions other than the West and for the 





Incidence Rates per 1,000 p-y for IS in the Year Prior to Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 173 11,389.9 15.19 13.01 - 17.63 
Age at Diagnosis 66-69 23 1,928.83 11.92 7.56 - 17.89 
 70-74 34 3,124.33 10.88 7.54 - 15.21 
 75-79 56 2,842.75 19.70 14.88 - 25.58 
 80-84 30 2,061.08 14.56 9.82 - 20.78 
 85+ 30 1,432.92 20.94 14.13 - 29.89 
Race Black - - 19.21 11.19 - 30.76 
 Other/Unknown < 11 - 11.55 5.28 - 21.92 
 White 147 9,725.75 15.11 12.77 - 17.76 
Gender Female 73 5,101.08 14.31 11.22 - 17.99 
 Male 100 6,288.83 15.90 12.94 - 19.34 
Geographic Region Midwest 38 1,434.50 26.49 18.75 - 36.36 
 Northeast 38 2,373.83 16.01 11.33 - 21.97 
 South 49 3,079.83 15.91 11.77 - 21.03 
 West 48 4,501.75 10.66 7.86 - 14.14 
Year of Diagnosis 2004 22 1,836.67 11.98 7.51 - 18.14 
 2005 33 1,941.33 17.00 11.70 - 23.87 
 2006 30 1,928.42 15.56 10.50 - 22.21 
 2007 27 1,989.08 13.57 8.95 - 19.75 
 2008 34 1,882.08 18.07 12.51 - 25.24 
 2009 27 1,812.33 14.90 9.82 - 21.68 
Histology Group Chromophobe  < 11  - 7.29 1.50 - 21.31 
 Clear Cell 129 8,621.08 14.96 12.49 - 17.78 
 Other RCC 26 1,108.67 23.45 15.32 - 34.36 
 Papillary 13 971.25 13.38 7.13 - 22.89 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 81 5,667.33 14.29 11.35 - 17.76 
 Stage II  < 11  - 11.84 5.68 - 21.77 
 Stage III 25 1,647.08 15.18 9.82 - 22.41 
 Stage IV 34 2,061.25 16.49 11.42 - 23.05 
 Stage Unknown -  - 19.67 12.47 - 29.51 
History of Condition No -  - 14.54 12.40 - 16.94 
 Yes  < 11  - 83.46 38.16 - 158.44 
History of CVD No 135 9,839.83 13.72 11.50 - 16.24 
 Yes 38 1,550.08 24.51 17.35 - 33.65 
CVCa No -  - 14.93 12.77 - 17.35 
 Yes  < 11  - 1,800.00 371.20 – 5,260.36 
High-risk Surgerya No  -  - 14.49 12.37 - 16.88 
 Yes  < 11  - 1,811.32 782.00 – 3,569.02 
Charlson Score 0 35 5,258.33 6.66 4.64 - 9.26 
 1 44 3,167.75 13.89 10.09 - 18.65 
 2 to 3 65 2,302.33 28.23 21.79 - 35.98 
 4+ 29 661.50 43.84 29.36 - 62.96 
Note. Numbers less than 11 and the associated person-years have been suppressed. Cells with numbers 
greater than 11 are also suppressed so that the counts for other cells cannot be derived. 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); IS = ischemic stroke; RCC 
= renal cell carcinoma. 
a More than 30 days before the outcome. 
 
The follow-up period after kidney cancer diagnosis. In the follow-up period 
after cancer diagnosis, the incidence rate for any VTE was 53.00 per 1,000 p-y (Table 
15). The incidence rates increased with increasing age, year of diagnosis, stage at 
diagnosis, and increasing Charlson score. The rates were higher in patients who were 
Black, female, treated with chemotherapy, treated with immunotherapy, history of any 
VTE, and history of CVD. Patients treated with nephrectomy had lower incidence rates 




treatment indicated for lower stage tumors. Lower stage tumors had lower incidence rates 
than higher staged tumors. The incidence rates were highest in the Northeast and South, 
followed by the Midwest and West region. Incidence rates also differed by histology 
group. The incidence rates were highest in the patients with other RCC (76.03, 95% CI 
63.52-90.17), followed by transitional cell tumors (64.37, 95% CI 43.74-91.37), clear cell 
tumors (53.13, 95% CI 50.02-56.39), papillary (43.88, 95% CI 36.17- 52.76), and 
chromophobe (33.39, 95% CI 24.07-45.14). However, some of the histology groups have 






Incidence Rates per 1,000 p-y for Any VTE After Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 1,402 26,452.7 53.00 50.26 -55.85 
Age at Diagnosis 66-69 224 5,148.58 43.51 38.00 -49.59 
 70-74 394 7,965.67 49.46 44.70 -54.60 
 75-79 364 6,979.50 52.15 46.93 -57.80 
 80-84 255 4,247.00 60.04 52.90 -67.88 
 85+ 165 2,112.00 78.13 66.66 -91.00 
Race Black 138 1,813.33 76.10 63.94 -89.91 
 Other/Unknown 78 1,799.25 43.35 34.27 -54.10 
 White 1,186 22,840.2 51.93 49.01 -54.97 
Gender Female 676 11,840.2 57.09 52.87 -61.56 
 Male 726 14,612.5 49.68 46.13 -53.43 
Geographic Region Midwest 175 3,354.25 52.17 44.73 -60.50 
 Northeast 346 5,881.83 58.83 52.79 -65.36 
 South 379 6,860.00 55.25 49.82 -61.10 
 West 502 10,356.7 48.47 44.32 -52.90 
Year of Diagnosis 2004 266 6,239.17 42.63 37.66 -48.08 
 2005 254 5,703.83 44.53 39.22 -50.36 
 2006 249 5,076.58 49.05 43.15 -55.53 
 2007 233 4,366.42 53.36 46.73 -60.67 
 2008 213 3,112.92 68.42 59.54 -78.26 
 2009 187 1,953.83 95.71 82.48 -110.45 
Histology Group Chromophobe 42 1,257.75 33.39 24.07 -45.14 
 Clear Cell 1,084 20,402.3 53.13 50.02 -56.39 
 Other RCC 132 1,736.08 76.03 63.62 -90.17 
 Papillary 113 2,575.08 43.88 36.17 -52.76 
 Transitional cell 
tumor 







n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 550 16,442.3 33.45 30.71 -36.37 
 Stage II 88 2,364.33 37.22 29.85 -45.86 
 Stage III 328 3,802.75 86.25 77.17 -96.11 
 Stage IV 301 1,709.17 176.11 156.77 -197.17 
 Stage Unknown 135 2,134.25 63.25 53.03 -74.87 
Chemotherapy No 977 21,267.8 45.94 43.10 -48.91 
 Yes 425 5,185.00 81.97 74.36 -90.14 
Immunotherapy No 1,303 25,332.5 51.44 48.68 -54.31 
 Yes 99 1,120.25 88.37 71.83 -107.59 
Nephrectomy No 400 5,147.08 77.71 70.28 -85.72 
 Yes 1,002 21,305.7 47.03 44.16 -50.03 
History of Condition No 1,119 26,177.2 42.75 40.28 -45.33 
 Yes 283 275.50 1,027.22 911.02 -1,154.14 
History of CVD No 1,045 21,328.6 49.00 46.07 -52.06 
 Yes 357 5,124.17 69.67 62.63 -77.29 
CVCa No 1,229 26,147.7 47.00 44.41 - 49.71 
 Yes 173 305.08 567.06 485.71 - 658.14 
High-risk Surgerya No 1,264 26,193.1 48.26 45.63 - 50.99 
 Yes 138 259.67 531.45 446.48 - 627.88 
Charlson Score 0 193 4,777.17 40.40 34.90 -46.52 
 1 210 4,435.75 47.34 41.16 -54.20 
 2 to 3 458 9,258.92 49.47 45.04 -54.21 
 4+ 541 7,980.92 67.79 62.19 -73.75 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); RCC = renal cell 
carcinoma; VTE = venous thromboembolic event. 
a More than 30 days before the outcome. 
 
The incidence rate for DVT in the follow-up period after kidney cancer diagnosis 
was 35.56 per 1,000 p-y (Table 16). The incidence rates followed similar patterns as for 
any VTE. Unlike in the period prior to cancer diagnosis (Table 9), incidence increased 





Incidence Rates per 1,000 p-y for DVT After Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 972 27,336.6 35.56 33.36 -37.86 
Age at Diagnosis 66-69 144 5,313.08 27.10 22.86 -31.91 
 70-74 277 8,223.42 33.68 29.83 -37.89 
 75-79 236 7,265.50 32.48 28.47 -36.90 
 80-84 197 4,348.33 45.30 39.20 -52.09 
 85+ 118 2,186.25 53.97 44.68 -64.64 
Race Black 106 1,882.25 56.32 46.11 -68.11 
 Other/Unknown 47 1,869.50 25.14 18.47 -33.43 
 White 819 23,584.8 34.73 32.39 -37.19 
Gender Female 463 12,306.0 37.62 34.27 -41.21 
 Male 509 15,030.6 33.86 30.99 -36.94 
Geographic Region Midwest 128 3,463.00 36.96 30.84 -43.95 
 Northeast 248 6,097.83 40.67 35.77 -46.06 
 South 262 7,093.25 36.94 32.60 -41.69 
 West 334 10,682.5 31.27 28.00 -34.81 
Year of Diagnosis 2004 181 6,482.50 27.92 24.00 -32.30 
 2005 196 5,846.83 33.52 28.99 -38.56 
 2006 172 5,282.67 32.56 27.88 -37.81 
 2007 161 4,506.83 35.72 30.42 -41.69 
 2008 142 3,210.17 44.23 37.26 -52.14 
 2009 120 2,007.58 59.77 49.56 -71.47 
Histology Group Chromophobe 27 1,308.17 20.64 13.60 -30.03 
 Clear Cell 750 21,059.0 35.61 33.11 -38.26 
 Other RCC 90 1,794.50 50.15 40.33 -61.65 
 Papillary 80 2,681.00 29.84 23.66 -37.14 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 374 16,879.8 22.16 19.97 -24.52 
 Stage II 64 2,414.08 26.51 20.42 -33.85 
 Stage III 224 4,048.00 55.34 48.33 -63.08 
 Stage IV 220 1,770.83 124.24 108.36 -141.78 
 Stage Unknown 90 2,223.92 40.47 32.54 -49.74 
Chemotherapy No 666 21,907.9 30.40 28.13 -32.80 
 Yes 306 5,428.67 56.37 50.23 -63.05 
Immunotherapy No 909 26,121.1 34.80 32.57 -37.14 
 Yes 63 1,215.50 51.83 39.83 -66.31 
Nephrectomy No 295 5,262.67 56.06 49.84 -62.83 
 Yes 677 22,073.9 30.67 28.40 -33.07 
History of Condition No 803 27,165.9 29.56 27.55 -31.68 
 Yes 169 170.67 990.23 846.57 -1,151.30 
History of CVD No 703 22,032.9 31.91 29.59 -34.36 
 Yes 269 5,303.67 50.72 44.84 -57.16 
CVCa No 826 2,7074.4 30.51 28.46 - 32.66 
 Yes 146 262.17 556.90 470.23 - 654.91 
High-risk Surgerya No 856 27,127.7 31.55 29.48 - 33.74 
 Yes 116 208.83 555.47 458.99 - 666.23 
Charlson Score 0 122 4,908.50 24.85 20.64 -29.68 
 1 132 4,571.75 28.87 24.16 -34.24 
 2 to 3 314 9,551.00 32.88 29.34 -36.72 
 4+ 404 8,305.33 48.64 44.02 -53.63 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); DVT = deep vein 
thrombosis; RCC = renal cell carcinoma. 
a More than 30 days before the outcome. 
 
The incidence rate for pulmonary embolism in the follow-up period after kidney 
cancer diagnosis was 13.58 per 1,000 p-y (Table 17). There was no consistent trend in 
incidence rates by age at diagnosis or geographic region. Incidence rates increased with 




higher in Black patients, females, patients treated with chemotherapy or immunotherapy, 
history of pulmonary embolism, and history of CVD. Patients treated with nephrectomy 
had lower rates of pulmonary embolism. Less than 11 patients with chromophobe or 
transitional cell tumors had pulmonary embolism and so the incidence rates had very 
wide confidence intervals. The incidence rates for the other histology groups ranged from 
13.77 to 19.26, with overlapping confidence intervals. 
Unlike the year prior to cancer diagnosis (Table 10), the incidence rates for 
pulmonary embolism in females (14.88, 95% CI 12.84-17.15) was only slightly larger 
than the incidence rate for males (12.52, 95% CI 10.83-14.40) in the period after cancer 





Incidence Rates per 1,000 p-y for PE After Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 386 28,421.4 13.58 12.26 -15.01 
Age at Diagnosis 66-69 84 5,425.33 15.48 12.35 -19.17 
 70-74 114 8,554.08 13.33 10.99 -16.01 
 75-79 96 7,514.08 12.78 10.35 -15.60 
 80-84 48 4,634.33 10.36 7.64 -13.73 
 85+ 44 2,293.58 19.18 13.94 -25.75 
Race Black 34 2,024.92 16.79 11.63 -23.46 
 Other/Unknown 16 1,926.08 8.31 4.75 -13.49 
 White 336 24,470.4 13.73 12.30 -15.28 
Gender Female 190 12,768.9 14.88 12.84 -17.15 
 Male 196 15,652.5 12.52 10.83 -14.40 
Geographic Region Midwest 52 3,599.50 14.45 10.79 -18.94 
 Northeast 92 6,384.08 14.41 11.62 -17.67 
 South 94 7,396.50 12.71 10.27 -15.55 
 West 148 11,041.3 13.40 11.33 -15.75 
Year of Diagnosis 2004 63 6,759.33 9.32 7.16 -11.92 
 2005 61 6,166.33 9.89 7.57 -12.71 
 2006 83 5,471.83 15.17 12.08 -18.80 
 2007 56 4,670.17 11.99 9.06 -15.57 
 2008 67 3,288.83 20.37 15.79 -25.87 
 2009 56 2,064.92 27.12 20.49 -35.22 
Histology Group Chromophobe < 11 - 5.17 2.08 -10.64 
 Clear Cell 302 21,932.6 13.77 12.26 -15.41 
 Other RCC 36 1,868.75 19.26 13.49 -26.67 
 Papillary 38 2,749.25 13.82 9.78 -18.97 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 163 17,349.6 9.40 8.01 -10.95 
 Stage II 30 2,489.00 12.05 8.13 -17.21 
 Stage III 67 4,364.83 15.35 11.90 -19.49 
 Stage IV 98 1,876.33 52.23 42.40 -63.65 
 Stage Unknown 28 2,341.67 11.96 7.95 -17.28 
Chemotherapy No 253 22,681.8 11.15 9.82 -12.62 
 Yes 133 5,739.58 23.17 19.40 -27.46 
Immunotherapy No 357 27,151.0 13.15 11.82 -14.59 
 Yes 29 1,270.42 22.83 15.29 -32.78 
Nephrectomy No 112 5,469.00 20.48 16.86 -24.64 
 Yes 274 22,952.4 11.94 10.57 -13.44 
History of Condition No 325 28,346.2 11.47 10.25 -12.78 
 Yes 61 75.25 810.63 620.07 -1,041.29 
History of CVD No 289 22,785.3 12.68 11.26 -14.23 
 Yes 97 5,636.08 17.21 13.96 -21.00 
CVCa No 329 28,326.7 11.61 10.39 - 12.94 
 Yes 57 94.75 601.58 455.63 - 779.42 
High-risk Surgerya No 339 28,338.7 11.96 10.72 - 13.31 
 Yes 47 82.75 567.98 417.33 - 755.29 
Charlson Score 0 47 4,989.75 9.42 6.92 -12.53 
 1 56 4,682.00 11.96 9.03 -15.53 
 2 to 3 128 9,893.42 12.94 10.79 -15.38 
 4+ 155 8,856.25 17.50 14.85 -20.48 
Note. Numbers less than 11 and the associated person-years have been suppressed. 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); PE = pulmonary embolism; 
RCC = renal cell carcinoma. 
a More than 30 days before the outcome. 
 
The incidence rates for other VTE in the period after kidney cancer diagnosis was 
13.35 per 1,000 p-y (Table 18). There was no clear trend in incidence rates for age at 
diagnosis, race, gender, treatment with nephrectomy, history of CVD, or Charlson score; 
however, some of the groups had very wide confidence intervals. The incidence rates 




other RCC, diagnosed with Stage III or IV kidney cancer, treated with chemotherapy or 





Incidence Rates per 1,000 p-y for Other VTE After Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 378 28,321.7 13.35 12.03 -14.76 
Age at Diagnosis 66-69 58 5,461.00 10.62 8.06 -13.73 
 70-74 106 8,495.67 12.48 10.22 -15.09 
 75-79 117 7,480.17 15.64 12.94 -18.75 
 80-84 58 4,611.67 12.58 9.55 -16.26 
 85+ 39 2,273.25 17.16 12.20 -23.45 
Race Black 27 2,039.83 13.24 8.72 -19.26 
 Other/Unknown 26 1,886.42 13.78 9.00 -20.19 
 White 325 24,395.5 13.32 11.91 -14.85 
Gender Female 179 12,755.5 14.03 12.05 -16.25 
 Male 199 15,566.3 12.78 11.07 -14.69 
Geographic Region Midwest 32 3,661.58 8.74 5.98 -12.34 
 Northeast 105 6,326.33 16.60 13.57 -20.09 
 South 100 7,355.17 13.60 11.06 -16.54 
 West 141 10,978.7 12.84 10.81 -15.15 
Year of Diagnosis 2004 76 6,677.08 11.38 8.97 -14.25 
 2005 61 6,182.00 9.87 7.55 -12.68 
 2006 70 5,454.75 12.83 10.00 -16.21 
 2007 61 4,654.67 13.11 10.02 -16.83 
 2008 62 3,294.92 18.82 14.43 -24.12 
 2009 48 2,058.33 23.32 17.19 -30.92 
Histology Group Chromophobe < 15 - 9.74 5.19 -16.66 
 Clear Cell 297 21,862.8 13.58 12.08 -15.22 
 Other RCC 33 1,853.92 17.80 12.25 -25.00 
 Papillary 29 2,761.33 10.50 7.03 -15.08 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 131 17,407.8 7.53 6.29 -8.93 
 Stage II 19 2,491.42 7.63 4.59 -11.91 
 Stage III 123 4,223.50 29.12 24.20 -34.75 
 Stage IV 59 1,899.42 31.06 23.65 -40.07 
 Stage Unknown 46 2,299.67 20.00 14.64 -26.68 
Chemotherapy No 263 22,640.4 11.62 10.25 -13.11 
 Yes 115 5,681.33 20.24 16.71 -24.30 
Immunotherapy No 342 27,085.6 12.63 11.32 -14.04 
 Yes 36 1,236.17 29.12 20.40 -40.32 
Nephrectomy No 81 5,481.67 14.78 11.73 -18.37 
 Yes 297 22,840.1 13.00 11.57 -14.57 
History of Condition No 297 28,178.1 10.54 9.38 -11.81 
 Yes 81 143.67 563.81 447.74 -700.76 
History of CVD No 306 22,664.0 13.50 12.03 -15.10 
 Yes 72 5,657.75 12.73 9.96 -16.03 
CVCa No 331 28,241.1 11.72 10.49 - 13.05 
 Yes 47 80.67 582.64 428.11 - 774.79 
High-risk Surgerya No 333 28,239.4 11.79 10.56 - 13.13 
 Yes 45 82.33 546.56 398.66 - 731.34 
Charlson Score 0 57 4,957.83 11.50 8.71 -14.90 
 1 66 4,676.50 14.11 10.92 -17.96 
 2 to 3 131 9,808.17 13.36 11.17 -15.85 
 4+ 124 8,879.25 13.97 11.62 -16.65 
Note. Numbers less than 11 and the associated person-years have been suppressed. Additional cells were 
suppressed where necessary so that the number in an individual cell with counts less than 11 could not be 
determined. 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); Other VTE = other venous 
thromboembolic event; RCC = renal cell carcinoma. 
a More than 30 days before the outcome. 
 
The incidence rate for any ATE in the period after kidney cancer diagnosis was 
39.68 per 1,000 p-y (Table 19). Incidence rates increased with increasing age at diagnosis 




diagnosed outside of the West geographic region, diagnosed with Stage IV or unknown 
stage, with other RCC, not treated with nephrectomy, with history of any ATE, history of 
CVD, placement of CVC, and high-risk surgery. There was no clear difference in rates 






Incidence Rates per 1,000 p-y for Any ATE After Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 1,083 27,290.4 39.68 37.36 - 42.12 
Age at Diagnosis 66-69 151 5,277.75 28.61 24.23 - 33.56 
 70-74 272 8,267.58 32.90 29.11 - 37.05 
 75-79 309 7,164.67 43.13 38.45 - 48.22 
 80-84 209 4,381.58 47.70 41.45 - 54.62 
 85+ 142 2,198.83 64.58 54.39 - 76.12 
Race Black 108 1,944.50 55.54 45.56 - 67.06 
 Other/Unknown 58 1,865.42 31.09 23.61 - 40.19 
 White 917 23,480.5 39.05 36.57 - 41.67 
Gender Female 482 12,337.2 39.07 35.66 - 42.72 
 Male 601 14,953.3 40.19 37.04 - 43.54 
Geographic Region Midwest 150 3,484.08 43.05 36.44 - 50.52 
 Northeast 263 6,054.25 43.44 38.35 - 49.02 
 South 306 7,055.83 43.37 38.64 - 48.51 
 West 364 10,696.3 34.03 30.62 - 37.71 
Year of Diagnosis 2004 231 6,364.50 36.30 31.77 - 41.29 
 2005 235 5,839.00 40.25 35.27 - 45.73 
 2006 203 5,297.08 38.32 33.23 - 43.97 
 2007 161 4,545.58 35.42 30.16 - 41.33 
 2008 148 3,225.25 45.89 38.79 - 53.90 
 2009 105 2,019.00 52.01 42.54 - 62.96 
Histology Group Chromophobe 44 1,305.67 33.70 24.49 - 45.24 
 Clear Cell 840 20,989.0 40.02 37.36 - 42.82 
 Other RCC 92 1,801.83 51.06 41.16 - 62.62 
 Papillary 88 2,702.50 32.56 26.12 - 40.12 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 581 16,625.3 34.95 32.16 - 37.91 
 Stage II 92 2,395.67 38.40 30.96 - 47.10 
 Stage III 160 4,203.92 38.06 32.39 - 44.44 
 Stage IV 122 1,866.58 65.36 54.28 - 78.04 
 Stage Unknown 128 2,199.00 58.21 48.56 - 69.21 
Chemotherapy No 871 21,709.5 40.12 37.50 - 42.88 
 Yes 212 5,580.92 37.99 33.04 - 43.46 
Immunotherapy No 1,040 26,059.9 39.91 37.52 - 42.41 
 Yes 43 1,230.50 34.95 25.29 - 47.07 
Nephrectomy No 317 5,263.17 60.23 53.78 - 67.24 
 Yes 766 22,027.3 34.78 32.36 - 37.33 
History of Condition No 968 26,741.0 36.20 33.95 - 38.55 
 Yes 115 549.42 209.31 172.81 - 251.25 
History of CVD No 750 23,176.8 32.36 30.09 - 34.76 
 Yes 333 4,113.58 80.95 72.49 - 90.13 
CVCa No 936 26,932.4 34.75 32.56 - 37.05 
 Yes 147 358.00 410.61 346.92 - 482.62 
High-risk Surgerya No 936 26,937.5 34.75 32.56 - 37.05 
 Yes 147 352.92 416.53 351.92 - 489.57 
Charlson Score 0 90 5,727.17 15.71 12.64 - 19.32 
 1 145 5,055.58 28.68 24.20 - 33.75 
 2 to 3 374 9,852.00 37.96 34.21 - 42.01 
 4+ 474 6,655.67 71.22 64.95 - 77.93 
Note. Any ATE = any arterial thromboembolic event (MI or IS); CVC = central venous catheter; CVD = 
cardiovascular disease (myocardial infarction, ischemic stroke, new onset congestive heart failure, angina 
or transient ischemic attack); IS = ischemic stroke; MI = myocardial infarction; RCC = renal cell 
carcinoma. 
a More than 30 days before the outcome. 
 
The incidence rates for myocardial infarction in the period after kidney cancer 
diagnosis was 21.91 per 1,000 p-y (Table 20). The incidence rates increased with 
increasing age at diagnosis and Charlson score. The patterns for the incidence rates were 




histology group was for patients with Transitional cell tumors. The confidence intervals 
for incidence rates by histology groups were very wide except for clear cell tumor which 
was the most frequently type of histology diagnosed. The incidence rates for myocardial 
infarction were higher than for pulmonary embolism and other VTE, which was 






Incidence Rates per 1,000 p-y for MI After Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 615 28,065.1 21.91 20.22 -23.72 
Age at Diagnosis 66-69 95 5,381.50 17.65 14.28 -21.58 
 70-74 150 8,478.75 17.69 14.97 -20.76 
 75-79 168 7,426.00 22.62 19.33 -26.31 
 80-84 122 4,516.25 27.01 22.43 -32.25 
 85+ 80 2,262.58 35.36 28.04 -44.01 
Race Black 63 1,999.25 31.51 24.21 -40.32 
 Other/Unknown 32 1,900.75 16.84 11.52 -23.77 
 White 520 24,165.1 21.52 19.71 -23.45 
Gender Female 256 12,713.5 20.14 17.74 -22.76 
 Male 359 15,351.6 23.39 21.03 -25.93 
Geographic Region Midwest 88 3,575.42 24.61 19.74 -30.32 
 Northeast 157 6,246.17 25.14 21.36 -29.39 
 South 157 7,305.25 21.49 18.26 -25.13 
 West 213 10,938.3 19.47 16.95 -22.27 
Year of Diagnosis 2004 135 6,589.17 20.49 17.18 -24.25 
 2005 126 6,055.75 20.81 17.33 -24.77 
 2006 115 5,454.67 21.08 17.41 -25.31 
 2007 93 4,627.08 20.10 16.22 -24.62 
 2008 85 3,286.08 25.87 20.66 -31.98 
 2009 61 2,052.33 29.72 22.74 -38.18 
Histology Group Chromophobe 25 1,332.25 18.77 12.14 -27.70 
 Clear Cell 469 21,633.4 21.68 19.76 -23.73 
 Other RCC 53 1,841.92 28.77 21.55 -37.64 
 Papillary 51 2,760.83 18.47 13.75 -24.29 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 324 17,129.4 18.91 16.91 -21.09 
 Stage II 58 2,447.25 23.70 18.00 -30.64 
 Stage III 88 4,324.33 20.35 16.32 -25.07 
 Stage IV 67 1,899.92 35.26 27.33 -44.78 
 Stage Unknown 78 2,264.17 34.45 27.23 -42.99 
Chemotherapy No 502 22,325.9 22.49 20.56 -24.54 
 Yes 113 5,739.17 19.69 16.23 -23.67 
Immunotherapy No 589 26,799.7 21.98 20.24 -23.83 
 Yes 26 1,265.33 20.55 13.42 -30.11 
Nephrectomy No 180 5,398.17 33.34 28.65 -38.59 
 Yes 435 22,666.9 19.19 17.43 -21.08 
History of Condition No 543 27,773.2 19.55 17.94 -21.27 
 Yes 72 291.92 246.65 192.99 -310.61 
History of CVD No 373 22,666.0 16.46 14.83 -18.21 
 Yes 242 5,399.08 44.82 39.35 -50.84 
CVCa No 1,349 25,498.4 52.91 50.12 - 55.81 
 Yes 205 349.42 586.69 509.12 - 672.74 
High-risk Surgerya No 1,370 25,491.0 53.74 50.94 - 56.67 
 Yes 184 356.83 515.65 443.83 - 595.78 
Charlson Score 0 24 5,029.42 4.77 3.06 -7.10 
 1 62 4,690.08 13.22 10.14 -16.95 
 2 to 3 155 9,868.92 15.71 13.33 -18.38 
 4+ 374 8,476.67 44.12 39.76 -48.83 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); MI = myocardial infarction; 
RCC = renal cell carcinoma. 
a More than 30 days before the outcome. 
 
The incidence rate for ischemic stroke in the period after kidney cancer diagnosis 
was 19.39 per 1,000 p-y (Table 21). The incidence rates by histology group were 15.59, 
19.95, 24.11, and 16.60 for Chromophobe, Clear cell, Other RCC, and Papillary, 




be statistically significant. The incidence rates increased with increasing age at diagnosis 





Incidence Rates per 1,000 p-y for IS After Kidney Cancer Diagnosis 
 Level 
 
n Person-Years Incidence Rate  95% CI 
TOTAL TOTAL 548 28,256.5 19.39 17.80 - 21.09 
Age at Diagnosis 66-69 71 5,451.00 13.03 10.17 - 16.43 
 70-74 144 8,521.33 16.90 14.25 - 19.90 
 75-79 165 7,435.75 22.19 18.93 - 25.85 
 80-84 97 4,573.75 21.21 17.20 - 25.87 
 85+ 71 2,274.67 31.21 24.38 - 39.37 
Race Black 55 2,039.58 26.97 20.31 - 35.10 
 Other/Unknown 28 1,909.50 14.66 9.74 - 21.19 
 White 465 24,307.4 19.13 17.43 - 20.95 
Gender Female 260 12,735.5 20.42 18.01 - 23.05 
 Male 288 15,521.0 18.56 16.47 - 20.83 
Geographic Region Midwest 72 3,620.50 19.89 15.56 - 25.04 
 Northeast 127 6,340.67 20.03 16.70 - 23.83 
 South 171 7,290.08 23.46 20.07 - 27.25 
 West 178 11,005.3 16.17 13.89 - 18.73 
Year of Diagnosis 2004 115 6,663.75 17.26 14.25 - 20.72 
 2005 131 6,058.92 21.62 18.08 - 25.66 
 2006 104 5,473.75 19.00 15.52 - 23.02 
 2007 75 4,678.75 16.03 12.61 - 20.09 
 2008 72 3,314.92 21.72 16.99 - 27.35 
 2009 51 2,066.42 24.68 18.38 - 32.45 
Histology Group Chromophobe - - 15.59 9.65 - 23.83 
 Clear Cell 434 21,756.8 19.95 18.12 - 21.92 
 Other RCC 45 1,866.25 24.11 17.59 - 32.26 
 Papillary 46 2,771.08 16.60 12.15 - 22.14 
 Transitional cell 
tumor 








n Person-Years Incidence Rate  95% CI 
Stage at Diagnosis Stage I 306 17,188.9 17.80 15.86 - 19.91 
 Stage II 36 2,481.83 14.51 10.16 - 20.08 
 Stage III 86 4,357.83 19.73 15.79 - 24.37 
 Stage IV 58 1,913.33 30.31 23.02 - 39.19 
 Stage Unknown 62 2,314.58 26.79 20.54 - 34.34 
Chemotherapy No 428 22,504.8 19.02 17.26 - 20.91 
 Yes 120 5,751.75 20.86 17.30 - 24.95 
Immunotherapy No 525 26,975.9 19.46 17.83 - 21.20 
 Yes 23 1,280.58 17.96 11.39 - 26.95 
Nephrectomy No 158 5,434.83 29.07 24.72 - 33.97 
 Yes 390 22,821.7 17.09 15.43 - 18.87 
History of Condition No 515 27,958.4 18.42 16.86 - 20.08 
 Yes 33 298.08 110.71 76.21 - 155.47 
History of CVD No 390 23,816.9 16.37 14.79 - 18.08 
 Yes 158 4,439.58 35.59 30.26 - 41.59 
CVCa No 473 28,073.9 16.85 15.36 - 18.44 
 Yes 75 182.58 410.77 323.10 - 514.91 
High-risk Surgerya No 459 28,024.1 16.38 14.91 - 17.95 
 Yes 89 232.42 382.93 307.53 - 471.23 
Charlson Score 0 53 5,770.08 9.19 6.88 - 12.01 
 1 87 5,142.42 16.92 13.55 - 20.87 
 2 to 3 201 10,105.8 19.89 17.23 - 22.84 
 4+ 207 7,238.17 28.60 24.83 - 32.77 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); IS = ischemic stroke; RCC 
= renal cell carcinoma. 
a More than 30 days before the outcome. 
 
The incidence rates of thromboembolic events were higher in the period after 
cancer diagnosis than in the period before diagnosis for each outcome. Consistently, 
incidence rates increased with history of the condition, history of CVD, and increasing 




patterns seen for the any ATE tables. The incidence rates of ATEs were higher than 
expected, however appears to be due to the inclusion of ischemic stroke. The incidence 
rate for ischemic stroke of 60.12 per 1,000 p-y was higher than the incidence rate for any 
of the venous thromboembolic events.  
Descriptive Analysis 2 
The purpose of descriptive analysis 2 was to describe the incidence proportions of 
thromboembolic events in the kidney cancer cohort in discrete periods after kidney 
cancer diagnosis. Tables 21 to 23 contain the results for each outcome with incidence 
proportions within 90 days, 91 to 180 days, 181 to 270 days, and 271 to 365 days after 
the cancer diagnosis. The incidence proportions in the entire follow-up period were also 
provided. 
Within the first year after cancer diagnosis, the highest incidence proportions of 
VTEs and ATEs occurred in the first 90 days (Tables 22 to 24). The trend was that the 
incidence proportions decreased in later time periods for all outcomes except other VTE 
and ATEs (any, myocardial infarction, or ischemic stroke); however there were wide, 
overlapping confidence intervals and so the incidence proportions may not have been 
different at a statistically significant level. The highest incidence proportions occurred in 





Incidence Proportions for Any VTE and DVT After Kidney Cancer Diagnosis 
 Any VTE DVT 
Period Incidence 
Proportion 
95% CI Incidence 
Proportion 
95% CI 
0 - 90 days 6.38% 5.94% - 6.84% 4.29% 3.93% - 4.68% 
91 - 180 days 1.37% 1.15% - 1.62% 0.90% 0.72% - 1.10% 
181 - 270 days 0.98% 0.79% - 1.21% 0.78% 0.61% - 0.99% 
271 - 365 days 0.82% 0.64% - 1.04% 0.50% 0.36% - 0.67% 
Entire Follow-up Period 12.2% 11.6% - 12.8% 8.48% 7.98% - 9.00% 
Note. DVT = deep vein thrombosis; VTE = venous thromboembolic event. 
 
Table 23 
Incidence Proportions for PE and Other VTEs After Kidney Cancer Diagnosis 
 PE Other VTE 
Period Incidence 
Proportion 
95% CI Incidence 
Proportion 
95% CI 
0 - 90 days 1.64% 1.42% - 1.89% 1.57% 1.35% - 1.81% 
91 - 180 days 0.41% 0.29% - 0.55% 0.44% 0.32% - 0.59% 
181 - 270 days 0.30% 0.20% - 0.43% 0.19% 0.11% - 0.30% 
271 - 365 days 0.20% 0.12% - 0.32% 0.27% 0.17% - 0.40% 
Entire Follow-up Period 3.37% 3.04% - 3.71% 3.30% 2.98% - 3.64% 






Incidence Proportions for ATEs After Kidney Cancer Diagnosis 
 Any ATE MI IS 
Period IP 95% CI IP 95% CI IP 95% CI 
0 - 90 days 3.19% 2.88% - 3.53% 1.82% 1.59% - 2.09% 1.47% 1.26% - 1.71% 
91 - 180 days 0.90% 0.72% - 1.10% 0.58% 0.45% - 0.75% 0.36% 0.25% - 0.49% 
181 - 270 days 0.67% 0.51% - 0.86% 0.34% 0.23% - 0.48% 0.36% 0.25% -0.50% 
271 - 365 days 0.78% 0.61% - 0.99% 0.41% 0.28% - 0.56% 0.40% 0.28% - 0.56% 
Entire Follow-up Period 9.45% 8.92% - 10.0%  5.37% 4.96% - 5.79% 4.78% 4.40% - 5.19% 
Note. Any ATE = any arterial thromboembolic event (MI or IS); IS = ischemic stroke; MI = myocardial 
infarction. 
 
Research Question 1 
Research Question 1: How do the incidence rates of VTEs and ATEs in elderly 
exposed (kidney cancer) patients 12 months before index date compare to a matched 
unexposed (noncancer) Medicare population during the same 12-month timeframe? 
HA1: In the year prior to index date, the incidence rates of VTEs or of ATEs are 
statistically significantly greater in the exposed patients than in the unexposed patients. 
H01: There is no statistically significant difference in the incidence rates of VTEs 
or ATEs in the year prior to the index date in the exposed patients and in the matched 
unexposed patients. 
The purpose of Research Question 1 was to compare the incidence rates in the 
exposed to unexposed cohorts in the year prior to index date. The incidence rate ratios 
were estimated by the hazard ratio and all models were adjusted for the matching factors. 
Adjusted models were run twice, first using kidney disease and diabetes as potential 
confounders and effect measure modifiers; second, using the Charlson score as a 




components of the Charlson comorbidity score. Using backward selection, variables were 
retained in the model if they had a p-value of less than 0.05. The hazard ratios were 
stratified by variables whose interaction terms with gender had a p-value less than 0.05 in 
the full model. 
The incidence rate for any VTE was higher in the exposed cohort than in the 
unexposed cohort in the crude and adjusted models (Table 25). The crude hazard ratio 
comparing the incidence rate in the exposed to the unexposed was 1.44 (95% CI 1.23 – 
1.69). After adjusting for other factors, the hazard ratio increased. Using the first method, 
the hazard ratio was 1.65 (95% CI 1.30 - 2.09) after adjusting by atherosclerosis, varicose 
veins, placement of central venous catheter more than 30 days prior to the outcome, 
kidney disease and history of VTE. Using the Charlson comorbidity score instead of 
kidney disease and diabetes variables in the full model, the adjusted hazard ratio was 1.81 
(95% CI 1.42 – 2.28) and the adjusting factors were Charlson score, varicose veins, 
central venous catheter and history of VTE. 
The incidence rate for DVT was higher in the exposed cohort than the unexposed 
cohort in the year prior to index date (Table 25). The crude hazard ratio was 1.69 (95% 
CI 1.38 – 2.08), but decreased slightly after adjusting for confounders. The confounders 
in the first adjusted model were atherosclerosis, varicose veins, kidney disease and 
history of CVD and the hazard ratio was 1.50 (95% CI 1.19-1.89). The model adjusted by 
the Charlson score yielded a hazard ratio of 1.57 (95% CI 1.24 – 1.98) and was adjusted 
by atherosclerosis and varicose veins. After adjusting for the Charlson score, history of 




The incidence rate for pulmonary embolism in the year prior to index date was 
higher in the exposed cohort than the unexposed cohort for all models (Table 25). The 
crude hazard ratio (HR = 1.62, 95% CI 1.16 – 2.27) was between the two adjusted hazard 
ratios. 
Unlike any VTE, DVT, and pulmonary embolism, the incidence rate for other 
VTEs in the year prior to index date was not consistently higher for the exposed than the 
unexposed at a statistically significant level (Table 25). The crude hazard ratio was 1.32 
(95% CI 1.01 - 1.71). However, in the first model the history of CVD was an EMM and 
the incidence rate ratio was greater than one in the population without history of CVD 
(HR = 1.41, 95% CI 1.02 – 1.96). The hazard ratio for patients with a history of CVD was 
0.83 (95% CI 0.38 – 1.80) and was not statistically significant at the 0.05 level. The 
hazard ratio for the model adjusted by the Charlson score was greater than 1 (HR = 1.23, 





Incidence Rate Ratios for Venous Thromboembolic Events in the Year Prior to Index 
Date (N = 22,926) 
 Crude HR (95% CI)
a
 Adjusted HR (95% 
CI) 
Adjusted HR (95% 
CI) 
Any VTE  
(n = 394 events in cancer cohort; n = 271 events in noncancer cohort) 
Cancer vs. noncancer  1.44 (1.23 - 1.69)*** 1.65 (1.30 - 2.09)
b




(n = 246 events in cancer cohort; n = 147 events in noncancer cohort) 
Cancer vs. noncancer  1.69 (1.38 - 2.08)*** 1.50 (1.19 -1.89)
 d




(n = 90 events in cancer cohort; n = 55 events in noncancer cohort) 
Cancer vs. noncancer  1.62 (1.16 - 2.27)** 1.52 (1.07 - 2.18)
f




(n = 129 events in cancer cohort; n = 98 events in noncancer cohort) 
Cancer vs. noncancer  1.32 (1.01 - 1.71)*  1.23 (0.93 - 1.62)
i
 
Without history of 
CVD 
 1.41 (1.02 - 1.96)
h
*  
With history of CVD  0.83 (0.38 - 1.80)
h
  
Note. CVD = cardiovascular disease (myocardial infarction, ischemic stroke, new onset congestive heart 
failure, angina or transient ischemic attack); DVT = deep vein thrombosis; Other VTE = other venous 





Model adjusted only for matching 
b 
Model adjusted for matching and atherosclerosis, varicose veins, central venous catheter, kidney disease, 
and history of VTE. Placement of central venous catheter was more than 30 days before outcome. 
c 
Model adjusted for matching and Charlson Comorbidity Score, varicose veins, central venous catheter, 
and history of VTE. Placement of central venous catheter was more than 30 days before outcome. 
d
 Model adjusted for matching and atherosclerosis, varicose veins, kidney disease and history of CVD. 
e
 Model adjusted for matching and Charlson Comorbidity Score, atherosclerosis, and varicose veins. 
f
 Model adjusted for matching, type 2 diabetes and kidney disease. 
g
 Model adjusted for matching and Charlson Comorbidity Score. 
h
 Model adjusted for matching and type 2 diabetes and varicose veins. Stratified by history of CVD. 
i
 Model adjusted for matching and Charlson Comorbidity Score and varicose veins. 
* p < .05. ** p < .01. *** p < .001. 
 
The incidence rate ratio was greater than 1.0 comparing the exposed to unexposed 
cohorts for any ATE in the year prior to index date, but only for the crude model (Table 
26). After adjusting for other factors including type 2 diabetes, kidney disease, Charlson 
Comorbidity Score, atherosclerosis, varicose veins, high-risk surgery, history of CVD, 
and history of ATE, there was no statistically significant difference in the incidence rates 
of any ATE for cancer patients and noncancer patients.  
The incidence rate ratio for myocardial infarction in the year prior to index date 
differed by history of CVD (Table 26). Although the hazard ratio was greater than 1 for 
the crude model (HR = 1.26, 95% CI 1.20 – 1.56), the hazard ratio was not significantly 




– 1.59). In patients without a history of CVD, the hazard ratio was greater than 1 (HR = 
1.46, 95% CI 1.05 – 2.05). The hazard ratio was less than 1.0 for patients with a history 
of CVD (HR = 0.48, 95% CI 0.24 – 0.97). 
Elderly kidney cancer patients did not have a higher incidence rate of ischemic 
stroke than the matched, noncancer comparison group. Although the hazard ratios were 
greater than 1.0, for neither the crude nor adjusted models were the results statistically 
different from 1.0 (Table 26). The crude hazard ratio was 1.20, but after adjusting for 






Incidence Rate Ratios for Arterial Thromboembolic Events in the Year Prior to Index 
Date (N = 22,926) 
 Crude HR (95% CI)
a
 Adjusted HR (95% 
CI) 
Adjusted HR (95% 
CI) 
Any ATE 
(n = 354 events in cancer cohort; n = 291 events in noncancer cohort) 
Cancer vs. noncancer   1.23 (1.05 - 1.43)* 1.11 (0.92 - 1.34) b 1.14 (0.93 - 1.39) c 
MI 
(n = 192 events in cancer cohort; n = 153 events in noncancer cohort) 
Cancer vs. noncancer  1.26 (1.02 - 1.56)*  1.18 (0.88 - 1.59)e 
Without history of 
CVD 
 1.46 (1.05 - 2.04)
d
**  




(n = 173 events in cancer cohort; n = 145 events in noncancer cohort) 
Cancer vs. noncancer   1.20 (0.96 - 1.50) 1.04 (0.81 - 1.34)f 1.09 (0.84 - 1.42)g 
Note. Any ATE = any arterial thromboembolic event (MI or IS); CVD = cardiovascular disease 
(myocardial infarction, ischemic stroke, new onset congestive heart failure, angina or transient ischemic 





 Model adjusted only for matching 
b
 Model adjusted for matching and type 2 diabetes, atherosclerosis, high-risk surgery, kidney disease, 
history of CVD, and history of ATE. High-risk surgery was more than 30 days before outcome. 
c
 Model adjusted for matching and Charlson Comorbidity Score, atherosclerosis, high-risk surgery and 
history of ATE. High-risk surgery was more than 30 days before outcome. 
d
 Model adjusted for matching and type 2 diabetes and kidney disease. Stratified by history of CVD. 
e
 Model adjusted for matching and Charlson Comorbidity Score and history of MI . 
f
 Model adjusted for matching and type 1 diabetes, atherosclerosis, history of ischemic stroke, and kidney 
disease. High-risk surgery was more than 30 days before outcome. 
g
 Model adjusted for matching and Charlson Comorbidity Score, atherosclerosis, and history of IS.  
* p < .05. ** p < .01. *** p < .001. 
 
 
For most outcomes, the incidence rate of thromboembolic events was higher in 
the exposed cohort than the unexposed cohort in the year prior to index date. For other 
VTEs, any ATE, myocardial infarction, and ischemic stroke, history of CVD was an 
EMM with the incidence rate of events higher in the exposed cohort for patients without 
a history of CVD. In patients with a history of CVD, the incidence rate was lower in the 
exposed cohort or not statistically significantly different than the unexposed cohort. 
Thus, the null hypothesis was rejected for any VTE, DVT and pulmonary 
embolism after adjusting for other factors in the model. The null hypothesis could not be 
rejected for other VTEs and myocardial infarction in patients with a history of CVD 




could also not be rejected for other VTEs, any ATE, myocardial infarction, and ischemic 
stroke after adjusting by the Charlson comorbidity score. 
Research Question 2 
Research Question 2: How do the incidence rates of VTEs and rates of ATEs in 
elderly exposed (kidney cancer) patients after index date compare to a matched 
unexposed (noncancer) Medicare population during the same timeframe? 
HA2: In the follow-up period after the index date, the incidence rates of VTEs or 
of ATEs are statistically significantly greater in the exposed patients than in the 
unexposed patients. 
H02: There is no statistically significant difference in the incidence rates of VTEs 
or ATEs in the period after index date in the exposed patients and in the matched 
unexposed patients. The purpose of Research Question 2 was to compare the incidence 
rates in the exposed to unexposed cohorts in the follow-up period after index date. The 
methodology was the same as for Research Question 1. 
The incidence rate for any VTE was higher in the exposed cohort than the 
unexposed cohort in the follow-up period (Table 27). In the first model, Type 2 diabetes 
and kidney disease were EMMs. The rate was more than five times higher in the exposed 
population than the unexposed population in patients who had neither type 2 diabetes nor 
kidney disease (5.42, 95% CI 4.18 – 7.02). The incidence rate was twice as high in the 
exposed population in patients with type 2 diabetes only or kidney disease only. The 
incidence rate was not statistically significantly different for the exposed to the 




0.78 – 1.68). In the second model, the incidence rate was more than three times as high in 
the exposed population (HR = 3.44, 95% CI 2.97 – 3.99) and no factors were EMMs. 
The incidence rate for DVT in the exposed cohort was higher than in the 
unexposed cohort in the follow-up period after index date (Table 27). In the first model, 
atherosclerosis and kidney disease were EMMs. The incidence rate ratios were higher in 
the exposed cohort for patients without both disease and for patients with only 
atherosclerosis or kidney disease. The hazard ratio was 0.88 (95% CI 0.53 – 1.49) for 
patients with both atherosclerosis and kidney disease. In the second model, 
atherosclerosis was an EMM. The incidence rate ratio estimates were greater than 1.0 in 
patients without atherosclerosis (HR = 3.56, 95% CI 2.88 – 4.41) and in patients with 
atherosclerosis (HR = 1.75, 95% CI 1.13 – 2.72). 
The incidence rate ratio for pulmonary embolism was approximately three times 
higher in the exposed cohort than the unexposed cohort in the follow-up period (Table 
27). Both adjusted models yielded similar hazard ratios. The first model hazard ratio was 
2.95 (95% CI 2.31 – 3.77) and the second model adjusted hazard ratio was 3.28 (95% CI 
2.60 – 4.14). Both models were adjusted by atherosclerosis, with the first model also 
adjusted by kidney disease and the second model also adjusted by the Charlson score. 
The incidence rate ratio for other VTEs differed by type 2 diabetes and kidney 
disease in the first model (Table 27). In patients without diabetes and kidney disease, the 
hazard ratio was 4.31 (95% CI 2.89 – 6.43); in patients with kidney disease the hazard 
ratio was 1.80 (95% CI 0.90 – 3.57); in patients with type 2 diabetes the hazard ratio was 




the hazard ratio was 0.87 (95% CI 0.47 – 1.61). In the second model, there were no 
EMMs and the incidence rate ratio in the exposed cohort was 2.6 times that of the 
unexposed cohort after adjusting for Charlson score, varicose veins, and placement of 





Incidence Rate Ratios for Venous Thromboembolic Events in Follow-up Period After 
Index Date (N = 22,926) 
 Crude HR (95% CI)a Adjusted HR (95% CI) Adjusted HR (95% CI) 
Any VTE 
(n = 1,402 events in cancer cohort; n = 441 events in noncancer cohort) 
Cancer vs. noncancer  3.41 (3.05 - 3.81)***  3.44 (2.97 - 3.99) c*** 
Without type 2 diabetes or kidney 
disease. 
 5.42 (4.18 - 7.02) b***  
Without type 2 diabetes, with kidney 
disease. 
 2.19 (1.48 - 3.23) b ***  
With type 2 diabetes, without kidney 
disease. 
 2.84 (2.00 - 4.04) b ***  
With type 2 diabetes and kidney 
disease. 
 1.15 (0.78 - 1.68) b  
DVT 
(n = 972 events in cancer cohort; n = 289 events in noncancer cohort) 
Cancer vs. noncancer  3.55 (3.10 - 4.06) ***   
Without atherosclerosis or kidney 
disease. 
 4.45 (3.37 - 5.89)d***  
Without atherosclerosis, with kidney 
disease. 
 1.57 (1.04 - 2.38) d *  
With atherosclerosis, without kidney 
disease. 
 2.51 (1.48 - 4.23) d **  
With atherosclerosis and kidney 
disease. 
 0.88 (0.53 - 1.49) d  
Without atherosclerosis   3.56 (2.88 - 4.41)e** 
With atherosclerosis   1.75 (1.13 - 2.72) e** 
PE 
(n = 386 events in cancer cohort; n = 100 events in noncancer cohort) 
Cancer vs. noncancer  3.88 (3.11 - 4.84) *** 2.95 (2.31 - 3.77) f*** 3.28 (2.60 - 4.14) g*** 
Other VTE 
(n = 378 events in cancer cohort; n = 127 events in noncancer cohort) 
Cancer vs. noncancer  3.07 (2.50 - 3.76) ***  2.66 (2.11 - 3.36)i*** 
Without type 2 diabetes or kidney 
disease. 
 4.31 (2.89 - 6.43)h**  
Without type 2 diabetes, with kidney 
disease. 
 1.80 (0.90 - 3.57) h  
With type 2 diabetes, without kidney 
disease. 
 2.08 (1.19 - 3.64) h**  
With type 2 diabetes and kidney 
disease. 
 0.87 (0.47 - 1.61) h  
Note. DVT = deep vein thrombosis; Other VTE = other venous thromboembolic event; PE = pulmonary 





 Model adjusted only for matching. 
b
 Model adjusted for matching and type 1 diabetes, atherosclerosis, varicose veins, high-risk surgery, 
central venous catheter, and history of VTE. Stratified by type 2 diabetes and kidney disease. High-risk 
surgery was more than 30 days before outcome. 
c
 Model adjusted for matching and Charlson Comorbidity Score, varicose veins, high-risk surgery, central 
venous catheter, and history of VTE. High-risk surgery was more than 30 days before outcome. 
d
 Model adjusted for matching and. Stratified by atherosclerosis and kidney disease. 
e
 Model adjusted for matching and Charlson Comorbidity Score, varicose veins, high-risk surgery, central 
venous catheter, and history of DVT. Stratified by atherosclerosis. High-risk surgery and central venous 
catheter were more than 30 days before outcome. 
f
 Model adjusted for matching and atherosclerosis and kidney disease. 
g
 Model adjusted for matching and Charlson Comorbidity Score and atherosclerosis. 
h
 Model adjusted for matching and varicose veins and central venous catheter. Stratified by type 2 diabetes 
and kidney disease. Placement of central venous catheter was more than 30 days before outcome. 
i
 Model adjusted for matching and Charlson Comorbidity Score, varicose veins, and central venous 
catheter. Placement of central venous catheter was more than 30 days before outcome. 
* p < .05. ** p < .01. *** p < .001. 
 
The incidence rate ratio for any ATE comparing the exposed to unexposed cohort 
was 1.81 (95% CI 1.64 – 2.01) for the crude model (Table 28). After adjusting for other 
factors, the incidence rate was higher for the exposed cohort in patients without 
atherosclerosis and without kidney disease for the first model; and in patients without 




lower for the exposed cohort in patients who had both atherosclerosis and kidney disease 
(HR = 0.59, 95% CI 0.40 - 0.86). 
The incidence rate ratios for myocardial infarction in the follow-up period 
differed in the exposed and unexposed cohorts by history of myocardial infarction (Table 
28). In the first model, presence of atherosclerosis also impacted the incidence rate ratio. 
In patients without atherosclerosis or history of myocardial infarction, the exposed cohort 
had higher incidence rates of myocardial infarction (HR = 1.42, 95% CI 1.10 – 1.84). In 
patients with history of myocardial infarction or atherosclerosis, the incidence rate was 
lower in the unexposed cohort than the exposed cohort. In the second model, patients in 
the exposed cohort with a history of myocardial infarction had a higher incidence rate 
than the unexposed cohort without a history of myocardial infarction (HR = 1.35, 95% CI 
1.11 – 1.65). Patients in the exposed cohort with history of had a much lower incidence 
rate than patients in the unexposed cohort (HR = 0.05, 95% CI 0.00 – 0.72). 
The incidence rate ratio for ischemic stroke in the follow-up period comparing the 
exposed to unexposed differed by presence of kidney disease in the first model, and by 
the presence of atherosclerosis in the second model which also adjusted by the Charlson 
comorbidity score (Table 28). In the first model, the incidence rates for ischemic stroke 
were higher for the exposed cohort in patients without kidney disease, but lower for the 
exposed cohort in patients with kidney disease. The second model results were similar in 
that the incidence rate was lower for the exposed cohort in patients with atherosclerosis. 









Incidence Rate Ratios for Arterial Thromboembolic Events in Follow-up Period After 
Index Date (N = 22,926) 
 Crude HR (95% CI)
a
 Adjusted HR (95% CI) Adjusted HR (95% CI) 
Any ATE 
(n = 1,083 events in cancer cohort; n = 625 events in noncancer cohort) 
Cancer vs. noncancer   1.81 (1.64 - 2.01)***   
Without atherosclerosis 
and without kidney 
disease 




with kidney disease 




without kidney disease 
 0.89 (0.61 - 1.30)
 b
  
With atherosclerosis and 
kidney disease 
  0.59 (0.40 - 0.86)
 b
*  
Without atherosclerosis   1.27 (1.08 - 1.49)
 c
* 




(n = 615 events in cancer cohort; n = 291 events in noncancer cohort) 
Cancer vs. noncancer  2.17 (1.89 - 2.51)***   
Without atherosclerosis 
or history of MI. 




with history of MI. 




without history of MI. 
 0.80 (0.50 - 1.27)
 d
  
With atherosclerosis and 
history of MI. 
 0.02 (0.00 - 0.25)
 d
**  
Without history of MI   1.35 (1.11 - 1.65)
 e
** 




(n = 548 events in cancer cohort; n = 370 events in noncancer cohort) 
Cancer vs. noncancer   1.47 (1.29 - 1.68)***   
Without kidney disease  1.34 (1.06 - 1.70)
 f
*  
With kidney disease  0.52 (0.35 - 0.78)
 f
***  
Without atherosclerosis   1.04 (0.84 - 1.29)
 g
 
With atherosclerosis   0.55 (0.34 - 0.90)
 g
* 
Note. Any ATE = any arterial thromboembolic event (MI or IS); CVD = cardiovascular disease 
(myocardial infarction, ischemic stroke, new onset congestive heart failure, angina or transient ischemic 





 Model adjusted only for matching 
b
 Model adjusted for matching and type 2 diabetes, high-risk surgery, central venous catheter, kidney 
disease, history of ATE and history of CVD. Stratified by atherosclerosis and kidney disease. Central 
venous catheter and high-risk surgery were more than 30 days before outcome. 
c
 Model adjusted for matching and Charlson Comorbidity Score, high-risk surgery, central venous 
catheter, and history of ATE. Stratified by atherosclerosis. Central venous catheter and high-risk surgery 
were more than 30 days before outcome. 
d
 Model adjusted for matching, Type 2 diabetes, high-risk surgery, central venous catheter, kidney disease, 
and history of CVD. Stratified by atherosclerosis and history of MI. Central venous catheter and high-risk 
surgery were more than 30 days before outcome. 
e
 Model adjusted for matching and Charlson Comorbidity Score, high-risk surgery and central venous 
catheter. Stratified by history of MI. Central venous catheter and high-risk surgery were more than 30 days 
before outcome. 
f
 Model adjusted for matching and type 2 diabetes, atherosclerosis, high-risk surgery, central venous 
catheter, and history of IS. Stratified by kidney disease. Central venous catheter and high-risk surgery were 
more than 30 days before outcome. 
g
 Model adjusted for matching and Charlson Comorbidity Score, high-risk surgery, central venous 
catheter, and history of IS. Stratified by atherosclerosis. Central venous catheter and high-risk surgery 
were more than 30 days before outcome. 
* p < .05. ** p < .01. *** p < .001. 
 
In the follow-up period after index date, the incidence rate was higher in the 
exposed cohort than the unexposed cohort for thromboembolic events. The null 
hypothesis was rejected for any VTE, DVT, pulmonary embolism, and other VTEs after 




higher incidence rates in the exposed cohort were mostly limited to the patients without 
the EMM condition (e.g., type 2 diabetes, kidney disease, or atherosclerosis). The null 
hypothesis was rejected for any ATE in patients without atherosclerosis and without 
kidney disease in the first model, and in patients without atherosclerosis in the second 
model which adjusted for Charlson comorbidity score. The null hypothesis was rejected 
for myocardial infarction in patients after adjusting for the Charlson comorbidity score, 
and rejected for ischemic stroke in patients without atherosclerosis after adjusting for the 
Charlson comorbidity score. The null hypothesis could not be rejected for any ATE in 
patients with atherosclerosis or kidney disease but not both; for myocardial infarction in 
patients with atherosclerosis but without a history of myocardial infarction; and for 
ischemic stroke in patients without atherosclerosis after adjusting for the Charlson 
comorbidity score. In outcomes where both models contained EMMs or no models 
contained EMMS, the two models yielded similar results.  
Research Question 3 
Research Question 3: In the follow-up period after kidney cancer diagnosis, what 
are the risk factors associated with time to newly diagnosed, individual VTE (DVT, PE, 
or OTE)? 
HA3: No factors are statistically significantly associated with the time to newly 
diagnosed VTEs in the period after kidney cancer diagnosis. 
H03: Tumor histology and other factors are statistically significantly associated 




The purpose of Research Question 3 was to identify risk factors for venous 
thromboembolic events in the exposed cohort in the follow-up period after kidney cancer 
diagnosis. A Cox proportional hazard model was used for each outcome to identify 
factors associated with time to event at the 0.05 significance level. Backward selection 
was used to determine which variables were kept in the model. In both models, histology 
group was kept in regardless of statistical significance. 
The risk factors associated with incidence of any VTE in the follow-up period 
were the oldest age group at diagnosis (80 years or older); Black race; Northeast region; 
Stage III, IV or unknown; history of any VTE; placement of CVC more than 30 days 
prior to VTE; varicose veins; treatment by chemotherapy; and being male without high-
risk surgery more than 30 days prior to VTE (Table 29). In the first model transitional 
cell tumor, kidney disease and type 1 diabetes were also identified as risk factors. In the 
second model Charlson score of 2 or greater, year of diagnosis, and history of CVD were 





Risk Factors Associated With Incidence of Any VTE in Follow-up Period After Kidney 
Cancer Diagnosis (N = 11,463) 
 Level 
 
Adjusted HR (95% CI)a Adjusted HR (95% 
CI)b 
Age at Diagnosis 66-69 (Ref) (Ref) 
 70-74 1.06 (0.89, 1.25) 1.06 (0.90, 1.26) 
 75-79 1.11 (0.93, 1.32) 1.14 (0.95, 1.35) 
 80-84 1.22 (1.01, 1.47)* 1.26 (1.04, 1.53)* 
 85+ 1.26 (1.01, 1.56)* 1.32 (1.06, 1.64)* 
Histology Group Clear Cell (Ref) (Ref) 
 Chromophobe/Other 
RCC 
0.92 (0.77, 1.09) 0.93 (0.78, 1.10) 
 Papillary 1.08 (0.88, 1.32) 1.08 (0.88, 1.32) 
 Transitional cell tumor 0.67 (0.46, 0.97)* 0.70 (0.48, 1.02) 
Charlson Score 0 - (Ref) 
 1 - 1.20 (0.98, 1.46) 
 2 to 3 - 1.26 (1.06, 1.50)* 
 4+ - 1.49 (1.24, 1.80)*** 
Race White (Ref) (Ref) 
 Black 1.23 (1.02, 1.48)* 1.22 (1.01, 1.47)* 
 Other/Unknown 0.79 (0.62, 1.02) 0.77 (0.60, 0.99)* 
Geographic Region West (Ref) (Ref) 
 Midwest 1.02 (0.85, 1.23) 1.01 (0.84, 1.21) 
 Northeast 1.20 (1.04, 1.39)* 1.20 (1.04, 1.39)* 
 South 1.06 (0.92, 1.23) 1.06 (0.92, 1.22) 
Year of Diagnosis  - 1.04 (1.00, 1.08)* 
Stage at Diagnosis Stage I (Ref) (Ref) 
 Stage II 1.09 (0.87, 1.38) 1.11 (0.89, 1.40) 
 Stage III 2.26 (1.95, 2.61)*** 2.26 (1.96, 2.61)*** 
 Stage IV 2.62 (2.24, 3.07)*** 2.65 (2.26, 3.11)*** 
 Stage Unknown 1.24 (1.01, 1.52)* 1.28 (1.04, 1.57)* 
History of Condition No (Ref) (Ref) 








Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
History of CVD No (Ref) (Ref) 
 Yes - 0.79 (0.69, 0.92)** 
CVCc No (Ref) (Ref) 
 Yes 4.34 (3.40, 5.54)*** 4.45 (3.49, 5.68)*** 
Varicose veins No (Ref) (Ref) 
 Yes 1.92 (1.45, 2.53)*** 1.87 (1.41, 2.47)*** 
Kidney Disease No (Ref) (Ref) 
 Yes 1.33 (1.19, 1.50)*** - 
Chemotherapy No (Ref) (Ref) 
 Yes 1.33 (1.17, 1.52)*** 1.33 (1.17, 1.51)*** 
Type 1 Diabetes No (Ref) (Ref) 
 Yes 0.80 (0.67, 0.95)* - 
Gender Female (Ref) (Ref) 
 Male without high-
risk surgery 
0.82 (0.73, 0.92)* 0.82 (0.73, 0.92)* 
 Male with high-risk 
surgery 
1.29 (0.86, 1.92) 1.32 (0.88, 1.96) 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); RCC = renal cell 
carcinoma; VTE = venous thromboembolic event. 
a Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier 
(EMM). 
b Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and 
diabetes were components of the Charlson score and were not assessed in the model. 
c More than 30 days before the outcome. 
* p < .05. ** p < .01. *** p < .001. 
 
The risk factors associated with incidence of DVT in the follow-up period were 
other or unknown race; Stage III, IV, or unknown stage; history of DVT; high risk 
surgery; placement of central venous catheter; varicose veins; and treatment by 
chemotherapy (Table 30). In the first model, type I diabetes, kidney disease, and female 
gender were also identified as risk factors. In the second model, Charlson score and 





Risk Factors Associated With Incidence of DVT in Follow-up Period After Kidney 
Cancer Diagnosis (N = 11,463) 
 Level 
 
Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
Age at Diagnosis 66-69 (Ref) (Ref) 
 70-74 1.18 (0.96, 1.46) 1.17 (0.95, 1.45) 
 75-79 1.15 (0.92, 1.42) 1.14 (0.92, 1.41) 
 80-84 1.55 (1.24, 1.94)*** 1.54 (1.23, 1.93)*** 
 85+ 1.44 (1.11, 1.87)** 1.46 (1.12, 1.89)** 
Histology Group Clear Cell (Ref) (Ref) 
 Chromophobe/Other 
RCC 
1.00 (0.81, 1.22) 0.99 (0.81, 1.22) 
 Papillary 1.16 (0.91, 1.47) 1.16 (0.91, 1.48) 
 Transitional cell tumor 0.87 (0.57, 1.33) 0.91 (0.60, 1.39) 
Charlson Score 0 (Ref) (Ref) 
 1 - 1.22 (0.95, 1.57) 
 2 to 3 - 1.32 (1.06, 1.63)* 
 4+ - 1.54 (1.24, 1.91)*** 
Race White (Ref) (Ref) 
 Black 1.24 (1.00, 1.54) 1.23 (0.98, 1.53) 
 Other/Unknown 0.63 (0.46, 0.85)** 0.63 (0.46, 0.86)** 
Geographic Region West (Ref) (Ref) 
 Midwest - 0.93 (0.75, 1.16) 
 Northeast - 1.20 (1.01, 1.43)* 
 South - 1.01 (0.85, 1.20) 
Stage at Diagnosis Stage I (Ref) (Ref) 
 Stage II 1.19 (0.90, 1.56) 1.22 (0.93, 1.60) 
 Stage III 2.25 (1.89, 2.68)*** 2.27 (1.91, 2.71)*** 
 Stage IV 2.74 (2.28, 3.31)*** 2.83 (2.34, 3.42)*** 
 Stage Unknown 1.43 (1.12, 1.82)** 1.41 (1.11, 1.80)** 
History of Condition No (Ref) (Ref) 








Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
High-risk surgeryc No (Ref) (Ref) 
 Yes 4.11 (3.03, 5.57)*** 4.00 (2.95, 5.43)*** 
Type 1 Diabetes No (Ref) (Ref) 
 Yes 0.78 (0.63, 0.96)* - 
CVCc No (Ref) (Ref) 
 Yes 6.26 (4.73, 8.30)*** 6.30 (4.76, 8.33)*** 
Varicose veins No (Ref) (Ref) 
 Yes 1.87 (1.35, 2.60)*** 1.75 (1.26, 2.42)*** 
Kidney Disease No (Ref) (Ref) 
 Yes 1.44 (1.25, 1.66)*** - 
Chemotherapy No (Ref) (Ref) 
 Yes 1.31 (1.13, 1.52)*** 1.33 (1.14, 1.54)*** 
Gender Female (Ref) (Ref) 
 Male 0.83 (0.73, 0.95)** 0.85 (0.75, 0.98)* 
Note. CVC= central venous catheter; DVT = deep vein thrombosis; RCC = renal cell carcinoma. 
a Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier 
(EMM). 
b Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and 
diabetes were components of the Charlson score and were not assessed in the model. 
c More than 30 days before the outcome. 
* p < .05. ** p < .01. *** p < .001. 
 
The risk factors for incidence of pulmonary embolism in the follow-up period 
were age; papillary and transition cell tumor histology; Stage III or IV; history of 
pulmonary embolism; high-risk surgery more than 30 days prior to event; placement of 
central venous catheter more than 30 days prior to event; treatment by chemotherapy or 
nephrectomy; and gender (Table 31). Type 1 diabetes and kidney disease were also 
associated with pulmonary embolism in the first model, whereas the Charlson score was 





Risk Factors Associated With Incidence of PE in Follow-up Period After Kidney Cancer 
Diagnosis (N = 11,463) 
 Level 
 
Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
Age at Diagnosis 66-69 (Ref) (Ref) 
 70-74 0.89 (0.66, 1.19) 0.86 (0.64, 1.16) 
 75-79 0.67 (0.49, 0.92)* 0.67 (0.49, 0.91)* 
 80-84 0.63 (0.43, 0.91)* 0.62 (0.43, 0.90)* 
 85+ 0.83 (0.56, 1.23) 0.84 (0.56, 1.25) 
Histology Group Clear Cell (Ref) (Ref) 
 Chromophobe/Other 
RCC 
0.95 (0.68, 1.32) 0.96 (0.69, 1.33) 
 Papillary 1.50 (1.06, 2.14)* 1.53 (1.08, 2.18)* 
 Transitional cell tumor 0.28 (0.09, 0.90)* 0.30 (0.09, 0.96)* 
Charlson Score 0 (Ref) (Ref) 
 1 - 1.28 (0.86, 1.90) 
 2 to 3 - 1.51 (1.07, 2.12)* 
 4+ - 1.68 (1.19, 2.38)** 
Stage at Diagnosis Stage I (Ref) (Ref) 
 Stage II 0.98 (0.64, 1.49) 0.98 (0.64, 1.50) 
 Stage III 1.53 (1.13, 2.06)** 1.52 (1.12, 2.05)** 
 Stage IV 2.43 (1.80, 3.28)*** 2.50 (1.85, 3.38)*** 
 Stage Unknown 0.75 (0.47, 1.18) 0.78 (0.50, 1.23) 
History of Condition No (Ref) (Ref) 
 Yes 38.08(27.19,53.32)*** 34.65(24.76,48.51)*** 
High-risk surgeryc No (Ref) (Ref) 
 Yes 5.14 (3.04, 8.70)*** 5.42 (3.18, 9.23)*** 
CVCc No (Ref) (Ref) 
 Yes 9.04 (5.52, 14.80)*** 8.42 (5.13, 13.82)*** 
Type 1 Diabetes No (Ref) (Ref) 
 Yes 0.70 (0.50, 1.00)* - 
Kidney Disease No (Ref) (Ref) 








Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
Chemotherapy No (Ref) (Ref) 
 Yes 1.56 (1.23, 1.96)*** 1.57 (1.24, 1.98)*** 
Nephrectomy No (Ref) (Ref) 
 Yes 0.71 (0.54, 0.94)* 0.75 (0.57, 0.99)* 
Gender Female (Ref) (Ref) 
 Male 0.75 (0.60, 0.93)** 0.75 (0.61, 0.93)** 
Note. CVC = central venous catheter; PE = pulmonary embolism; RCC = renal cell carcinoma. 
a Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier 
(EMM). 
b Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and 
diabetes were components of the Charlson score and were not assessed in the model. 
c More than 30 days before the outcome. 
* p < .05. ** p < .01. *** p < .001. 
 
The risk factors associated with other VTE in the follow-up period were age at 
diagnosis; Northeast region; year of diagnosis; Stage III, IV, and unknown Stage; history 
of other VTE; history of CVD; high-risk surgery; and central venous catheter (Table 32). 
In the first model, treatment by chemotherapy was also a risk factor and a diagnosis of 
varicose veins was an EMM. Histology group was not a statistically significant risk factor 






Risk Factors Associated With Incidence of Other VTE in Follow-up Period After Kidney 
Cancer Diagnosis (N = 11,463) 
 Level 
 
Adjusted HR (95% 
CI)a 
Adjusted HR (95% CI)b 
Age at Diagnosis 66-69 (Ref) (Ref) 
 70-74 1.05 (0.75, 1.47) 1.02 (0.73, 1.43) 
 75-79 1.41 (1.01, 1.96)* 1.41 (1.02, 1.96)* 
 80-84 0.97 (0.66, 1.44) 0.86 (0.59, 1.27) 
 85+ 1.42 (0.92, 2.19) 1.36 (0.89, 2.09) 
Histology Group Clear Cell (Ref) (Ref) 
 Chromophobe/Other RCC 0.93 (0.67, 1.30) 0.94 (0.67, 1.30) 
 Papillary 0.98 (0.66, 1.46) 0.98 (0.66, 1.45) 
 Transitional cell tumor 0.58 (0.26, 1.33) 0.61 (0.27, 1.39) 
Charlson Score 0 (Ref) (Ref) 
 1 - 0.97 ( 0.67, 1.42 ) 
 2 to 3 - 1.19 ( 0.86, 1.63 ) 
 4+ - 1.22 ( 0.87, 1.73 ) 
Geographic Region West (Ref) (Ref) 
 Midwest 0.77 (0.52, 1.14) 0.81 (0.54, 1.19) 
 Northeast 1.40 (1.07, 1.83)* 1.47 (1.12, 1.91)** 
 South 1.16 (0.89, 1.51) 1.20 (0.92, 1.56) 
Year of Diagnosis  1.07 (1.00, 1.15)* 1.09 (1.02, 1.17)* 
Stage at Diagnosis Stage I (Ref) (Ref) 
 Stage II 0.92 (0.57, 1.50) 0.94 (0.57, 1.52) 
 Stage III 3.12 (2.42, 4.04)*** 3.13 (2.42, 4.04)*** 
 Stage IV 1.66 (1.18, 2.34)** 1.57 (1.11, 2.22)* 
 Stage Unknown 1.62 (1.11, 2.36)* 1.73 (1.20, 2.50)** 
History of Condition No (Ref) (Ref) 
 Yes 28.94 (21.46, 39.04)*** 26.33 (19.62, 35.33)*** 
History of CVD No (Ref) (Ref) 
 Yes 0.63 (0.48, 0.84)** 0.62 (0.46, 0.83)** 
High-risk surgeryc No (Ref) (Ref) 








Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
CVCc No (Ref) (Ref) 
 Yes 3.82 (2.29, 6.38)*** 3.88 (2.31, 6.52)*** 
Chemotherapy No (Ref) (Ref) 
 Yes 1.31 (1.02, 1.67)* 1.26 (0.99, 1.62) 
Gender Female (Ref) (Ref) 
 Male without varicose veins 0.97 (0.78, 1.20) - 
 Male with varicose veins 0.13 (0.04, 0.38)*** - 
Note. CVC= central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); Other VTE = other venous 
thromboembolic event; RCC = renal cell carcinoma. 
a Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier 
(EMM). 
b Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and 
diabetes were components of the Charlson score and were not assessed in the model. 
c More than 30 days before the outcome. 
* p < .05. ** p < .01. *** p < .001. 
 
The null hypotheses could not be rejected for any of the venous thromboembolic 
events as at least one factor was associated with the occurrence of a new event after 
kidney cancer diagnosis. With regards to histology group, the null hypothesis was not 
rejected for any VTE, except when the model was adjusted by the Charlson comorbidity 
score. It was also not rejected for pulmonary embolism in either model. The null 
hypothesis would have been rejected for DVT and other VTEs if only considering 
histology. 
Post-hoc analyses. Because the number of patients with ATEs was larger than 
expected, models to assess the risk factors associated with these outcomes were produced 
in the post-hoc analyses. The risk factors associated with any ATE were age of 75 or 
older at diagnosis, geographic region (Northeast or South versus West), year of diagnosis, 




atherosclerosis, chemotherapy and nephrectomy (Table 33). Receipt of chemotherapy or 
nephrectomy were associated with a decreased risk of ATE. In the first model, type 1 
diabetes and kidney disease were also risk factors for any ATE. In the second model, the 
risk increased with Charlson comorbidity score (HR = 1.97 for a score of 1, HR = 3.01 





Risk Factors Associated With Incidence of Any ATE in Follow-up Period After Kidney 
Cancer Diagnosis (N = 11,463) 
 Level 
 
Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
Age at Diagnosis 66-69 (Ref) (Ref) 
 70-74 1.05 (0.86 - 1.29) 1.04 (0.85 - 1.28) 
 75-79 1.30 (1.06 - 1.58)* 1.27 (1.04 - 1.55)* 
 80-84 1.36 (1.10 - 1.69)** 1.32 (1.06 - 1.63)* 
 85+ 1.53 (1.20 - 1.96)*** 1.50 (1.17 - 1.91)** 
Histology Group Clear Cell (Ref) (Ref) 
 Chromophobe/Other RCC 1.00 (0.83 - 1.21) 1.00 (0.83 - 1.20) 
 Papillary 0.99 (0.79 - 1.24) 0.99 (0.79 - 1.24) 
 Transitional cell tumor 0.75 (0.47 - 1.21) 0.78 (0.48 - 1.26) 
Charlson Score 0 (Ref) (Ref) 
 1 - 1.97 (1.43 - 2.72)*** 
 2 to 3 - 3.01 (2.26 - 4.00)*** 
 4+ - 4.50 (3.39 - 5.99)*** 
Geographic Region West (Ref) (Ref) 
 Midwest 1.25 (1.03 - 1.52)* 1.19 (0.98 - 1.44) 
 Northeast 1.22 (1.04 - 1.44)* 1.20 (1.02 - 1.41)* 
 South 1.30 (1.11 - 1.51)** 1.25 (1.07 - 1.45)** 
Stage at Diagnosis Stage I (Ref) (Ref) 
 Stage II 1.18 (0.94 - 1.48) 1.18 (0.94 - 1.48) 
 Stage III 1.09 (0.91 - 1.30) 1.10 (0.92 - 1.32) 
 Stage IV 1.38 (1.11 - 1.71)** 1.44 (1.16 - 1.78)*** 
 Stage Unknown 1.08 (0.88 - 1.33) 1.10 (0.90 - 1.36) 
Year of Diagnosis (continuous) 1.05 (1.01 - 1.09)* 1.05 (1.01 - 1.09)* 
History of Condition No (Ref) (Ref) 
 Yes 2.93 (2.31 - 3.71)*** 2.99 (2.43 - 3.68)*** 
History of CVD No (Ref) (Ref) 
 Yes 1.30 (1.11 - 1.52)** - 
High-risk surgeryc No (Ref) (Ref) 








Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
CVCc No (Ref) (Ref) 
 Yes 4.31 (3.32 - 5.60)*** 4.38 (3.37 - 5.69)*** 
Type 1 Diabetes No (Ref) (Ref) 
 Yes 1.45 (1.24 - 1.71)*** - 
Kidney Disease No (Ref) (Ref) 
 Yes 1.65 (1.44 - 1.89)*** - 
Atherosclerosis No (Ref) (Ref) 
 Yes 1.40 (1.23 - 1.60)*** 1.26 (1.10 - 1.45)*** 
Chemotherapy No (Ref) (Ref) 
 Yes 0.84 (0.72 - 0.98)* 0.81 (0.70 - 0.95)** 
Nephrectomy No (Ref) (Ref) 
 Yes 0.76 (0.65 - 0.89)*** 0.75 (0.64 - 0.88)*** 
Note. Any ATE = any arterial thromboembolic event (MI or IS); CVC= central venous catheter; CVD = 
cardiovascular disease (myocardial infarction, ischemic stroke, new onset congestive heart failure, angina 
or transient ischemic attack); IS = ischemic stroke; MI = myocardial infarction; RCC = renal cell 
carcinoma. 
a Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier 
(EMM). 
b Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and 
diabetes were components of the Charlson score and were not assessed in the model. 
c More than 30 days before the outcome. 
* p < .05. ** p < .01. *** p < .001. 
 
The risk factors associated with myocardial infarction were region (Midwest or 
Northeast where West was the reference), year of diagnosis, stage IV (versus stage I) at 
diagnosis, history of myocardial infarction, high-risk surgery and placement of CVD 
(Table 34). Chemotherapy and nephrectomy were protective against myocardial 
infarction with hazard ratios ranging from 0.75 to 0.77. In the first model, history of 
CVD, Type 1 diabetes, atherosclerosis, and kidney disease were associated with greater 
rates of myocardial infarction. In the second model, the hazard ratio increased with 





Risk Factors Associated With Incidence of MI in Follow-up Period After Kidney Cancer 
Diagnosis (N = 11,463) 
 Level 
 
Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
Age at Diagnosis 66-69 (Ref) (Ref) 
 70-74 0.98 (0.76, 1.28) 0.97 (0.75, 1.26) 
 75-79 1.01 (0.78, 1.31) 1.01 (0.78, 1.30) 
 80-84 1.23 (0.93, 1.62) 1.20 (0.91, 1.58) 
 85+ 1.36 (0.99, 1.88) 1.35 (0.98, 1.86) 
Histology Group Clear Cell (Ref) (Ref) 
 Chromophobe/Other RCC 1.06 (0.83, 1.36) 1.05 (0.82, 1.35) 
 Papillary 1.05 (0.78, 1.41) 1.06 (0.79, 1.42) 
 Transitional cell tumor 1.03 (0.60, 1.75) 1.04 (0.61, 1.78) 
Charlson Score 0 (Ref) (Ref) 
 1 - 2.63 (1.64, 4.22)*** 
 2 to 3 - 3.35 (2.18, 5.16)*** 
 4+ - 6.95 (4.56, 10.59)*** 
Geographic Region West (Ref) (Ref) 
 Midwest 1.40 (1.09, 1.81)** 1.33 (1.03, 1.71)* 
 Northeast 1.24 (1.00, 1.54* 1.26 (1.02, 1.55)* 
 South 1.17 (0.95, 1.44) 1.12 (0.91, 1.38) 
Year of Diagnosis  1.08 (1.02, 1.14)** 1.08 (1.02, 1.14)** 
Stage at Diagnosis Stage I (Ref) (Ref) 
 Stage II 1.34 (1.01, 1.80)* 1.31 (0.98, 1.74) 
 Stage III 1.07 (0.84, 1.37) 1.08 (0.85, 1.37) 
 Stage IV 1.48 (1.11, 1.98)** 1.50 (1.12, 1.99)** 
 Stage Unknown 1.13 (0.86, 1.48) 1.14 (0.87, 1.50) 
History of Condition No (Ref) (Ref) 
 Yes 4.80 (3.55, 6.48)*** 5.01 (3.81, 6.60)*** 
History of CVD No (Ref) (Ref) 
 Yes 1.36 (1.12, 1.64)** - 
High-risk surgeryc No (Ref) (Ref) 








Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
CVCc No (Ref) (Ref) 
 Yes 4.87 (3.40, 6.96)*** 5.23 (3.64, 7.51)*** 
Diabetes Type 1 No (Ref) (Ref) 
 Yes 1.54 (1.25, 1.89)*** - 
Atherosclerosis No (Ref) (Ref) 
 Yes 1.24 (1.03, 1.49)* - 
Kidney Disease No (Ref) (Ref) 
 Yes 2.30 (1.89, 2.80)*** - 
Chemotherapy No (Ref) (Ref) 
 Yes 0.77 (0.62, 0.95)* 0.76 (0.61, 0.94)* 
Nephrectomy No (Ref) (Ref) 
 Yes 0.75 (0.61, 0.93)** 0.76 (0.62, 0.94)* 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); MI = myocardial infarction; 
RCC = renal cell carcinoma. 
a Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier 
(EMM). 
b Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and 
diabetes were components of the Charlson score and were not assessed in the model. 
c More than 30 days before the outcome. 
* p < .05. ** p < .01. *** p < .001. 
 
Age at diagnosis 75 years or older, history of ischemic stroke, history of CVD, 
atherosclerosis, CVC, high-risk surgery and diagnoses in the South region were 
associated with greater risk of ischemic stroke after kidney cancer diagnosis (Table 35). 
ischemic stroke occurred less frequently in patients with transitional cell tumors 
compared to patients with clear cell tumors (HR = 0.22 for model 1; HR = 0.21 in model 
2). The risk of ischemic stroke was also lower in patients who had a nephrectomy 
compared to patients who did not. In the first model, males with Type 1 were at greater 
risk of ischemic stroke. In the second model, the risk increased with increasing Charlson 








Risk Factors Associated With Incidence of IS in Follow-up Period After Kidney Cancer 
Diagnosis (N = 11,463) 
 Level 
 
Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
Age at Diagnosis 66-69 (Ref) (Ref) 
 70-74 1.04 (0.78 - 1.39) 1.05 (0.78 - 1.40) 
 75-79 1.38 (1.04 - 1.83)* 1.34 (1.01 - 1.78)* 
 80-84 1.41 (1.04 - 1.93)* 1.33 (0.98 - 1.82) 
 85+ 1.68 (1.19 - 2.37)** 1.61 (1.14 - 2.27)** 
Histology Group Clear Cell (Ref) (Ref) 
 Chromophobe/Other RCC 1.01 (0.78 - 1.31) 1.00 (0.76 - 1.30) 
 Papillary 0.97 (0.71 - 1.32) 1.01 (0.74 - 1.38) 
 Transitional cell tumor 0.22 (0.05 - 0.87)* 0.21 (0.05 - 0.85)* 
Charlson Score 0 (Ref) (Ref) 
 1 - 1.61 (1.04 - 2.49)* 
 2 to 3 - 2.83 (1.95 - 4.11)*** 
 4+ - 3.02 (2.07 - 4.41)*** 
Geographic Region West (Ref) (Ref) 
 Midwest 1.10 (0.84 - 1.46) 1.07 (0.81 - 1.41) 
 Northeast 1.05 (0.83 - 1.33) 1.04 (0.82 - 1.31) 
 South 1.52 (1.23 - 1.88)*** 1.49 (1.20 - 1.84)*** 
Stage at Diagnosis Stage I (Ref) (Ref) 
 Stage II - 0.96 (0.67 - 1.36) 
 Stage III - 1.17 (0.91 - 1.50) 
 Stage IV - 1.38 (1.02 - 1.87)* 
 Stage Unknown - 1.14 (0.85 - 1.53) 
History of Condition No (Ref) (Ref) 
 Yes 2.23 (1.48 - 3.36)*** 2.44 (1.67 - 3.58)*** 
History of CVD No (Ref) (Ref) 
 Yes 1.29 (1.04 - 1.59)* - 
High-risk surgeryc No (Ref) (Ref) 








Adjusted HR (95% 
CI)a 
Adjusted HR (95% 
CI)b 
CVCc No (Ref) (Ref) 
 Yes 4.30 (2.76 - 6.70)*** 4.05 (2.61 - 6.29)*** 
Atherosclerosis No (Ref) (Ref) 
 Yes 1.57 (1.31 - 1.90)*** 1.45 (1.20 - 1.75)*** 
Type 1 Diabetes No (Ref) (Ref) 
 Yes 1.38 (1.10 - 1.74)** - 
Nephrectomy No (Ref) (Ref) 
 Yes 0.74 (0.60 - 0.90)** 0.72 (0.58 - 0.90)** 
Note. CVC = central venous catheter; CVD = cardiovascular disease (myocardial infarction, ischemic 
stroke, new onset congestive heart failure, angina or transient ischemic attack); IS = ischemic stroke; RCC 
= renal cell carcinoma. 
a Model assessing kidney disease, Type 1 and Type 2 diabetes as a potential confounder or effect measure modifier 
(EMM). 
b Model assessing Charlson score as a potential confounder or effect measure modifier (EMM). Kidney disease and 
diabetes were components of the Charlson score and were not assessed in the model. 
c Central venous catheter and high-risk surgery were more than 30 days before outcome. 
* p < .05. ** p < .01. *** p < .001. 
 
Summary 
After applying inclusion criteria, exclusion criteria, and matching the exposed 
kidney cancer cohort to the unexposed noncancer cohort, 11,463 patients in each cohort 
were included in this study. The first descriptive analysis objectives were to describe the 
incidence rates of venous and arterial thromboembolic events in the exposed cohort. 
Tables 8 to 14 described the incidence rates of VTEs and ATEs in the year prior to 
kidney cancer diagnosis in the exposed cohort. The incidence rates varied greatly across 
type of thromboembolic event. For VTEs, the lowest incidence rate occurred for 
pulmonary embolism (7.88 per 1,000 p-y) and the highest rate occurred for DVT (21.71 
per 1,000 p-y). The incidence rate for any VTE (pulmonary embolism, DVT, or other 




per 1,000 p-y while the rate for ischemic stroke was 76.02 per 1,000 p-y. The incidence 
rate for any ATE (myocardial infarction or ischemic stroke) was 31,32 per 1,000 p-y. The 
incidence rates varied across strata and outcome, however consistently the incidence rates 
were higher in patients who had a history of the condition in the year prior to the period 
start and increased with increasing Charlson score. 
The second objective of the first descriptive analysis was to describe the incidence 
rates of thromboembolic events in the follow-up period after kidney cancer diagnosis. 
Tables 15 to 21 describe the incidence rates in this period overall and by patient 
characteristics and covariates. For any VTE, DVT, and PVT the incidence rates after 
kidney cancer diagnosis were higher than the rates in the year prior to kidney cancer 
diagnosis. The incidence rates for other VTE and for myocardial infarction were slightly 
higher in the follow-up period than in the year prior to kidney cancer diagnosis. The 
incidence rate for ischemic stroke was lower in the year prior to kidney cancer diagnosis 
(15.19 per 1,000 p-y) than in the period after kidney cancer diagnosis (19.39 per 1,000 p-
y). Similar to the period prior to kidney cancer diagnosis, for each outcome the incidence 
rate was much higher in patients with a history of the condition in the year prior and 
increased with increasing Charlson score. 
The objective of the second descriptive analysis was to describe the incidence 
proportions of thromboembolic events in discrete periods after kidney cancer diagnosis. 
Table 22 to 24 show the incidence rates within 90 days, 91 to 181 days, 181 to 270 days, 
271 to 365 days, and for the entire follow-up period. Within the first year after the 




and decreased in later periods. The incidence proportions were highest for the entire 
follow-up period. 
The first research question modeled the incidence rate ratios for thromboembolic 
events in the exposed cohort compared to the unexposed cohort in the year prior to index 
date. Tables 25 and 26 show the results for the crude and adjusted models. For every 
thromboembolic event except ischemic stroke, the crude hazard ratio was significantly 
greater than 1.0 at the 0.05 level. After adjusting the models, the incidence rate ratios 
were greater than 1.0 for any VTE, DVT, and pulmonary embolism. For other VTEs, the 
incidence rate was higher in the exposed cohort than the unexposed cohort in patients 
without a history of CVD (HR = 1.41, 95% CI 1.02 – 1.96) after adjusting for matching, 
type 2 diabetes and a diagnosis of varicose veins. For any arterial thromboembolic events 
and ischemic stroke, the adjusted hazard ratios were not statistically different from 1.0. 
The second research question modeled the incidence rate ratios for 
thromboembolic events in the exposed cohort compared to the unexposed cohort in the 
follow-up period after the index date. Tables 27 and 28 show the results for the crude and 
adjusted models. The crude incidence rates for venous thromboembolic events in the 
exposed cohort were three times the incidence rates in the unexposed cohort (Table 27). 
After adjusting the models, for most patients the incidence rates for VTEs in the exposed 
cohort were 57% to 542% greater than the rates in the unexposed cohort. For arterial 
thromboembolic events, the crude hazard ratios ranged from 1.47 to 2.17 and were 
statistically significant at the 0.05 level (Table 28). After adjusting, the incidence rate 




patients without atherosclerosis and without kidney disease (HR = 1.47, 95% CI 1.21 – 
1.79); and without atherosclerosis (HR = 1.27, 95% CI 1.08 – 1.49) in the second model 
adjusted for the Charlson score and other factors. For myocardial infarction, the adjusted 
incidence rate ratio was greater than 1.0 in patients without atherosclerosis and without 
history of myocardial infarction (HR = 1.42, 95% CI 1.10 – 1.84) in the first model; in 
the second model, the incidence rate ratio was greater than 1.0 in patients without history 
of myocardial infarction (HR = 1.35, 95% CI 1.11 – 1.65). In patients with a history of 
myocardial infarction, the incidence rate ratio was 0.05 or less in both models (Table 28). 
For ischemic stroke, the adjusted incidence rate ratio was statistically greater than 1.0 in 
patients without kidney disease in the first model (HR = 1.34, 95% CI 1.06-1.70). The 
incidence rate ratio was 0.52 for patients with kidney disease. In the second model, 
patients with atherosclerosis had an adjusted hazard ratio of 0.55 (95% CI 0.34 – 0.90) 
which was statistically significant at the 0.05 level (Table 28). 
Research question 3 assessed potential risk factors for venous thromboembolic 
events in kidney cancer patients after kidney cancer diagnosis. Histology group was only 
statistically significantly associated with incidence of pulmonary embolism (Table 31). 
Placement of a CVC, Stage III, and Stage IV tumors at diagnosis were risk factors for any 
VTE, DVT, pulmonary embolism, and other VTEs. Other characteristics were not 
consistent risk factors across the types of venous thromboembolic events.  
Due to sufficient numbers of patients with myocardial infarction and ischemic 
stroke, the risk factors for these arterial thromboembolic events were also assessed 




high-risk surgery, and Stage IV tumors at diagnosis were risk factors for any ATE, 
myocardial infarction, and ischemic stroke. Nephrectomy appeared protective against the 
arterial outcomes. 
The incidence rates and risk factors for venous and arterial thromboembolic 
events differed by each type of event as well as demographic and patient characteristics 
in kidney cancer patients. In the year prior to index date, the incidence rates were higher 
for the exposed cohort than the unexposed cohort for any VTE, DVT, and pulmonary 
embolism. For other VTEs and myocardial infarction the incidence rates for the outcomes 
were higher in the exposed cohort than the unexposed cohort in patients without a history 
of CVD. In the follow-up period after index date, the incidence rates were higher in the 
exposed cohort than the unexposed cohort for all of the venous thromboembolic events; 
but the relationship was less consistent for the arterial thromboembolic events. In chapter 
5, I discuss the interpretations of the findings, the limitations of the study, 





Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this study was to describe the incidence rates of venous and 
arterial thromboembolic events in elderly kidney cancer patients; describe incidence 
proportions of thromboembolic events in elderly kidney cancer patients in the period 
following cancer diagnosis; compare the incidence rates of thromboembolic events in 
elderly kidney cancer patients to matched noncancer patients in the year prior to index 
date and in the follow-up period after index date; and assess risk factors for venous 
thromboembolic events in elderly kidney cancer patients after cancer diagnosis. Because 
there were sufficient number of patients with myocardial infarction and ischemic stroke, 
risk factors for those arterial thromboembolic events in elderly kidney cancer patients 
were also assessed as post-hoc analyses. I conducted a retrospective cohort study using 
linked cancer registry and administrative claims data in elderly patients with Medicare 
coverage to achieve the study objectives. Use of the linked database provided population-
based data containing cancer-specific information including histology type and stage 
along with demographic, treatment, outcome, and potential confounder information. 
The incidence rates of VTEs and ATEs differed by patient and tumor 
characteristics in the period before and period after kidney cancer diagnosis. In the period 
after cancer diagnosis, the incidence rates for most thromboembolic events were higher 
than in the year prior to the cancer diagnosis. Within the first year after cancer diagnosis, 




event (Tables 22 to 24). It was hypothesized that the incidence rates of VTEs and ATEs 
in the kidney cancer patients would be higher than rates in the noncancer patients. In the 
year prior to the index date, the null hypothesis could not be rejected for any VTE, DVT, 
or pulmonary embolism. The incidence rates for these outcomes were higher in kidney 
cancer patients than in the noncancer patients in the year prior to the index date. In the 
period after the index date, the null hypothesis could also not be rejected for any VTE, 
DVT, or pulmonary embolism. For these outcomes, the incidence rates were higher in the 
kidney cancer patients than in the noncancer patients in the follow-up period after the 
index date. Several factors were identified which affected the risk of VTEs or ATEs after 
kidney cancer diagnosis. This chapter interprets the findings for each of the descriptive 
analyses and research questions, describes the study limitations, and provides 
recommendations for further research. The implications for positive social change are 
discussed and the study conclusion stated.  
Interpretation of the Findings 
Descriptive Analysis 1 
The year prior to kidney cancer diagnosis. The incidence rates of DVT, 
pulmonary embolism, and other VTEs in the year prior to kidney cancer diagnosis were 
21.7, 7.9 and 11.3 per 1,000 p-y, respectively (Tables 9 to 11). These rates are much 
lower than the rates for RCC patients reported by Connelly-Frost et al. (2013) of 32.2, 
8.0, and 23.7 per 1,000 p-y in their analysis of RCC patients diagnosed between 1991 and 
2003. Walker et al. (2013) reported that the incidence rates for venous thromboembolic 




were diagnosed with kidney cancer in later years than patients in the Connelly-Frost et al. 
(2013) study, it would have been expected for the incidence rates to be higher than 
previously reported, not lower. The inclusion of other kidney cancer histology groups 
does not explain the difference in rates. One possible reason for the lower incidence rates 
is that possible invalid diagnoses or rule-out diagnoses were removed from the analysis 
data prior to identifying the outcomes and comorbid conditions. Diagnoses were included 
if they were on inpatient claims, or there were at least two different physician or 
outpatient claims that were more than 30 days apart. The program to do this was 
publically available from the SEER-Medicare web site 
(http://healthcaredelivery.cancer.gov/seermedicare/program/comorbidity.html). 
Connelly-Frost et al. (2013) did not apply these exclusions to the claims data. If those 
exclusions had not been applied, the incidence rates for DVT, pulmonary embolism, and 
other VTEs were 39.1, 11.5, and 19.2 per 1,000 p-y, respectively. Those rates are more 
similar to those reported by Connelly-Frost et al. (2013) in the 12 months prior to the 
cancer diagnosis. 
The incidence rates for any ATE (myocardial infarction or ischemic stroke), 
myocardial infarction, and ischemic stroke in the year prior to cancer diagnosis were 
31.3, 16.9, and 15.2 per 1,000 p-y (Tables 12 to 14). The incidence rates for these 
conditions in kidney cancer patients prior to the cancer diagnosis were not identified in 
the published literature. For Medicare beneficiaries, the incidence rates of hospitalization 
for acute myocardial infarction decreased from 10.2 per 1,000 p-y in 2004 to 8.7 per 




myocardial infarction from this study is higher than the incidence rate for acute 
myocardial infarction in Medicare patients in general, which is not surprising as the 
definition of myocardial infarction used for this study was not restricted to only acute 
events. 
The incidence rate for ischemic stroke in cancer patients in this study (15.2 per 
1,000 p-y) was higher than the rate of ischemic stroke in the general Medicare 
population. The annual incidence rate for ischemic stroke in Medicare beneficiaries in 
2008 was 11.5 per 1,000 (Casper, Nwaise, Crost, & Nilasena, 2008).  
The follow-up period after kidney cancer diagnosis. The incidence rate of DVT 
in the follow-up period after kidney cancer diagnosis, 53.0 per 1,000 person-years (Table 
15), was higher than the rate of any VTE (14.0 per 1,000 person-years) reported by 
Walker et al. (2013) but less than the rate for DVT of 108.2 per 1,000 person-years 
reported by Connelly-Frost et al. (2013). Part of the reason for the discrepancy was 
differences in methodologies used including not excluding patients with a history of the 
condition, use of entire follow-up period even if longer than 12 months, and removing 
potential rule-out diagnoses prior to calculating the incidence rates. Walker et al. (2013) 
excluded patients with a VTE prior to cancer; however, the incidence rate in patients 
without a history of any VTE was 42.75 (Table 15) which is still much higher than the 
rate reported by Walker et al. (2013). One difference is that only 12 months prior to the 
study period of interest were included for identifying history of VTE, whereas Walker et 
al. (2013) excluded patients if they had a VTE any time prior to the first cancer diagnosis. 




VTE may be a contributing factor for the differences in reported incidence rates. Another 
factor may be this study population included American patients whereas Walker et al. 
(2013) reported rates in patients in the United Kingdom. Walker et al. (2013) reported an 
incidence rate of 4.3 per 1,000 p-y for VTEs in the noncancer cohort age 60 or older. The 
incidence rates for VTEs in a U.S. population by age group ranged from 1.69 to 8.49 per 
1,000 p-y for females, and 1.63 to 9.84 per 1,000 p-y for males (Silverstein et al., 1998). 
Both Walker et al. (2013) and I allowed for follow-up periods of longer than 12 months. 
Connelly-Frost et al. (2013) included patients with a history of VTE prior to cancer 
diagnosis but restricted follow-up to 12 months. Without the rule-out diagnosis exclusion 
applied, the incidence rates for DVT, pulmonary embolism, and other VTEs in the 
follow-up period after cancer diagnosis were 66.5, 21.7, and 27.7, respectively as 
compared to 108.2, 30.0, and 49.0 as reported by Connelly-Frost et al. (2013). The 
combination of the removal of the rule-out diagnoses and the longer follow-up period is 
the probable reason for the lower incidence rates in this study as compared with 
Connelly-Frost et al. (2013).  
The incidence rates of any ATE, myocardial infarction, and ischemic stroke were 
39.7, 21.9, and 19.4 per 1,000 p-y, respectively (Table 19 to Table 21). These incidence 
rates were higher than expected based on the literature found, however that may be due to 
differences in the real world population included in this study and clinical trial 
populations. Arterial events were rare in clinical trial patients of chemotherapy-treated 
RCC patients (Bayer HealthCare Pharmaceuticals, 2013; Choueiri et al., 2010; 




definition of ATE for several studies (Choueiri et al., 2010; Petrelli et al., 2012). The 
number of clinical trial participants was small compared to this population-based study, 
include stricter inclusion and exclusion criteria for the study participants, and were not 
restricted solely to elderly patients with Medicare coverage. 
Descriptive Analysis 2 
The incidence proportions of venous thromboembolic events were higher in the 
period closest to cancer diagnosis then decreased in later periods. These findings were 
consistent with other published studies (Chew et al., 2008; Connelly-Frost et al., 2013; 
Moore et al., 2011; Walker et al., 2013). None of these studies reported the incidence 
proportions for the entire follow-up period so that could not be compared. Incidence 
proportions of arterial thromboembolic events in cancer patients were not identified in the 
published literature. 
Research Question 1 
The incidence rate ratios estimates for DVT and pulmonary embolism in the year 
prior to the index date were not dissimilar from the relative risks presented by Connelly-
Frost et al. (2013). Connelly-Frost et al. (2013) reported a relative risk of 1.6 (95% CI 1.3 
– 1.9) for DVT, while the two models in this study estimated the incidence rate ratio to be 
1.50 to 1.57 (Table 25). Connelly-Frost et al. (2013) reported a relative risk of 1.8 (95% 
CI 1.3 – 2.6) for pulmonary embolism; the estimates from this study were 1.5 and 1.8 
(Table 25). I did not find a statistically significant difference in the incidence rate ratios 
for other VTEs after adjusting for other factors (Table 28), however Connelly-Frost et al. 




incidence rate ratios for other VTEs stratified by history of CVD. The incidence rate ratio 
was higher in cancer patients than the noncancer patients for patients without a history of 
CVD. Connelly-Frost et al. (2013) reported 1.7 (95% CI 1.3 – 2.1) and this analysis 
resulted in an incidence rate ratio of 1.4 (95% CI 1.0 – 2.0) (Table 25). Neither study 
found a significant difference in the incidence rates for the patients with a history of CVD 
(HR = 0.8, 95% CI 0.4 – 1.8 from this study; OR = 1.0, 95% CI 0.7 – 1.4 from Connelly-
Frost et al., 2013).  
The incidence rate ratios estimated in this study for venous thromboembolic 
events were in the same direction, but lower than the standardized incidence ratio 
reported for kidney cancer patients diagnosed in California. White et al. (2005) reported a 
standardized incidence ratio of 2.5 (95% CI 1.5 – 3.9) for the year prior to cancer 
diagnosis. The difference in the estimates may be due to the differences in the 
populations as the White et al. (2005) study analyzed adults aged 18 or older diagnosed 
with cancer in California prior to 2000. The participants in this study were 66 years or 
older at first cancer diagnosis, more geographically distributed and diagnosed in later 
years. Another difference is in the measures used by the two studies. While White et al. 
(2005) calculated a standardized incidence ratio, I calculated hazard ratios to estimate 
incidence rate ratios. 
No studies were found in the published literature of the incidence rate ratios of 
myocardial infarction or ischemic stroke comparing kidney cancer cohort to a noncancer 
cohort in the year prior to the index date. After adjusting for other factors, the incidence 




between the two cohorts. For myocardial infarction the incidence rates were higher in the 
kidney cancer cohort than the noncancer cohort in the patients without a history of CVD. 
Conversely, in patients with a history of CVD the first model (which assessed diabetes 
and kidney disease instead of the Charlson score as potential confounders and effect 
measure modifiers) found that the incidence rates were lower in the kidney cancer 
patients. The second model, which adjusted by the Charlson score, produced a hazard 
ratio of 1.18; however it was not statistically significant at the 0.05 level. This is 
consistent with the findings of lung cancer patients in the Netherlands who did not have a 
statistically significant increased incidence of myocardial infarction or ischemic stroke in 
the year prior to cancer diagnosis (van Herk-Sukel et al., 2013). While the incidence rates 
of ATEs may be higher in cancer patients than in the general Medicare population, it does 
not appear that kidney tumors are the reason for the higher rates. Other factors in the 
cancer population such as comorbidity score are more likely the drivers for the incidence 
rates of ATEs in this population. 
Research Question 2 
The incidence rate ratios for venous thromboembolic events in the follow-up 
period after index date were higher in the kidney cancer cohort than the noncancer cohort 
(Table 27). Blom et al. (2005) also reported a higher risk of VTE after kidney cancer 
diagnosis compared to noncancer patients (adjusted OR = 6.2, 95% CI 0.8 – 46.5), even 
though it was not statistically significant at the 0.05 level. Connelly-Frost et al. (2013) 
reported higher incidence rate ratios in the cancer cohort than the noncancer cohort for 




higher incidence rates of DVT in the cancer cohort than noncancer cohort in patients 
without atherosclerosis (HR = 3.6, 95% CI 2.9 – 4.4) and with atherosclerosis (HR = 1.8, 
95% CI 1.1 – 2.7) (Table 27). The first model in this study included higher incidence 
rates in the cancer cohort except for those with both atherosclerosis and kidney disease 
(Table 27). Although Connelly-Frost et al. (2013) restricted their maximum duration of 
follow-up to 12 months, their study similarly reported higher incidence rates for DVT in 
the cancer cohort stratified by atherosclerosis (HR = 2.0, 95% CI 1.5 – 2.6 for patients 
with atherosclerosis; HR = 4.1, 95% CI 3.5 – 4.9 for patients without atherosclerosis) 
(Connelly-Frost et al., 2013).  
The incidence rate ratio for pulmonary embolism was approximately three fold 
higher in the kidney cancer patients than the noncancer cohort (Table 27). Connelly-Frost 
et al. (2013) reported a hazard ratio of 4.3 (95% CI 3.2 – 5.7) for pulmonary embolism in 
the year after index date. The incidence rate ratio for other VTE was higher for the cancer 
cohort as well. The second model yielded an adjusted hazard ratio of 2.7 (95% CI 2.1 – 
3.4) (Table 27). The hazard ratio for other VTE reported by Connelly-Frost et al. (2013) 
was very similar (HR = 2.4, 95% CI 2.0 – 2.8). The first model reported higher incidence 
rates in the cancer cohort for patients without type 2 diabetes and without kidney disease 
(HR = 4.3, 95% CI 2.9 – 6.4). There was a two-fold increase for patients with only one of 
kidney disease or type 2 diabetes, but the result was only statistically significant for 
patients without kidney disease (Table 27). 
In the follow-up period after the kidney cancer diagnosis, the results for arterial 




cohort. For any ATE, the first adjusted model yielded an adjusted hazard ratio of 1.5 for 
patients without atherosclerosis and without kidney disease (Table 28). For patients with 
both atherosclerosis and kidney disease, the adjusted hazard ratio was 0.6. The second 
model similarly reported an adjusted hazard ratio greater than 1.0 for patients without 
atherosclerosis (HR = 1.3), but a lower hazard ratio of 0.77 for patients with 
atherosclerosis. For myocardial infarction, the incidence rate for the cancer cohort was 
higher than the noncancer cohort for patients without a history of atherosclerosis or 
history of myocardial infarction (the first model) or patients without a history of 
myocardial infarction (second model). For ischemic stroke, the incidence rates were 
higher in the cancer cohort in patients who did not have kidney disease; incidence rates 
were lower in the cancer cohort in patients with kidney disease. After adjusting for the 
comorbidity score and other factors, the incidence rates of ischemic stroke were similar 
for the cancer and noncancer cohorts in patients without atherosclerosis (Table 28). For 
patients with atherosclerosis, the incidence rate for ischemic stroke was lower in the 
cancer cohort after adjusting for the Charlson comorbidity score and other factors (HR = 
0.6) (Table 28). The incidence rates for ATEs in cancer patients were higher than 
noncancer patients in the absence of atherosclerosis and kidney disease. In patients with 
atherosclerosis and kidney disease, the incidence rates of ATEs in cancer patients were 
half or less than the rates in noncancer patients. Cancer patients with more chronic 
conditions have greater healthcare utilization, including more primary care or specialist 
visits and hospitalizations, than cancer patients with less chronic conditions (Legler, 




Timing may also be a factor in whether or not the incidence rates were higher in cancer 
patients compared to noncancer patients. The hazard ratios for myocardial infarction and 
for ischemic stroke comparing lung cancer to noncancer patients were 1.0 or greater in 
the first six months after cancer diagnosis, but less than 1.0 for more than six months 
after diagnosis (van Herk-Sukel et al., 2011). 
Research Question 3 
Age was a risk factor for some venous thromboembolic events in the follow-up 
period after kidney cancer diagnosis. Age of 80 or older increased the risk of any VTE 
and DVT in kidney cancer patients compared to ages 66 to 69 at diagnosis (Tables 29 to 
30). For other VTEs, only age of 75 to 79 increased the risk of the event while age 80 or 
older at diagnosis was not a statistically significant predictor (Table 32). For pulmonary 
embolism, the risk of event decreased with increasing age at diagnosis (Table 31). Chew 
et al. (2006) nor Connelly-Frost et al. (2013) found age to be a statistically significant 
predictor for venous thromboembolic events in kidney cancer or elderly RCC patients. 
The differences in the study populations and duration of follow-up after cancer diagnosis 
may be the reasons some association with age was reported from this analyses but Chew 
et al. (2006) did not find the same association. Where age was assessed by 5-year age 
increments in this study and the population was elderly patients, the population studied 
by Chew et al. (2006) included patients of all ages and was younger (median age of 64 
years). Chew et al. (2006) also looked for an association of venous thromboembolic 
events in the 12 months after cancer diagnosis with 10-year age increments. I did not 




al. (2013) also assessed age as a risk factor in the 12 months after cancer diagnosis. I and 
Connelly-Frost et al. (2013) used the same 5-year age increments; however this study 
reported very different incidence rates due to the differences in duration of follow-up and 
use of the algorithm to remove potential rule-out diagnoses as discussed earlier. The 
percent changes in incidence rates from the 66 to 69 year olds to the 85 years or older in 
the Connelly-Frost et al. (2013) study were 38%, 2%, and 58% for DVT, pulmonary 
embolism, and other VTEs respectively. The percent changes for the incidence rates in 
this study were 99%, 24%, and 62%. So I may have found some association with age 
even though Connelly-Frost et al. (2006) did not due to the differences in the observed 
incidence rates and the pattern of rates by age group. Age was also not a risk factor for 
pulmonary embolism in lung cancer patients in the first six months after lung cancer 
diagnosis (van Herk-Sukel et al., 2013). However, age of 65 years or older at diagnosis 
was associated with higher risk of myocardial infarction and ischemic stroke in lung 
cancer patients compared to lung cancer patients less than 65 years old (van Herk-Sukel 
et al., 2013). 
Research on the risk of venous thromboembolism by histology group in kidney 
cancer patients was not found in the published literature. Histology was not a statistically 
significant risk factor for DVT or other VTEs in elderly kidney cancer patients (Tables 30 
and 32). The risk of any VTE was lower in transitional cell tumors compared to patients 
with clear cell tumors (Table 29). The hazard ratio from the second model (0.70) was 
very similar to the hazard ratio from the first model (0.67), however it was not 




against pulmonary embolism as well, with hazard ratios of 0.28 to 0.30. The risk of 
pulmonary embolism was increased in patients with papillary tumors as compared to 
clear cell tumors (Table 31). This is the first known study to examine this relationship in 
kidney cancer patients. This is the first evidence of any difference in risk of venous and 
thromboembolic events by histology type in kidney cancer patients. In other tumors, any 
difference in risk of thromboembolic events by histology type is inconsistent (Alcalay et 
al., 2006; Blom et al., 2004; Chew et al., 2007, 2008; Matsuo et al., 2015; van Herk-
Sukel et al., 2013). The findings from this study of elderly kidney cancer patients 
suggests that the thromboembolism preventive measures or care for these patients do not 
need to differ based on histology type. 
Compared to patients with Stage I tumors at diagnosis, patients diagnosed with 
Stage III or IV were at higher risk of any VTE, DVT, pulmonary embolism, and other 
VTEs (Tables 29 to 32). Unknown and unstaged tumors also increased the risk for any 
VTE, DVT and other VTEs, but not pulmonary embolism. Connelly-Frost et al. (2013) 
also found that later stage (regional or distant) tumors increased the risk of venous 
thromboembolism compared to localized tumors in elderly RCC patients. Other studies 
also reported higher risk of venous thromboembolic events in patients with metastatic or 
Stage IV tumors of other cancer types (Agnelli et al, 2006; Blom et al., 2005; Chavez-
MacGregor et al., 2011; Hall et al., 2009). 
History of the event in the 12 months prior to kidney cancer diagnosis was a 
significant risk factor for all types of venous thromboembolic events. The hazard ratios 




(first model, Table 31). These estimates consistent with the findings but higher than 
reported by previous studies (Agnelli et al., 2006; Connelly-Frost et al., 2013). 
Conversely, history of cardiovascular disease decreased the risk of any VTE and of other 
VTEs (Tables 29 and 32). As discussed below for the post hoc analysis, history of CVD 
increased the risk for any ATE, myocardial infarction and ischemic stroke (Tables 33 to 
35). One hypothesis as to why history of CVD would decrease the risk of VTEs is that 
those patients were more likely to die before having a venous event. Alternatively, the 
patients with a history of CVD may have been given medical therapy or therapeutic 
lifestyle changes as secondary prevention of coronary artery disease. These secondary 
prevention techniques include smoking cessation, physical activity regimens, dietary 
modification, weight management and pharmacologic treatments (Hall & Lorenc, 2010). 
These techniques may improve patient health and reduce the risk of not only coronary 
artery disease but also thromboembolic events. However, assessing that hypothesis is 
beyond the scope and capabilities of this study methodology. Additionally, as cardiac 
surgeries is one type of surgical procedure which can increase the risk of thromboembolic 
events, the healthcare provider may be more likely to give cardiac surgery patients 
prophylactic therapy or keep the patients under closer observation for thromboembolic 
events. 
Nephrectomy decreased the risk of pulmonary embolism, but was not a risk factor 
for the other venous thromboembolic events (Table 31). Connelly-Frost et al. (2013) did 
not find nephrectomy to be a risk factor for any venous thromboembolic event, but the 




tumor types also reported that cancer-directed surgery was not associated with venous 
thromboembolic events after adjusting for other factors (Blom et al., 2006; Hall et al., 
2009). I also found that nephrectomy was protective against any ATE, myocardial 
infarction, and ischemic stroke. One researcher reported that cancer-directed surgery in 
lung cancer patients was not associated with myocardial infarction or ischemic stroke 
(van Herk-Sukel et al., 2013). However, cancer-directed surgeries for different tumor 
types vary in body system affected, in type of surgery, and invasiveness. Thus, even 
though the findings from this study are consistent with findings in other tumor types, the 
comparison of findings across tumor types may not be appropriate. 
Chemotherapy however increased in the risk of all types of venous 
thromboembolic events in this study (Tables 29 to 32). This is consistent with the finding 
by Connelly-Frost et al. (2013) for DVT and other VTEs, but the Connelly-Frost et al. 
(2013) study did not find chemotherapy to be a risk factor for pulmonary embolism. The 
difference in findings may be due to different chemotherapy treatments used to treat RCC 
and kidney cancer patients prior to 2004. Chemotherapy was protective against any ATE 
and myocardial infarction. A study of lung cancer patients found no association between 
receipt of chemotherapy and myocardial infarction or ischemic stroke (van Herk-Sukel et 
al., 2013). Doyle et al. (2005) also did not find an association between receipt of 
chemotherapy and myocardial infarction in a study of elderly breast cancer patients. 
High-risk cardiac and vascular surgeries were not risk factors for DVT, but 
greatly increased the risk for pulmonary embolism and for other VTEs (Tables 30 to 32). 




result was not statistically significant (Table 29). Compared to females, men without 
high-risk surgery were at lower risk of any VTE (Table 29). Placement of a central 
venous catheter before an event significantly increased the risk of all venous 
thromboembolic events by 3.8 to 9-fold (Tables 29 to 32). These findings are the opposite 
of those reported by Connelly-Frost et al. (2013) where high-risk surgery or CVC before 
an event was a protective factor. The Chavez-MacGregor et al. (2011) study reported 
higher risk of VTEs in the year after breast cancer diagnosis with placement of a CVC. It 
is unclear why I found results the opposite of the Connelly-Frost et al. (2013) study. 
However, similar to other findings of this study which contradicted the results of the 
Connelly-Frost et al. (2013) study, the answer may lie in the difference in the follow-up 
period and the removal of the potential rule-out diagnoses. 
A Charlson score of two or greater, compared to a Charlson score of zero, was a 
risk factor for any VTE, DVT, and pulmonary embolism (Tables 29 to 31). For these 
events, in the first model which assessed diabetes and kidney disease instead, kidney 
disease increased the risk of the event however type 1 diabetes decreased the risk. Type 2 
diabetes was not a statistically significant risk factor for any of the venous 
thromboembolic events. The increased risk of DVT due to kidney disease is consistent 
with Connelly-Frost et al. (2013); however the risk of DVT was higher in patients 
without kidney disease. The risk of pulmonary embolism and other VTEs was not 
increased in patients with kidney disease (Connelly-Frost et al., 2013).  
I reported differences in the risks of any VTE and DVT by race and differences of 




Neither race, year of diagnosis, nor geographic region was reported to be statistically 
significant predictors of venous thromboembolic events in the study by Connelly-Frost et 
al. (2013). Several researchers adjusted for race and did not report the risk for events by 
racial groups (Chew et al., 2006; Doyle et al., 2005; Moore et al., 2011).  
A diagnosis of varicose veins was a risk factor for DVT in the Connelly-Frost et 
al. (2013) study and in this study (Table 30). A varicose veins diagnosis was also a risk 
factor in this study for any VTE (Table 29). Similar to Connelly-Frost et al. (2013), male 
gender was protective against DVT and pulmonary embolism (Tables 30 to 31). One 
model in this study also found that male gender was protective against other VTEs, 
however only in male patients with a diagnosis of varicose veins (Table 32). When an 
association is found, the presence of varicose veins and male gender are generally found 
to increase the risk of thromboembolic events in cancer patients compared to patients 
without varicose veins and female gender, respectively (Khorana & Connolly, 2009; 
Konigsbrugge et al., 2013). However, I and Connelly-Frost et al. (2013) reported 
opposite findings for an association with gender. The unexpected finding of lower risk of 
any VTE in males with varicose veins may be an artifact of the study population or the 
model. Further research will be needed to determine whether the result can be replicated. 
Post-hoc Analysis 
As the number of any ATE, myocardial infarction, and ischemic stroke were 
higher than expected, the risk factors for these events were also assessed. Kidney cancer 
patients with age at diagnosis of 70 or older were at higher risk of any ischemic stroke 




were at increased risk for any ATE (myocardial infarction or ischemic stroke) (Table 33). 
Increased risk for ischemic stroke in the older cancer patients is consistent with studies in 
other cancer types (Chen et al., 2011; van Herk-Sukel et al., 2011, 2013). Although I did 
not find age to be a statistically significant risk factor for myocardial infarction, another 
researcher and colleagues reported increased risk for myocardial infarction in older 
cancer patients (van Herk-Sukel et al., 2011, 2013). 
Patients with transitional cell tumors were at decreased risk for ischemic stroke 
compared to patients with clear cell tumors (Table 35). Histology group was not at risk 
factor for myocardial infarction or any ATE. van Herk-Sukel et al. (2013) found that the 
subtype of lung cancer did not increase the risk for myocardial infarction or ischemic 
stroke. However, the histology types were specific to lung cancer and are not 
generalizable to the histology groupings for kidney cancer.  
Patients with a history of the arterial event were at greater risk for any ATE, 
myocardial infarction and ischemic stroke (Tables 33 to 35). This finding is consistent 
with the findings in lung cancer patients as reported by van Herk-Sukel et al. (2013). A 
history of CVD was also still an independent risk factor for these arterial events after 
adjusting for history of the event and other factors.  
Patients with Stage IV tumors at diagnosis, Charlson score of one or greater, had a 
diagnosis of atherosclerosis, a diagnosis of kidney disease, or who had a CVC inserted 
were also at higher risk for any ATE, myocardial infarction, and ischemic stroke (Tables 
33 to 35). Geographic region other than the West was a risk factor for myocardial 




myocardial infarction (Table 34). Patients in the Northeast were also at higher risk for 
any ATE (Table 33). Males were at higher risk than females for any ATE and ischemic 
stroke if they also had a diagnosis of diabetes or high-risk surgery (Tables 33 and 35). 
Nephrectomy was protective against myocardial infarction or any ATE in kidney cancer 
patients (Tables 33 to 34). Chemotherapy was protective against myocardial infarction as 
well (Table 34). 
Theoretical Framework 
The advanced epidemiologic triangle as described by Merrill (2009) was the 
theoretical framework used to interpret the association between incident VTEs and ATEs 
with causative factors, environment and lifestyle factors, and population characteristics. 
In this study, the causative factors were kidney cancer, cancer stage and cancer 
treatments. The environment and lifestyle factors were high-risk surgeries and placement 
of central venous catheter. The population characteristics were age, region of diagnosis, 
race, Charlson comorbidity score and individual comorbidities. Time is also considered 
in the advanced epidemiologic triangle. 
The first research question examined the incidence rate ratios of thromboembolic 
events in cancer patients compared to noncancer patients in the year prior to the index 
date. In the advanced epidemiologic triangle used for this study, being diagnosed with 
kidney cancer was a causative factor. Because this time period is prior to diagnosis, the 
framework seemed to suggest that there should not be any difference in incidence rates of 
thromboembolic events in the cancer patients and noncancer patients. However, the 




was not diagnosed yet. Kidney cancer can be asymptomatic and there are no routine 
screening tests specific for kidney cancer (American Cancer Society, 2014). Thus, the 
framework is still applicable during this period and the findings of increased incidence of 
any VTE, DVD, and pulmonary embolism in the cancer cohort are not inconsistent with 
the framework (Table 25).  
The second research question examined the incidence rate ratios of 
thromboembolic events in the follow-up period after the index date. The incidence rates 
of events were higher in the cancer patients than the noncancer patients (Tables 27 and 
28). This finding is consistent with the theoretical framework as kidney cancer diagnosis 
and cancer characteristics were characterized as causative factors. The incidence rate 
ratios differed by the diagnosis of other comorbidities, and the environmental and other 
population characteristics were statistically significant confounders in most of the 
models. 
The third research question was analyzed in the cancer patient cohort only. Other 
than the cancer itself, the causative factors included cancer stage and treatments. Stage, 
particularly late stage, and chemotherapy were associated with increased risk of venous 
thromboembolic events (Tables 29 to 32). Nephrectomy, another cancer treatment, was 
associated with a decreased risk of pulmonary embolism (Table 31). The population 
characteristics and environment and lifestyle factors including older age, comorbidities, 





In each research question, the effect of cancer diagnosis differed by type of 
thromboembolic event, comorbidities (i.e., population factors), high-risk surgery and 
placement of central venous catheter (i.e., environment and lifestyle factors). The 
differences in findings across the three research questions suggest that within the 
framework the relationships of the factors to the events may be different for venous and 
arterial events. Before the index date, the incidence rates of most venous thromboembolic 
events were higher in cancer patients than noncancer patients, but that was not the case 
for ischemic stroke. After the index date, the incidence rates of venous thromboembolic 
events were higher in the kidney cancer patients, while they were higher in arterial 
thromboembolic events but only in patients without certain comorbidities (Tables 25 to 
28). Within the kidney cancer patient cohort receipt of chemotherapy increased the risk of 
venous thromboembolic events, whereas it was protective for myocardial infarction and 
not statistically significant for ischemic stroke (Tables 29 to 35). Future frameworks 
developed for studies of venous and arterial thromboembolic events in cancer patients 
may benefit from developing two frameworks which model differences in the 
relationships of factors such as chemotherapy and outcome.  
Limitations of the Study 
The main limitation of this study as discussed in chapters 1 and 3 are that there 
are potential confounders and other factors which we cannot measure such as smoking 
status, platelet counts, lab values of other conditions, or severity of conditions. That data 
is simply not available in the administrative claims database utilized for this study. The 




large sample size, and contains high-quality and detailed cancer data. For the objectives 
of this study, these advantages outweigh the limitations of the unmeasured factors. 
Another limitation is that the study is limited to the diagnoses and procedures indicated in 
the claims data. Conditions, procedures, and medications which were not submitted and 
reimbursed by Medicare were missed. Although rule-out diagnoses were removed as 
much as possible, it is still possible that some rule-out diagnoses or diagnoses which were 
follow-up visits were included in the study data. Conversely, some legitimate diagnoses 
and procedures may have been removed during the data cleaning process. Other studies 
of thromboembolic events in cancer patients which use administrative claims databases 
have similar limitations. 
Recommendations 
I reported incidence rates, incidence proportions and risk factors for venous and 
arterial thromboembolic events in elderly kidney cancer patients and incidence rate ratios 
for the events comparing the cancer cohort to a matched noncancer cohort. New 
contributions to the research include incidence rates stratified by histology type, 
assessment of histology group as a risk factor for thromboembolic events, incidence rates 
and proportions for myocardial infarction and ischemic stroke, and assessment of risk 
factors for arterial thromboembolic events in kidney cancer patients. Future studies 
should include assessment of kidney cancer histology type as a risk factor for venous and 
arterial thromboembolic events in other populations and age groups. Given the incidence 
rates of myocardial infarction and ischemic stroke were as high as incidence rates of 




patient prognosis; more studies are needed of myocardial infarction and ischemic stroke 
in cancer patients of all cancer types including kidney cancer.  
Differences in cancer stage at diagnosis, healthcare utilization, and cancer 
survival have been shown in studies of different cancer types within the United States 
(Farkas, Greenbaum, Singhal, & Cosgrove, 2012; Niu, Roche, Pawlish,& Henry, 2013; 
Ward et al., 2008). Thus the findings from this study, which used a Medicare population 
who did not participate in a managed care plan, may not apply to the elderly who have 
different insurance coverage or are uninsured. It would be beneficial to determine 
whether these findings and relationships would be found in kidney cancer patients with 
other insurance coverage and in different age groups. If the associations between factors 
and thromboembolic events are different for patients with payers other than Medicare, 
who have a Medicare managed-care plan, or who are nonelderly; then applying the 
evidence generated by this study could lead to sub-optimal care and risk assessment for 
these other patient groups.  
The difference in risk by age group across thromboembolic event type was 
unexpected, and in future studies, risk factors for venous thromboembolic events should 
be assessed for any VTE as well as each VTE individually. By conducting studies which 
just report findings for the group of thromboembolic events, differences in trends and risk 
factors may be missed or incorrectly generalized to each individual event.  
In general, the models performed similarly when using the Charlson score versus 




use the Charlson score instead of running separate models which include the selected 
conditions which are components of the Charlson comorbidity score.  
Implications for Positive Social Change 
The findings from study have several implications for positive social change. 
Better understanding of the factors which affect the risk of venous and arterial 
thromboembolic events can inform patients and healthcare providers. This information 
can aid healthcare providers in determining which patients may benefit from closer 
observation or prophylaxis to prevent or minimize morbidity from these events. The risk 
of arterial thromboembolic events was not previously researched in kidney cancer 
patients and so the findings from this study provide additional information to patients, 
healthcare providers, and other researchers. I also contributed research on incidence rates 
by histology type in kidney cancer patients and whether histology type impacted the risk 
of venous and arterial thromboembolic events. Based on the findings of this study, 
healthcare providers have no reason to believe the risks of venous and arterial 
thromboembolic events differ by histology group within RCC patients with Clear cell, 
Chromophobe, Papillary or other RCC. For the outcomes other than pulmonary embolism 
and ischemic stroke, there was no difference in incidence of thromboembolic events in 
kidney cancer patients with RCC or transitional cell tumors. Thus healthcare providers 
would not need any change in observation, prophylaxis, or treatment in this regard based 
on histologic type of RCC. Similarly the lower risk of VTEs in patients with transitional 
cell tumors compared to patients with clear cell tumors indicates that no additional care 




care for elderly kidney cancer patients. The increased risk of pulmonary embolism in 
patients with papillary histology may warrant additional consideration by the healthcare 
provider during the risk assessment for thromboembolic events. 
Conclusion 
This population-based, retrospective cohort study of elderly Medicare 
beneficiaries with and without kidney cancer provided new and useful information on the 
incidence and risk factors for venous and arterial thromboembolic events. Incidence rates 
of myocardial infarction were calculated, and were as high as the incidence rates of the 
venous thromboembolic events. I confirmed that incidence rates of thromboembolic 
events are higher in kidney cancer patients in the follow-up period after cancer diagnosis 
than in the year prior to diagnosis. Similar to other studies the incidence proportions in 
the first year after cancer diagnosis were highest in the first three months. Prior to the 
index date, the incidence rates of venous thromboembolic events were higher in the 
cancer (exposed) cohort than the noncancer comparator cohort. For any ATE and 
ischemic stroke, there were no statistically significant differences in incidence rates 
between the two cohorts. In the follow-up period after index date, the incidence rates of 
most thromboembolic events were different in the cancer cohort than in the noncancer 
cohort when the patients were stratified by kidney disease, type 2 diabetes, or 
atherosclerosis. Unexpectedly, the incidence rate ratios were greater than 1.0 for patients 
without kidney disease, type 2 diabetes, or atherosclerosis. More research is needed to 
understand why the presence of these comorbidities would differentially impact the 




was the first study (to my knowledge) in which the relationship of histology groups of 
kidney cancer and thromboembolic events were assessed and to report that kidney cancer 
patients with transitional cell tumors appear to be at lower risk for pulmonary embolism 
and ischemic stroke compared to patients diagnosed with clear cell tumors. A better 
understanding of the risk factors for thromboembolic events in elderly kidney cancer 
patients may inform patients and healthcare providers, in turn proving beneficial for 





Agnelli, G., Bolis, G., Capussotti, L., Scarpa, R.M., Tonelli, F., Bonizzoni, E… Gussoni, 
G. (2006). A clinical outcome-based prospective study on venous 
thromboembolism after cancer surgery: The @RISTOS Project. Annals of 
Surgery, 243(1), 89-95. doi: 10.1097/01.sla.0000193959.44677.48 
Alcalay, A., Wun, T., Khatri, V., Chew, H.K., Harvey, D., Zhou, H., & White, R.H. 
(2006). Venous thromboembolism in patients with colorectal cancer: Incidence 
and effect on survival. Journal of Clinical Oncology, 24(7), 1112-1118. doi: 
10.1200/JCO.2005.04.2150 
American Joint Committee on Cancer. (2002). Cancer staging manual (6
th
 ed.). New 
York, NY: Springer. 
American Joint Committee on Cancer. (2013). Cancer staging. Retrieved from 
http://cancerstaging.org/ 
American Cancer Society. (2013). Cancer facts & figures 2013. Atlanta, GA: American 
Cancer Society. Retrieved from 
http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2013/index 
American Cancer Society. (2014). Kidney cancer (adult) - Renal cell carcinoma. 
Retrieved from http://www.cancer.org/cancer/kidneycancer/detailedguide/kidney-
cancer-adult-what-is-kidney-cancer 
American Cancer Society. (2015). Cancer facts & figures 2015. Atlanta, GA: American 





Applied Research Program. (2013). SEER-Medicare linked database. Retrieved 
September 21, 2013, from http://appliedresearch.cancer.gov/seermedicare/ 
Aschengrau, A., & Seage III, G.R. (2008). Essentials of epidemiology in public health 
(2
nd
 ed.). Sudbury, MA: Jones and Bartlett Publishers. 
Asper, F. (2012). Difference between RIF, LDS, and PUF data files. Retrieved September 
15, 2013, from http://www.resdac.org/resconnect/articles/148 
Asper, F., & Mann, E. (2011). Medicare managed care enrollees and the Medicare 
utilization files. Retrieved September 15, 2013, from 
http://www.resdac.org/resconnect/articles/114 
Bayer HealthCare Pharmaceuticals. (2013). Nexavar prescribing information. Retrieved 
from http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf 
Blom, J.W., Doggen, C.J.M., Osanto, S., & Rosendaal, F.R. (2005). Malignancies, 
prothrombotic mutations, and the risk of venous thrombosis. JAMA, 293(6), 715-
722. doi: 10.1001/jama.293.6.715 
Blom, J.W., Osanto, S., & Rosendaal, F.R. (2004). The risk of venous thrombotic event 
in lung cancer patients: Higher risk for adenocarcinoma than squamous cell 
carcinoma. Journal of Thrombosis and Haemostasis, 2(10), 1760-1765. doi: 
10.1111/j.1538-7836.2004.00928.x 
Blom, J.W., Vanderschoot, J.P.M., Oostindier, M.J., Osanto, S., Van Der Meer, J.M., & 
Rosendaal, F.R. (2006). Incidence of venous thrombosis in a large cohort of 66 
329 cancer patients: Results of a record linkage study. Journal of Thrombosis and 




Casper, M.L., Nwaise, I.A., Croft, J.B., & Nilasena, D.S. (2008). Atlas of stroke 
hospitalizations among Medicare beneficiaries. Atlanta, GA: U.S. Department of 
Health and Human Services, Centers for Disease Control and Prevention. 
Retrieved from http://www.cdc.gov/dhdsp/atlas/2008_stroke_atlas/index.htm 
Centers for Disease Control and Prevention. (2014). Deep vein thrombosis (DVT) / 
pulmonary embolism (PE): Blood clot forming in a vein. Retrieved from 
http://www.cdc.gov/ncbddd/dvt/index.html 
Centers for Medicare & Medicaid Services. (n.d.). Costs in the coverage gap. Retrieved 
from http://www.medicare.gov/part-d/costs/coverage-gap/part-d-coverage-
gap.html 
Centers for Medicare & Medicaid Services. (2013). Medicare program general 
information. Retrieved from http://www.cms.gov/Medicare/Medicare-General-
Information/MedicareGenInfo/index.html 
Chavez-MacGregor, M., Zhao, H., Kroll, M., Fang, S., Zhang, N., Hortobagyi, G.N., 
…Giordano, S.H. (2011). Risk factors and incidence of thromboembolic events 
(TEEs) in older men and women with breast cancer. Annals of Oncology, 22(11), 
2394-2402. doi: 10.1093/annonc/mdq777 
Chen, P.-C., Muo, C.-H., Lee, Y.-T., Yu, Y.-H., & Sung, F.-C. (2011). Lung cancer and 
incidence of stroke: A population-based cohort study. Stroke, 42(11), 3034-3039. 
doi: 10.1161/STROKEAHA.111.615534 
Chen, J., Normand, S.T., Wang, Y., Drye, E.E., Schreiner, G.C., & Krumholz, H.M. 




Medicare fee-for-service beneficiaries: Progress and continuing challenges. 
Circulation, 121(11), 1322-1328. doi: 10.1161/circulationaha.109.862094 
Chew, H.K., Wun, T., Harvey, D., Zhou, H., & White, R.H. (2006). Incidence of venous 
thromboembolism and its effect on survival among patients with common 
cancers. Archives of Internal Medicine, 166(4), 458-464. doi: 
10.1001/archinte.166.4.458 
Chew, H.K., Wun, T., Harvey, D.J., Zhou, H., & White, R.H. (2007). Incidence of 
venous thromboembolism and the impact on survival in breast cancer patients. 
Journal of Clinical Oncology, 25(1), 70-76. doi: 10.1200/JCO.2006.07.4393 
Chew, H.K., Davies, M., Wun, T., Harvey, D., Zhou, H., & White, R.H. (2008). The 
incidence of venous thromboembolism among patients with primary lung cancer. 
Journal of Thrombosis and Haemostasis, 6(4), 601-608. doi: 10.1111/j.1538-
7836.2008.02908.x 
Choueiri, T.K., Schutz, F.A.B., Je, Y., Rosenberg, J.E., & Bellmunt, J. (2010). Risk of 
arterial thromboembolic events with sunitinib and sorafenib: A systematic review 
and meta-analysis of clinical trials. Journal of Clinical Oncology, 28(13), 2280-
2285. doi: 10.1200/JCO.2009.27.2757 
Chu, C.N., Chen, S.W., Bai, L.Y., Mou, C.H., Hsu, C.Y., & Sung, F.C. (2011). Increase 
in stroke risk in patients with head and neck cancer: A retrospective cohort study. 
British Journal of Cancer, 105(9), 1419-1423. doi:10.1038/bjc.2011.361 
Clark, J.M., Kelley, B., Titze, J., Fung, H., Maciejewski, J., Nathan, S., …Kaufman, H.L. 




patients with metastatic melanoma and renal cell carcinoma. Oncology, 84(2), 
123-126. doi: 10.1159/000342764 
Connelly-Frost, A., Shantakumar, S., Kobayashi, M.G., Li, H., & Li, L. (2013). Older 
renal cell cancer patients experience increased rates of venous thromboembolic 
events: A retrospective cohort study of SEER-Medicare data. BMC Cancer,209. 
doi: 10.1186/1471-2407-13-209 
Creswell, J.W. (2009). Research design: Qualitative, quantitative, and mixed methods 
approaches (3rd ed.). Los Angeles: Sage Publications. 
DeCastro, G.J., & McKiernan, J.M. (2008). Epidemiology, clinical staging, and 
presentation of renal cell carcinoma. Urologic Clinics of North America, 35(4), 
581-592. doi:10.1016/j.ucl.2008.07.005 
Doyle, J.J., Neugut, A.I., Jacobson, J.S., Grann, V.R., & Hershman, D.L. (2005). 
Chemotherapy and cardiotoxicity in older breast cancer patients: A population-
based study. Journal of Clinical Oncology, 23(34), 8597-8605. doi: 
10.1200/JCO.2005.02.5841 
Earp, J, A., & Ennett, S.T. (1991). Conceptual models for health education research and 
practice. Health Education Research, 6(2), 163-171. 
Elsevier. (2014). Scopus: Facts & figures. Retrieved from 
http://www.elsevier.com/online-tools/scopus 
Farkas, D.T., Greenbaum, A., Singhal, V., and Cosgrove, J.M. (2012). Effect of insurance 
status on the stage of breast and colorectal cancers in a safety-net hospital. 




Geraci, J.M., Escalante, C.P., Freeman, J.L., & Goodwin, J.S. (2005). Comorbid disease 
and cancer: The need for more relevant conceptual models in health services 
research. Journal of Clinical Oncology, 23(3), 7399-7404. doi: 
10.1200/JCO.2004.00.9753 
GlaxoSmithKline. (2014). Votrient prescribing information. Retrieved from 
https://www.gsksource.com/gskprm/htdocs/documents/VOTRIENT-PI-MG.PDF 
Griffiths, R.I., O’Malley, C.D., Herbert, R.J., & Danese, M.D. (2013). Misclassification 
of incident conditions using claims data: Impact of varying the period used to 
exclude pre-existing disease. BMC Medical Research Methodology, 32. doi: 
10.1186/1471-2288-13-32 
Hall, I.E., Andersen, M.S., Krumholz, H.M., & Gross, C.P. (2009). Predictors of venous 
thromboembolism in patients with advanced common solid cancers. Journal of 
Cancer Epidemiology, 182521. doi: 10.1155/2009/182521 
Hall, S.L., & Lorenc, T. (2010). Secondary prevention of coronary artery disease. 
American Family Physician, 81(3), 289-296.  
Hoffman, K., Pischon, T., Schulz, M., Schulze, M.B., Ray, J., & Boeing, H. (2008). A 
statistical test for the equality of differently adjusted incidence rate ratios. 
American Journal of Epidemiology, 167(5), 517-522. doi: 10.1093/aje/kwm357 
Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Miller, D., Altekruse, S.F., 
…Cronin, K.A. (Eds.). (2014). SEER Cancer Statistics Review, 1975-2011. 
Retrieved from http://seer.cancer.gov/csr/1975_2011/ 




nephrectomy versus radial nephrectomy in patients with small renal tumors: Is 
there a difference in mortality and cardiovascular outcomes? The Journal of 
Urology, 181(1), 55-62. doi:10.1016/j.juro.2008.09.017 
Hurwitz, H.I., Saltz, L.B., Cutsem, E.V., Cassidy, J., Wiedemann, J., Sirzen, F.,…Rohr. 
(2011). Venous thromboembolic events with chemotherapy plus bevacizumab: A 
pooled analysis of patients in randomized Phase II and III studies. Journal of 
Clinical Oncology, 29(13), 1757-1764. doi: 10.1200/JCO.2010.32.3220 
International Society of Geriatric Oncology. (2011). The SIOG 10 Priorities Initiative. 
Retrieved from 
http://www.siog.org/images/SIOG_documents/siog_10_priorities_final.pdf 
Keegan, K.A., Schupp, C.W., Chamie, K., Hellenthal, N.J., Evans, C.P., & Koppie, T.M. 
(2012). Histopathology of surgically treated renal cell carcinoma: Survival 
differences by subtype and stage. The Journal of Urology, 188(2), 391-397. doi: 
10.1016/j.juro.2012.04.006 
Khorana, A.A., & Connolly, G.C. (2009). Assessing risk of venous thromboembolism in 
the patient with cancer. Journal of Clinical Oncology, 27(29), 4839-4847. doi: 
10.1200/JCO.2009.22.3271 
Khorana, A.A., Kuderer, N.M., Culakova, E., Lyman, G.H., & Francis, C.W. (2008). 
Development and validation of a predictive model for chemotherapy-associated 
thrombosis. Blood, 111(10), 4902-4907. doi: 10.1182/blood-2007-10-116327 





Klabunde, C.N., Legler, J.M., Warren, J.L., Baldwin, L.M., & Schrag, D. (2007). A 
refined comorbidity measurement algorithm for claims-based studies of breast, 
prostate, colorectal, and lung cancer patients. Annals of Epidemiology, 17(8), 584-
590. doi: 10.1016/j.annepidem.2007.03.011 
Klabunde, C.N., Potosky, A.L., Legler, J.M., & Warren, J.L. (2000). Development of a 
comorbidity index using physician claims data. Journal of Clinical Epidemiology, 
53(12), 1258-1267. doi: 10.1016/S0895-4356(00)00256-0 
Klabunde, C.N., Warren, J.L., Legler, J.M. (2002). Assessing comorbidity using claims 
data: An overview. Medical Care, 40(8 Suppl),IV-26-35. doi: 10.1097/00005650-
200208001-00004 
Konigsbrugge, O., Lotsch, F., Reitter, E.-M., Brodowicz, T., Zielinski, C., Pabinger, I., & 
Ay, C. (2013). Presence of varicose veins in cancer patients increases the risk for 
occurrence of venous thromboembolism. Journal of Thrombosis and 
Haemostasis, 11(11), 1993–2000. doi: 10.1111/jth.12408 
Kovacs, G., Akhtar, M., Beckwith, B.J., Bugert, P., Cooper, C.S., Delahunt, B., …, Zbar, 
B. (1997). The Heidelberg classification of renal cell tumours. Journal of 
Pathology, 183(2), 131-133. doi: 10.1002/(SICI)1096-
9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G 
Kuderer, N.M., Ortel, T.L., & Francis, C.W. (2009). Impact of venous thromboembolism 
and anticoagulation on cancer and cancer survival. Journal of Clinical Oncology, 
27(29), 4902-4910. doi: 10.1200/JCO.2009.22.4584 




health care utilization for patients with cancer using hospice. Journal of Palliative 
Medicine, 14(6), 751-756. doi: 10.1089/jpm.2010.0504 
Ljungberg, B., Campbell, S.C., Cho, H.Y., Jacqmin, D., Lee, J.E., Weikert, S., & 
Kiemeney, L.A. (2011). The epidemiology of renal cell carcinoma. European 
Urology, 60(4), 615–621. doi: 10.1016/j.eururo.2011.06.049 
Lopez-Beltran, A., Scarpelli, M., Montironi, R, & Kirkali, Z. (2006). 2004 WHO 
classification of the renal tumors of the adults. European Urology, 49(5), 798-
805. doi: 10.1016/j.eururo.2005.11.035 
Lund, J.L., Sturmer, T., Harlan, L.C., Sanoff, H., Sandler, R.S., … Warren, J.L. (2013). 
Identifying specific chemotherapeutic agents in Medicare data: A validation 
study. Medical Care, 51(5), e27-e34. doi: 10.1097/MLR.0b013e31823ab60f 
Matsuo, K., Hasegawa, K., Yoshino, K., Murakami, R., Hisamatsu, T., Stone, R.L., 
…Sood, A.K. (2015). Venous thromboembolism, interleukin-6 and survival 
outcomes in patients with advanced ovarian clear cell carcinoma. European 
Journal of Cancer, 51(14), 1978-1988. doi: 10.1016/j.ejca.2015.07.012 
MedlinePlus. (2014). MedlinePlus: Trusted health information for you. Retrieved from 
http://www.nlm.nih.gov/medlineplus/ 
Merrill, R.M. (2009). Introduction to epidemiology. Sudbury, MA: Jones & Bartlett. 
Monsuez, J.J., Charniot, J.C., Vignat, N., & Artigou, J.Y. (2010). Cardiac side-effects of 
cancer chemotherapy. International Journal of Cardiology, 144(1), 3-15. doi: 
10.1016/j.ijcard.2010.03.003 




…Hassoun, H. (2011). High incidence of thromboembolic events in patients 
treated with cisplatin-based chemotherapy: A large retrospective analysis. Journal 
of Clinical Oncology, 29(25), 3466-3473. 
National Cancer Data Base. (2013). Public NCDB benchmark reports. Retrieved 
February 9, 2014, from http://www.facs.org/cancer/ncdb/publicaccess.html 
National Cancer Institute. (2013). NCI Dictionary of cancer terms. Retrieved from 
http://www.cancer.gov/dictionary 
National Cancer Institute. (2010). What you need to know about kidney cancer (NIH 
Publication No.10-1569). Retrieved from 
http://www.cancer.gov/cancertopics/wyntk/kidney/ 
National Comprehensive Cancer Network. (2015). NCCN guidelines. Retrieved March 9, 
2015, from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp 
Navi, B.B., Reiner, A.S., Kamel, H., Iadecola, C., Elkind, M.S., Panageas, K.S., & 
DeAngelis, L.M. (2015). Association between Incident Cancer and Subsequent 
Stroke. Annals of Neurology, 77(2), 291-300. doi:10.1002/ana.24325 
Nilsson G, Holmberg L, Garmo H, Terent, A., & Blomqvist, C. (2005). Increased 
incidence of stroke in women with breast cancer. European Journal of Cancer, 
41(3), 423–9. doi:10.1016/j.ejca.2004.11.013 
Niu, X., Roche, L.M., Pawlish, K.S., & Henry, K.A. (2013). Cancer survival disparities 
by health insurance status. Cancer Medicine, 2(3), 403–411. doi: 
10.1002/cam4.84 




age? Retrieved from http://ohioline.osu.edu/ss-fact/0101.html 
Olshan, A.F., Kuo1, T.-M., Meyer, A.-M., Nielsen, M.E., Purdue, M.P., & Rathmell, 
W.K. (2013). Racial difference in histologic subtype of renal cell carcinoma. 
Cancer Medicine, 2(5), 744-749. doi: 10.1002/cam4.110 
Parpia, S., Juliana, J.A., Thabaneb, L., Leec, A.Y., Rickles, F.R., & Levine, M.N. (2011). 
Competing events in patients with malignant disease who are at risk for recurrent 
venous thromboembolism. Contemporary Clinical Trials, 32(6), 829–833. 
doi:10.1016/j.cct.2011.07.005 
Patard, J.-J., Leray, E., Rioux-Leclercq, N., Cindolo, L., Ficarra, V., Zisman, A., … 
Pantuck, A.J. (2005). Prognostic value of histologic subtypes in renal cell 
carcinoma: A multicenter experience. Journal of Clinical Oncology, 23(12), 
2763-2771. doi: 10.1200/JCO.2005.07.055 
Petrelli, F., Cabiddu, M., Borgonovo, K., & Barni, S. (2012). Risk of venous and arterial 
thromboembolic events associated with anti-EGFR agents: A meta-analysis of 
randomized clinical trials. Annals of Oncology, 23(7), 1672-1679. doi: 
10.1093/annonc/mdr592 
Piccirillo, J.F., Vlahiotis, A., Barrett, L.B., Flood, K.L., Spitznagel, E.L., & Steyerberg, 
E.W. (2008). The changing prevalence of comorbidity scores across the age 
spectrum. Critical Reviews in Oncology Hematology, 67, 124-132. doi: 
10.1016/j.critrevonc.2008.01.013 
Previtali, E., Bucciarelli, P., Passamonti, S.M., & Martinelli, I. (2011). Risk factors for 





Qi, W.X., Min, D.L., Shen, Z., Sun, Y.J., Lin, F., Tang, L.N, … Yao, Y. (2013). Risk of 
venous thromboembolic events associated with VEGFR-TKIs: A systematic 
review and meta-analysis. International Journal of Cancer, 132(1), 2967-2974. 
doi: 10.1002/ijc.27979 
Qi, W.-X., Shen, Z., Tang, L.-N., & Yao, Y. (2014). Risk of arterial thromboembolic 
events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: 
An up-to-date meta-analysis. Critical Reviews in Oncology Hematology, 92(2), 
71-82. doi: 10.1016/j.critrevonc.2014.04.004 
Repetto, L., Venturino, A., Fratino, L., Serraino, D., Troisi, G., Gianni, W., & 
Pietropaolo, M. (2003). Geriatric oncology: A clinical approach to the older 
patient with cancer. European Journal of Cancer, 39(7),870-880. 
doi:10.1016/S0959-8049(03)00062-5 
Richiardi, L., Bellocco, R., & Zugna, D. (2013). Mediation analysis in epidemiology: 
Methods, interpretation and bias. International Journal of Epidemiology, 42(5), 
1511-1519. doi: 10.1093/ije/dyt127 
Rothman, K.J. (1986). Modern epidemiology. Boston, MA: Little, Brown and Company. 
Sallah, S., Wan, J.Y., & Nguyen, N.P. (2002). Venous thrombosis in patients with solid 
tumors: Determination of frequency and characteristics. Thrombosis and 
Haemostasis, 87(4), 575-579. 
Scappaticci , F.A., Skillings , J.R., Holden , S.N., Gerber, H.P., Miller, K., Kabbinavar , 




metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the 
National Cancer Institute, 99(16), 1232 - 1239. doi: 10.1093/jnci/djm086 
Surveillance, Epidemiology, and End Results Program. (2012). SEER training modules. 
Retrieved from http://training.seer.cancer.gov 
Surveillance, Epidemiology, and End Results Program. (2013). Surveillance, 
Epidemiology, and End Results Program. Retrieved from http://seer.cancer.gov/ 
Shantakumar, S., Connelly-Frost, A., Kobayashi, M.G., Allis, R., & Li, L. (2015). Older 
soft tissue sarcoma patients experience increased rates of venous thromboembolic 
events: A retrospective cohort study of SEER-Medicare data. Clinical Sarcoma 
Research, 18. doi: 10.1186/s13569-015-0033-z 
Siegel, J.P., & Puri, R.K. (1991). Interleukin-2 toxicity. Journal of Clinical Oncology, 
9(4), 694-704. 
Silverstein, M.D., Heit, J.A., Mohr, D.N., Petterson, T.M., O’Fallon, W.M., & Melton III, 
L. (1998). Trends in the incidence of deep vein thrombosis and pulmonary 
embolism:A 25-year population-based study. Archives of Internal Medicine, 
158(6), 585-593. doi:10.1001/archinte.158.6.585 
Smith, A.B., Horvath-Puho, E., Nielsen, M.E., Lash, T.L., Baron, J.A., & Sørensen, H.T. 
(2014). Effect of comorbidity on risk of venous thromboembolism in patients with 
renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 
32(4), 466-472. doi: 10.1016/j.urolonc.2013.07.008 
Sonpavde, G., Je, Y., Schutz, F., Galsky, M.D., Paluri, R., Rosenberg, J.E, ... Choueiri, 




factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis 
of randomized clinical trials. Critical Reviews in Oncology Hematology, 87(1), 
80-89. doi: 10.1016/j.critrevonc.2012.12.006 
Sørensen, H.T., Mellemkjaer, L., Olsen, J.H., & Baron, J.A. (2000). Prognosis of cancers 
associated with venous thromboembolism. The New England Journal of 
Medicine, 343(25), 1846 – 1850. doi: 10.1056/NEJM200012213432504 
Spruance, S.L., Reid, J.E., Grace, M., & Samore, M. (2004). Hazard ratio in clinical 
trials. Antimicrobial Agents and Chemotherapy, 48(8), 2787-2792. doi: 
10.1128/AAC.48.8.2787–2792.2004 
Svoboda, M., Poprach, A., Dobes, S., Kiss, I., & Vyzula, R. (2012). Cardiac toxicity of 
targeted therapies used in the treatment for solid tumors: A review. 
Cardiovascular Toxicology, 12 (3), 191-207. doi: 10.1007/s12012-012-9164-0 
Szklo, M., & Nieto, J. (2006). Epidemiology: Beyond the basics (2
nd
 ed.). Burlington, 
MA: Jones & Bartlett Learning. 
Taylor, R. (1990). Interpretation of the correlation coefficient: A basic review. JDMS, 
1(1), 35-39. Retrieved from 
http://www.sagepub.com/salkind2study/articles/05Article01.pdf 
Tsai, S.J., Huang, Y.S., Tung, C.H., Lee, C.C., Lee, M.S., Chiou, W.Y., ... Hung, S.K. 
(2013). Increased risk of ischemic stroke in cervical cancer patients: A nationwide 
population-based study. Radiation Oncology, 41. doi:10.1186/1748-717X-8-41 
Tyson, M.D., Humphreys, M.R., Parker, A.S., Thiel,, D.D., Joseph, R.W., Andrews, P.E., 




United States adults. Urology, 82(1), 43-47. doi:10.1016/j.urology.2013.02.065 
United States Census Bureau. (2013). Census glossary. Retrieved from 
http://www.census.gov/glossary/ 
United States Food and Drug Administration. (2011). Harnessing the potential of data 
mining and information sharing. Retrieved from 
http://www.fda.gov/aboutfda/reportsmanualsforms/reports/ucm274442.htm 
United States Food and Drug Administration. (2013). Drugs@FDA. Retrieved from 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm 
van Herk-Sukel, M.P.P., Shantakumar, S., Kamphuisen, P.W., Penning-van Beest, F.J.A., 
& Herings, R.M.C. (2011). Myocardial infarction, ischaemic stroke and 
pulmonary embolism before and after breast cancer hospitalization. Thrombosis 
and Haemostasis, 106(1), 149-155. doi: 10.1160/TH10-12-0778 
van Herk-Sukel, M.P.P., Shantakumar, S., Penning-van Beest, F.J.A., Kamphuisen, P.W., 
Majoor, C.J., Overbeek, L.I., & Herings, R.M.C. (2013). Pulmonary embolism, 
myocardial infarction, and ischemic stroke in lung cancer patients: Results from a 
longitudinal study. Lung, 191(5), 501-509. doi: 10.1007/s00408-013-9485-1 
Walker, A.J., Card, T.R., West, J., Crooks, C., & Grainge, M.J. (2013). Incidence of 
venous thromboembolism in patients with cancer: A cohort study using linked 
United Kingdom databases. European Journal of Cancer, 49(6), 1404-1413. doi: 
10.1016/j.ejca.2012.10.021 
Ward, E., Halpern, M, Schrag, N., Cokkinides, V, DeSantis, C., Bandi, P., …Jemal, A. 




Cancer Journal for Clinicians, 58(1), 9–31. doi: 10.3322/CA.2007.0011 
Warren, J.L., Klabunde, C.N., Schrag, D., Bach, P.B., & Riley, G.F. (2002a). Overview 
of the SEER-Medicare data. Medical Care, 40(Suppl 8), IV-3–IV-18. doi: 
10.1097/00005650-200208001-00001 
Warren, J.L., Harlan, L.C., Fahey, A., Virnig, B.A., Freeman, J.L., Klabunde, C.N., 
…Knopf, K.B. (2002b). Utility of the SEER-Medicare data to identify 
chemotherapy use. Medical Care, 40(8 Suppl), IV-55–IV-61. doi: 
10.1097/00005650-200208001-00008 
Weikert, S., & Ljungberg, B. (2010). Contemporary epidemiology of renal cell 
carcinoma: Perspectives of primary prevention. World Journal of Urology, 28(3), 
247-252. doi: 10.1007/s00345-010-0555-1 
White, R.H., Chew, H.K., Zhou, H., Parikh-Patel, A., Harris, D., Harvey, D., & Wun, T. 
(2005). Incidence of venous thromboembolism in the year before the diagnosis of 
cancer in 528 693 adults. Archives of Internal Medicine, 165(15), 1782-1787. doi: 
10.1001/archinte.165.15.1782 
World Health Organization. (2013). International Classification of Diseases for 
Oncology, 3rd Edition (ICD-O-3). Retrieved from 
http://www.who.int/classifications/icd/adaptations/oncology/en/ 
Yeh, E.T.H. & Bickford, C.L. (2009). Cardiovascular complications of cancer therapy. 
Journal of the American College of Cardiology, 53(24), 2231-2247. 
doi:10.1016/j.jacc.2009.02.050 




chronic conditions, and healthcare costs. The American Journal of Managed 
Care, 10(12), 909-916. 
Zoller, B., Ji, J., Sundquist, J., & Sundquist, K. (2012). Risk of haemorrhagic and 
ischaemic stroke in patients with cancer: A nationwide follow-up study from 
Sweden. European Journal of Cancer, 48(12), 1875–83. 
doi:10.1016/j.ejca.2012.01.005 
Zulman, D.M., Chee, C.P., Wagner, T.H., Yoon, J., Cohen, D.M., Holmes, T.H., … 
Asch, S.M. (2015). Multimorbidity and healthcare utilisation among high-cost 





Appendix A: Abbreviations 
 Definition 
 
AJCC American Joint Committee on Cancer 
AMI Acute Myocardial Infarction 
ATE Arterial Thromboembolic Event 
CCI Charlson Comorbidity Index 
CDC Centers for Disease Control and Prevention 
CMS Centers for Medicare & Medicaid Services 
CPT Current Procedural Terminology 
CVC Central Venous Catheter 
CVD Cardiovascular Disease 
DVT Deep Venous Thrombosis 
EMM Effect Measure Modifier 
FDA United States Food and Drug Administration 
HCPCS Healthcare Common Procedure Coding System 
HF Heart Failure 
HIPAA Health Insurance Portability and Accountability Act 
HR Hazard Ratio 
ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification 
ICD-10-CM International Classification of Diseases, Tenth Revision, Clinical Modification 
ICD-O International Classification of Diseases for Oncology 
IL-2 Interleukin-2 
IRB Institutional Review Board 
IRR Incidence Rate Ratio 
IS Ischemic Stroke 
mTOR Mammalian Target Of Rapamycin  
MeSH Medical Subject Headings 
MHSA Mental Health and Substance Abuse 
MVT Motor Vehicle Traffic 
NCCN National Comprehensive Cancer Network 
NDC National Drug Code 
NEC Not Elsewhere Classified 
OR Odds Ratio 
OS Overall Survival 
OTE Other Thromboembolic Event 
PE Pulmonary Embolism 
PFS Progression-free Survival 
OS Overall Survival 
PH Proportional Hazard 
RCC Renal Cell Carcinoma 
RR Relative Risk 
SEER Surveillance, Epidemiology, and End Results Program 
SES Socioeconomic Status  
US United States 
VEGF Vascular Endothelial Growth Factor 
VHL von Hippel-Lindau 




Appendix B. Operational Definitions 
 Coding Definitions 
Kidney cancer ICD-O-3 site code C64.9, excluding histology codes for hematopoietic cancers 
(9590-9989), with malignant behavior. 
Transitional cell 
tumors of the 
kidney 
ICD-O-3 site code C64.9 and histology codes 8050-8130 (inclusive), with 
malignant behavior. 
RCC ICD-O-3 site code C64.9, excluding histology codes 8050-8130 (inclusive) and 
histology codes for hematopoietic cancers (9590-9989), with malignant behavior. 
RCC Histology  Clear Cell: ICD-O-3 and histology codes 8310, 8312 
Papillary: ICD-O-3 site code C64.9 and histology code 8260 
Chromophobe: ICD-O-3 site code C64.9 and histology codes 8317, 8270 
Other: ICD-O-3 site code C64.9, excluding histology codes 8050-8130 (inclusive) 
and 8310, 8312, 8317, and 8270 
Age at diagnosis 
(index date) 
The integer number of years between the year of birth and the year of diagnosis 
(index date). 
Race Use the race variable from the Medicare entitlement file. Exclude patients with 
unknown race. The race categories were combined into three race groups - White, 
Black, and other races.  
Geographic region This variable was categorized into the four United States Census regions of 
Northeast, Midwest, South and West. The states which make up the Northeast 
region are Maine, New Hampshire, Vermont, Massachusetts, Connecticut, Rhode 
Island, New Jersey, New York, Pennsylvania; the states in the Midwest region are 
North Dakota, South Dakota, Nebraska, Kansas, Missouri, Iowa, Minnesota, 
Wisconsin, Illinois, Michigan, Indiana, Ohio; the states in the South region are 
Maryland, Delaware, West Virginia, Virginia, Kentucky, Tennessee, North 
Carolina, South Carolina, Georgia, Florida, Alabama, Mississippi, Arkansas, 
Louisiana, Oklahoma, Texas, and District of Columbia; the states in the West region 
are Washington, Idaho, Montana, Wyoming, Oregon, California, Nevada, Utah, 
Colorado, Arizona, New Mexico, Alaska, and Hawaii (United States Census 
Bureau, 2013).  
Coverage by 
Medicare plans 
Part A and Part B 
For each month, the variable (mon1-mon264) is coded as 0 = Not entitled, 1= Part 
A only, 2 = Part B only, or 3 = Part A and B. The number of months of coverage 
was the total number of consecutive months with Part A and B coverage (where the 





For each month, the variable (gho1-gho264) is coded as 0 = Not a member of 
HMO, 1 = Non-Lock-in, CMS to process provider claims , 2 = Non-Lock-in, GHO 
to process in-plan Part A & in-area Part B claims, 4 = Chronic care disease 
management organizations-FFS plan , A = Lock-in, CMS to process provider 
claims, B = Lock-in, GHO to process in-plan Part A & in-area Part B claims, C = 
Lock-in, GHO to process all Part A and Part B claims. 
Participation in a managed care plan was identified by a month where the GHO 
variable has a value which is not 0. 
DVT ICD-9-CM diagnosis codes 451.11, 451.19, 451.2, 451.81, 451.83, 451.84, 453.1, 
453.2, 453.40, 453.41, 453.42, 453.8, 453.9 
PE ICD-9-CM diagnosis codes 415.1 and 415.19 
OTE ICD-9-CM diagnosis codes 362.35, 362.36, 437.6, 451.0, 451.82, 451.89 
MI ICD-9-CM diagnosis codes 410.0, 410.00, 410.01, 410.02, 410.1, 410.10, 410.11, 
410.12, 410.2, 410.20, 410.21, 410.22, 410.3, 410.30, 410.31, 410.32, 410.4, 




 Coding Definitions 
410.62, 410.7, 410.70, 410.71, 410.72, 410.8, 410.80, 410.81, 410.82, 410.9, 
410.90, 410.91, 410.92, 451.9 453.0, 453.3. 
IS ICD-9-CM diagnosis codes 433.0, 433.00, 433.01, 433.1, 433.10, 433.11, 433.2, 
433.20, 433.21, 433.3, 433.30, 433.31, 433.8, 433.80, 433.81, 433.9, 433.90, 
433.91, 434.0, 434.00, 434.01, 434.1, 434.10, 434.11, 434.9, 434.90, 434.91, 437.1 
Restrict to diagnoses captured on hospitalizations only. 
Any chemotherapy Use of any chemotherapy was defined by ICD-9-CM diagnosis codes V58.1, 
V58.11, V66.2, and V67.2; ICD-9-CM procedure codes 00.10, 99.25; a HCPCS 
code indicating chemotherapy or chemotherapy administration (96400-96549, 
C8953, C8954, C8955, C9214, C9239, C9257, J8999-J9999, Q2024, S0088, S0116, 
and for 2005 only, G0355-G0362 and Q0083-Q0085, excluding J9015, J9214); 
NDC codes in the Durable Medical Equipment or prescription drug event files 
indicating chemotherapy drugs (listed below); and revenue codes 0331, 0332, and 
0335 (Applied Research Program, 2013; Lund et al., 2013). 
 
NDC Code, Generic Name, Brand Name 
00008117901, TEMSIROLIMUS, TORISEL 
00008117905, TEMSIROLIMUS, TORISEL 
00026848858, SORAFENIB, NEXAVAR 
00069014501, AXITINIB, INLYTA 
00069015111, AXITINIB, INLYTA 
00069055030, SUNITINIB, SUTENT 
00069055038, SUNITINIB, SUTENT 
00069077030, SUNITINIB, SUTENT 
00069077038, SUNITINIB, SUTENT 
00069098030, SUNITINIB, SUTENT 
00069098038, SUNITINIB, SUTENT 
00078056651, EVEROLIMUS, AFINITOR 
00078056661, EVEROLIMUS, AFINITOR 
00078056751, EVEROLIMUS, AFINITOR 
00078056761, EVEROLIMUS, AFINITOR 
00078059451, EVEROLIMUS, AFINITOR 
00078059461, EVEROLIMUS, AFINITOR 
00078062051, EVEROLIMUS, AFINITOR 
00078062651, EVEROLIMUS, AFINITOR DISPERZ 
00078062851, EVEROLIMUS, AFINITOR DISPERZ 
00173080409, PAZOPANIB, VOTRIENT 
50242006001, BEVACIZUMAB, AVASTIN 
50242006002, BEVACIZUMAB, AVASTIN 
50242006101, BEVACIZUMAB, AVASTIN 
50242006201, ERLOTINIB, TARCEVA 
50242006301, ERLOTINIB, TARCEVA 
50242006401, ERLOTINIB, TARCEVA 
50419048858, SORAFENIB, NEXAVAR 
54569598300, SUNITINIB, SUTENT 
54868544700, ERLOTINIB, TARCEVA 
54868547400, ERLOTINIB, TARCEVA 
68817013450, PACLITAXEL, ABRAXANE 
00013128683, DOXORUBICIN, ADRIAMYCIN PFS 
00013126683, DOXORUBICIN, ADRIAMYCIN PFS 
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00013124691, DOXORUBICIN, ADRIAMYCIN PFS 
00013125679, DOXORUBICIN, ADRIAMYCIN PFS 
00013116683, DOXORUBICIN, ADRIAMYCIN PFS 
00013113691, DOXORUBICIN, ADRIAMYCIN PFS 
00013114694, DOXORUBICIN, ADRIAMYCIN PFS 
00013114691, DOXORUBICIN, ADRIAMYCIN PFS 
00013115679, DOXORUBICIN, ADRIAMYCIN PFS 
00013117687, DOXORUBICIN, ADRIAMYCIN PFS 
00013111683, DOXORUBICIN, ADRIAMYCIN RDF 
00013108691, DOXORUBICIN, ADRIAMYCIN RDF 
00013109694, DOXORUBICIN, ADRIAMYCIN RDF 
00013109691, DOXORUBICIN, ADRIAMYCIN RDF 
00013110679, DOXORUBICIN, ADRIAMYCIN RDF 
00013104694, FLUOROURACIL, ADRUCIL 
00703301812, FLUOROURACIL, ADRUCIL 
00013105694, FLUOROURACIL, ADRUCIL 
00703301912, FLUOROURACIL, ADRUCIL 
00703301513, FLUOROURACIL, ADRUCIL 
00013103691, FLUOROURACIL, ADRUCIL 
50242006001, BEVACIZUMAB, AVASTIN 
50242006101, BEVACIZUMAB, AVASTIN 
50242006002, BEVACIZUMAB, AVASTIN 
00009752902, IRINOTECAN, CAMPTOSAR 
00009752904, IRINOTECAN, CAMPTOSAR 
00009752901, IRINOTECAN, CAMPTOSAR 
55390015101, CARBOPLATIN, CARBOPLATIN 
63323016721, CARBOPLATIN, CARBOPLATIN 
10019091601, CARBOPLATIN, CARBOPLATIN 
10019091615, CARBOPLATIN, CARBOPLATIN 
50111096676, CARBOPLATIN, CARBOPLATIN 
00591222011, CARBOPLATIN, CARBOPLATIN 
00703327601, CARBOPLATIN, CARBOPLATIN 
00703326601, CARBOPLATIN, CARBOPLATIN 
55390015201, CARBOPLATIN, CARBOPLATIN 
63323016800, CARBOPLATIN, CARBOPLATIN 
10019091701, CARBOPLATIN, CARBOPLATIN 
50111096776, CARBOPLATIN, CARBOPLATIN 
00703326801, CARBOPLATIN, CARBOPLATIN 
00703327801, CARBOPLATIN, CARBOPLATIN 
00703326871, CARBOPLATIN, CARBOPLATIN 
55390015001, CARBOPLATIN, CARBOPLATIN 
63323016610, CARBOPLATIN, CARBOPLATIN 
10019091501, CARBOPLATIN, CARBOPLATIN 
50111096576, CARBOPLATIN, CARBOPLATIN 
00703327401, CARBOPLATIN, CARBOPLATIN 
00591221911, CARBOPLATIN, CARBOPLATIN 
00703326401, CARBOPLATIN, CARBOPLATIN 
66758004702, CARBOPLATIN, CARBOPLATIN 
10139006015, CARBOPLATIN, CARBOPLATIN 
63323016915, CARBOPLATIN, CARBOPLATIN 
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00409112911, CARBOPLATIN, CARBOPLATIN 
10019091202, CARBOPLATIN, CARBOPLATIN 
00591333712, CARBOPLATIN, CARBOPLATIN 
00703424601, CARBOPLATIN, CARBOPLATIN 
55390022101, CARBOPLATIN, CARBOPLATIN 
61703036022, CARBOPLATIN, CARBOPLATIN 
66758004703, CARBOPLATIN, CARBOPLATIN 
10139006045, CARBOPLATIN, CARBOPLATIN 
15210006612, CARBOPLATIN, CARBOPLATIN 
63323016945, CARBOPLATIN, CARBOPLATIN 
63323017245, CARBOPLATIN, CARBOPLATIN 
00409112912, CARBOPLATIN, CARBOPLATIN 
10019091203, CARBOPLATIN, CARBOPLATIN 
00591333889, CARBOPLATIN, CARBOPLATIN 
00703424801, CARBOPLATIN, CARBOPLATIN 
61703036050, CARBOPLATIN, CARBOPLATIN 
66758004701, CARBOPLATIN, CARBOPLATIN 
10139006005, CARBOPLATIN, CARBOPLATIN 
15210006112, CARBOPLATIN, CARBOPLATIN 
63323016905, CARBOPLATIN, CARBOPLATIN 
63323017205, CARBOPLATIN, CARBOPLATIN 
00409112910, CARBOPLATIN, CARBOPLATIN 
10019091201, CARBOPLATIN, CARBOPLATIN 
00591333626, CARBOPLATIN, CARBOPLATIN 
00703424401, CARBOPLATIN, CARBOPLATIN 
61703036018, CARBOPLATIN, CARBOPLATIN 
66758004704, CARBOPLATIN, CARBOPLATIN 
15210006712, CARBOPLATIN, CARBOPLATIN 
67817006712, CARBOPLATIN, CARBOPLATIN 
55390015601, CARBOPLATIN, CARBOPLATIN 
63323017260, CARBOPLATIN, CARBOPLATIN 
61703033956, CARBOPLATIN, CARBOPLATIN 
00703324911, CARBOPLATIN, CARBOPLATIN 
00591345460, CARBOPLATIN, CARBOPLATIN 
00015323111, CARBOPLATIN, CARBOPLATIN 
00015323211, CARBOPLATIN, CARBOPLATIN 
00015323011, CARBOPLATIN, CARBOPLATIN 
00015323311, CARBOPLATIN, CARBOPLATIN 
61703033922, CARBOPLATIN, CARBOPLATIN 
00703324611, CARBOPLATIN, CARBOPLATIN 
61703033950, CARBOPLATIN, CARBOPLATIN 
00703324811, CARBOPLATIN, CARBOPLATIN 
61703033918, CARBOPLATIN, CARBOPLATIN 
00703324411, CARBOPLATIN, CARBOPLATIN 
55390015401, CARBOPLATIN, CARBOPLATIN 
55390015501, CARBOPLATIN, CARBOPLATIN 
55390015301, CARBOPLATIN, CARBOPLATIN 
55390011299, CISPLATIN, CISPLATIN 
55390041499, CISPLATIN, CISPLATIN 
63323010365, CISPLATIN, CISPLATIN 
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63323010364, CISPLATIN, CISPLATIN 
63323010351, CISPLATIN, CISPLATIN 
10019091001, CISPLATIN, CISPLATIN 
55390009901, CISPLATIN, CISPLATIN 
55390011250, CISPLATIN, CISPLATIN 
55390041450, CISPLATIN, CISPLATIN 
00703574811, CISPLATIN, CISPLATIN-AQ 
00703574711, CISPLATIN, CISPLATIN-AQ 
00955102001, DOCETAXEL, DOCETAXEL 
00955102104, DOCETAXEL, DOCETAXEL 
61471029512, PEGYLATED LIPOSOMAL DOXORUBICIN, DOXIL 
17314960001, PEGYLATED LIPOSOMAL DOXORUBICIN, DOXIL 
59676096001, PEGYLATED LIPOSOMAL DOXORUBICIN, DOXIL 
17314960002, PEGYLATED LIPOSOMAL DOXORUBICIN, DOXIL 
59676096002, PEGYLATED LIPOSOMAL DOXORUBICIN, DOXIL 
10019092001, DOXORUBICIN, DOXORUBICIN HCL 
55390023110, DOXORUBICIN, DOXORUBICIN HCL 
55390024110, DOXORUBICIN, DOXORUBICIN HCL 
55390023210, DOXORUBICIN, DOXORUBICIN HCL 
55390023301, DOXORUBICIN, DOXORUBICIN HCL 
10019092102, DOXORUBICIN, DOXORUBICIN HCL 
55390024301, DOXORUBICIN, DOXORUBICIN HCL 
63323010161, DOXORUBICIN, DOXORUBICIN HCL 
55390023801, DOXORUBICIN, DOXORUBICIN HCL 
55390024801, DOXORUBICIN, DOXORUBICIN HCL 
00703504001, DOXORUBICIN, DOXORUBICIN HCL 
53905023606, DOXORUBICIN, DOXORUBICIN HCL 
63323088310, DOXORUBICIN, DOXORUBICIN HCL 
55390023610, DOXORUBICIN, DOXORUBICIN HCL 
55390024610, DOXORUBICIN, DOXORUBICIN HCL 
55390023701, DOXORUBICIN, DOXORUBICIN HCL 
00186153261, DOXORUBICIN, DOXORUBICIN HCL 
00703504601, DOXORUBICIN, DOXORUBICIN HCL 
00469883250, DOXORUBICIN, DOXORUBICIN HCL 
63323088330, DOXORUBICIN, DOXORUBICIN HCL 
55390024701, DOXORUBICIN, DOXORUBICIN HCL 
00074504601, DOXORUBICIN, DOXORUBICIN HCL 
00703504303, DOXORUBICIN, DOXORUBICIN HCL 
63323088305, DOXORUBICIN, DOXORUBICIN HCL 
55390023510, DOXORUBICIN, DOXORUBICIN HCL 
55390024510, DOXORUBICIN, DOXORUBICIN HCL 
00009509301, EPIRUBICIN, ELLENCE 
00009509101, EPIRUBICIN, ELLENCE 
00024059704, OXALIPLATIN, ELOXATIN 
00024059602, OXALIPLATIN, ELOXATIN 
00024059120, OXALIPLATIN, ELOXATIN 
00024059240, OXALIPLATIN, ELOXATIN 
00024059010, OXALIPLATIN, ELOXATIN 
61703034735, EPIRUBICIN, EPIRUBICIN HCL 
66758004202, EPIRUBICIN, EPIRUBICIN HCL 
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55390020801, EPIRUBICIN, EPIRUBICIN HCL 
61703035902, EPIRUBICIN, EPIRUBICIN HCL 
61703035959, EPIRUBICIN, EPIRUBICIN HCL 
00703306911, EPIRUBICIN, EPIRUBICIN HCL 
59762509301, EPIRUBICIN, EPIRUBICIN HCL 
66758004201, EPIRUBICIN, EPIRUBICIN HCL 
63323015125, EPIRUBICIN, EPIRUBICIN HCL 
25021020325, EPIRUBICIN, EPIRUBICIN HCL 
55390020701, EPIRUBICIN, EPIRUBICIN HCL 
61703035993, EPIRUBICIN, EPIRUBICIN HCL 
00703306711, EPIRUBICIN, EPIRUBICIN HCL 
59762509101, EPIRUBICIN, EPIRUBICIN HCL 
63323015175, EPIRUBICIN, EPIRUBICIN HCL 
66733094823, CETUXIMAB, ERBITUX 
66733095823, CETUXIMAB, ERBITUX 
00015340420, ETOPOSIDE, ETOPOPHOS 
54868535500, ETOPOSIDE, ETOPOSIDE 
51079096501, ETOPOSIDE, ETOPOSIDE 
51079096505, ETOPOSIDE, ETOPOSIDE 
00378326694, ETOPOSIDE, ETOPOSIDE 
55390029301, ETOPOSIDE, ETOPOSIDE 
55390049301, ETOPOSIDE, ETOPOSIDE 
55390029101, ETOPOSIDE, ETOPOSIDE 
55390049101, ETOPOSIDE, ETOPOSIDE 
00703566701, ETOPOSIDE, ETOPOSIDE 
63323010425, ETOPOSIDE, ETOPOSIDE 
00074564601, ETOPOSIDE, ETOPOSIDE 
00703564601, ETOPOSIDE, ETOPOSIDE 
00703565601, ETOPOSIDE, ETOPOSIDE 
63323010450, ETOPOSIDE, ETOPOSIDE 
00074148503, ETOPOSIDE, ETOPOSIDE 
00703565701, ETOPOSIDE, ETOPOSIDE 
10019093001, ETOPOSIDE, ETOPOSIDE 
00074148501, ETOPOSIDE, ETOPOSIDE 
00074564301, ETOPOSIDE, ETOPOSIDE 
00703564301, ETOPOSIDE, ETOPOSIDE 
00703565301, ETOPOSIDE, ETOPOSIDE 
63323010405, ETOPOSIDE, ETOPOSIDE 
55390029201, ETOPOSIDE, ETOPOSIDE 
55390049201, ETOPOSIDE, ETOPOSIDE 
51927277200, Etoposide, ETOPOSIDE 
00004190406, FLUOROURACIL, FLUOROURACIL 
38779002509, FLUOROURACIL, FLUOROURACIL 
38779002505, FLUOROURACIL, FLUOROURACIL 
38779002510, FLUOROURACIL, FLUOROURACIL 
38779002501, FLUOROURACIL, FLUOROURACIL 
51927108500, FLUOROURACIL, FLUOROURACIL 
49452317501, FLUOROURACIL, FLUOROURACIL 
38779002525, FLUOROURACIL, FLUOROURACIL 
38779002504, FLUOROURACIL, FLUOROURACIL 
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49452317502, FLUOROURACIL, FLUOROURACIL 
63370009535, FLUOROURACIL, FLUOROURACIL 
51552073305, FLUOROURACIL, FLUOROURACIL 
62991148604, FLUOROURACIL, FLUOROURACIL 
49452317504, FLUOROURACIL, FLUOROURACIL 
51552073301, FLUOROURACIL, FLUOROURACIL 
63370009525, FLUOROURACIL, FLUOROURACIL 
51552073304, FLUOROURACIL, FLUOROURACIL 
62991148602, FLUOROURACIL, FLUOROURACIL 
63370009515, FLUOROURACIL, FLUOROURACIL 
51552073302, FLUOROURACIL, FLUOROURACIL 
10139006301, FLUOROURACIL, FLUOROURACIL 
63323011761, FLUOROURACIL, FLUOROURACIL 
10139006350, FLUOROURACIL, FLUOROURACIL 
61703040932, FLUOROURACIL, FLUOROURACIL 
39769001210, FLUOROURACIL, FLUOROURACIL 
00004197701, FLUOROURACIL, FLUOROURACIL 
00187395364, FLUOROURACIL, FLUOROURACIL 
66758004401, FLUOROURACIL, FLUOROURACIL 
66758004403, FLUOROURACIL, FLUOROURACIL 
10139006310, FLUOROURACIL, FLUOROURACIL 
10139006311, FLUOROURACIL, FLUOROURACIL 
63323011710, FLUOROURACIL, FLUOROURACIL 
63323011720, FLUOROURACIL, FLUOROURACIL 
10139006312, FLUOROURACIL, FLUOROURACIL 
63323011751, FLUOROURACIL, FLUOROURACIL 
00182306863, FLUOROURACIL, FLUOROURACIL 
62991148601, Fluorouracil, FLUOROURACIL 
68152010100, LEVOLEUCOVORIN, FUSILEV 
63323012550, GEMCITABINE, GEMCITABINE HCL 
00781328379, GEMCITABINE, GEMCITABINE HCL 
00781328275, GEMCITABINE, GEMCITABINE HCL 
00409018701, GEMCITABINE, GEMCITABINE HCL 
00002750201, GEMCITABINE, GEMZAR 
00002750101, GEMCITABINE, GEMZAR 
00078037366, IMATINIB, GLEEVEC 
00078043815, IMATINIB, GLEEVEC 
54868528901, IMATINIB, GLEEVEC 
00078040105, IMATINIB, GLEEVEC 
54868528903, IMATINIB, GLEEVEC 
54868528900, IMATINIB, GLEEVEC 
54868528902, IMATINIB, GLEEVEC 
00078040134, IMATINIB, GLEEVEC 
54868542701, IMATINIB, GLEEVEC 
54868542700, IMATINIB, GLEEVEC 
00078040215, IMATINIB, GLEEVEC 
50242005656, TRASTUZUMAB, HERCEPTIN 
50242013468, TRASTUZUMAB, HERCEPTIN 
50242013460, TRASTUZUMAB, HERCEPTIN 
66758004802, IRINOTECAN, IRINOTECAN HCL 
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63323019305, IRINOTECAN, IRINOTECAN HCL 
55390029601, IRINOTECAN, IRINOTECAN HCL 
61703034909, IRINOTECAN, IRINOTECAN HCL 
00781306675, IRINOTECAN, IRINOTECAN HCL 
00591318926, IRINOTECAN, IRINOTECAN HCL 
00703443411, IRINOTECAN, IRINOTECAN HCL 
59762752902, IRINOTECAN, IRINOTECAN HCL 
61703034962, IRINOTECAN, IRINOTECAN HCL 
00703443491, IRINOTECAN, IRINOTECAN HCL 
66758004801, IRINOTECAN, IRINOTECAN HCL 
63323019302, IRINOTECAN, IRINOTECAN HCL 
10518010310, IRINOTECAN, IRINOTECAN HCL 
55390029501, IRINOTECAN, IRINOTECAN HCL 
61703034916, IRINOTECAN, IRINOTECAN HCL 
10019093401, IRINOTECAN, IRINOTECAN HCL 
00781306672, IRINOTECAN, IRINOTECAN HCL 
00591318902, IRINOTECAN, IRINOTECAN HCL 
00703443211, IRINOTECAN, IRINOTECAN HCL 
59762752901, IRINOTECAN, IRINOTECAN HCL 
49452403601, LEUCOVORIN, LEUCOVORIN CA 
51927269200, LEUCOVORIN, LEUCOVORIN CA 
49452403602, LEUCOVORIN, LEUCOVORIN CA 
00054849706, LEUCOVORIN, LEUCOVORIN CA 
00054449705, LEUCOVORIN, LEUCOVORIN CA 
00054449710, LEUCOVORIN, LEUCOVORIN CA 
67263034583, LEUCOVORIN, LEUCOVORIN CA 
00054849806, LEUCOVORIN, LEUCOVORIN CA 
00054449805, LEUCOVORIN, LEUCOVORIN CA 
58406062674, LEUCOVORIN, LEUCOVORIN CA 
00054449810, LEUCOVORIN, LEUCOVORIN CA 
00054849906, LEUCOVORIN, LEUCOVORIN CA 
62584076701, LEUCOVORIN, LEUCOVORIN CA 
51079058205, LEUCOVORIN, LEUCOVORIN CA 
00555048527, LEUCOVORIN, LEUCOVORIN CA 
51309074225, LEUCOVORIN, LEUCOVORIN CA 
62701090125, LEUCOVORIN, LEUCOVORIN CA 
00781122263, LEUCOVORIN, LEUCOVORIN CA 
00182187024, LEUCOVORIN, LEUCOVORIN CA 
00536414904, LEUCOVORIN, LEUCOVORIN CA 
00603418435, LEUCOVORIN, LEUCOVORIN CA 
00054449911, LEUCOVORIN, LEUCOVORIN CA 
51079058201, LEUCOVORIN, LEUCOVORIN CA 
49884023701, LEUCOVORIN, LEUCOVORIN CA 
00555048402, LEUCOVORIN, LEUCOVORIN CA 
58406062467, LEUCOVORIN, LEUCOVORIN CA 
51309074191, LEUCOVORIN, LEUCOVORIN CA 
62701090099, LEUCOVORIN, LEUCOVORIN CA 
00781122001, LEUCOVORIN, LEUCOVORIN CA 
00182186901, LEUCOVORIN, LEUCOVORIN CA 
00904231560, LEUCOVORIN, LEUCOVORIN CA 
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00054449625, LEUCOVORIN, LEUCOVORIN CA 
62584076601, LEUCOVORIN, LEUCOVORIN CA 
51079058101, LEUCOVORIN, LEUCOVORIN CA 
00555048401, LEUCOVORIN, LEUCOVORIN CA 
58406062462, LEUCOVORIN, LEUCOVORIN CA 
62701090030, LEUCOVORIN, LEUCOVORIN CA 
00781122031, LEUCOVORIN, LEUCOVORIN CA 
00536414807, LEUCOVORIN, LEUCOVORIN CA 
00054449613, LEUCOVORIN, LEUCOVORIN CA 
54868331001, LEUCOVORIN, LEUCOVORIN CA 
00054849619, LEUCOVORIN, LEUCOVORIN CA 
51079058106, LEUCOVORIN, LEUCOVORIN CA 
54868331000, LEUCOVORIN, LEUCOVORIN CA 
66479024725, LEUCOVORIN, LEUCOVORIN CA 
58406062307, LEUCOVORIN, LEUCOVORIN CA 
00074514001, LEUCOVORIN, LEUCOVORIN CA 
00703514001, LEUCOVORIN, LEUCOVORIN CA 
55390005210, LEUCOVORIN, LEUCOVORIN CA 
55390081810, LEUCOVORIN, LEUCOVORIN CA 
55390005301, LEUCOVORIN, LEUCOVORIN CA 
61703041050, LEUCOVORIN, LEUCOVORIN CA 
55390082401, LEUCOVORIN, LEUCOVORIN CA 
55390005401, LEUCOVORIN, LEUCOVORIN CA 
00703514501, LEUCOVORIN, LEUCOVORIN CA 
55390082501, LEUCOVORIN, LEUCOVORIN CA 
55390005110, LEUCOVORIN, LEUCOVORIN CA 
00074454102, LEUCOVORIN, LEUCOVORIN CA 
00517860525, LEUCOVORIN, LEUCOVORIN CA 
00074454104, LEUCOVORIN, LEUCOVORIN CA 
55390000901, LEUCOVORIN, LEUCOVORIN CA 
55390082601, LEUCOVORIN, LEUCOVORIN CA 
00641236441, LEUCOVORIN, LEUCOVORIN CA 
63323071100, LEUCOVORIN, LEUCOVORIN CA 
00641236941, LEUCOVORIN, LEUCOVORIN CA 
38779017806, Leucovorin Calcium, LEUCOVORIN CALCIUM 
49452403604, Leucovorin Calcium, LEUCOVORIN CALCIUM 
38779003506, METHOTREXATE, METHOTREXATE 
38779003511, METHOTREXATE, METHOTREXATE 
63370015410, METHOTREXATE, METHOTREXATE 
62991120001, METHOTREXATE, METHOTREXATE 
38779003504, METHOTREXATE, METHOTREXATE 
63370015425, METHOTREXATE, METHOTREXATE 
38779003503, METHOTREXATE, METHOTREXATE 
63370015415, METHOTREXATE, METHOTREXATE 
62991120002, METHOTREXATE, METHOTREXATE 
51552105409, METHOTREXATE, METHOTREXATE 
49452460003, METHOTREXATE, METHOTREXATE 
49452460101, METHOTREXATE, METHOTREXATE 
51552105401, METHOTREXATE, METHOTREXATE 
51927156500, METHOTREXATE, METHOTREXATE 




 Coding Definitions 
49452460002, METHOTREXATE, METHOTREXATE 
38779003510, Methotrexate Sodium, METHOTREXATE 
38779003515, Methotrexate Sodium, METHOTREXATE 
38779003525, Methotrexate Sodium, METHOTREXATE 
61703040804, METHOTREXATE, METHOTREXATE LPF 
58406068318, METHOTREXATE, METHOTREXATE LPF 
66479013613, METHOTREXATE, METHOTREXATE LPF 
58406068312, METHOTREXATE, METHOTREXATE LPF 
66479013619, METHOTREXATE, METHOTREXATE LPF 
58406068316, METHOTREXATE, METHOTREXATE LPF 
58406068315, METHOTREXATE, METHOTREXATE LPF 
66479013611, METHOTREXATE, METHOTREXATE LPF 
61703040807, METHOTREXATE, METHOTREXATE LPF 
54868382601, METHOTREXATE, METHOTREXATE SOD 
54868382600, METHOTREXATE, METHOTREXATE SOD 
54868382602, METHOTREXATE, METHOTREXATE SOD 
00677161001, METHOTREXATE, METHOTREXATE SOD 
54868382605, METHOTREXATE, METHOTREXATE SOD 
00378001401, METHOTREXATE, METHOTREXATE SOD 
21695011100, METHOTREXATE, METHOTREXATE SOD 
52959024400, METHOTREXATE, METHOTREXATE SOD 
67253032010, METHOTREXATE, METHOTREXATE SOD 
00555057202, METHOTREXATE, METHOTREXATE SOD 
51285050902, METHOTREXATE, METHOTREXATE SOD 
68115063200, METHOTREXATE, METHOTREXATE SOD 
62701094099, METHOTREXATE, METHOTREXATE SOD 
00781107601, METHOTREXATE, METHOTREXATE SOD 
00182153901, METHOTREXATE, METHOTREXATE SOD 
00904174960, METHOTREXATE, METHOTREXATE SOD 
00536399801, METHOTREXATE, METHOTREXATE SOD 
00364249901, METHOTREXATE, METHOTREXATE SOD 
00603449921, METHOTREXATE, METHOTREXATE SOD 
00005450723, METHOTREXATE, METHOTREXATE SOD 
00054455025, METHOTREXATE, METHOTREXATE SOD 
00405464301, METHOTREXATE, METHOTREXATE SOD 
59911587401, METHOTREXATE, METHOTREXATE SOD 
00904601260, METHOTREXATE, METHOTREXATE SOD 
00054855025, METHOTREXATE, METHOTREXATE SOD 
00555057246, METHOTREXATE, METHOTREXATE SOD 
51079067086, METHOTREXATE, METHOTREXATE SOD 
00054855005, METHOTREXATE, METHOTREXATE SOD 
00555057247, METHOTREXATE, METHOTREXATE SOD 
51079067087, METHOTREXATE, METHOTREXATE SOD 
00054855006, METHOTREXATE, METHOTREXATE SOD 
00555057248, METHOTREXATE, METHOTREXATE SOD 
54868382603, METHOTREXATE, METHOTREXATE SOD 
00054855007, METHOTREXATE, METHOTREXATE SOD 
49999038024, METHOTREXATE, METHOTREXATE SOD 
00555057249, METHOTREXATE, METHOTREXATE SOD 
23490588900, METHOTREXATE, METHOTREXATE SOD 




 Coding Definitions 
54868382604, METHOTREXATE, METHOTREXATE SOD 
51079067001, METHOTREXATE, METHOTREXATE SOD 
51079067005, METHOTREXATE, METHOTREXATE SOD 
55289092430, METHOTREXATE, METHOTREXATE SOD 
67253032036, METHOTREXATE, METHOTREXATE SOD 
00555057235, METHOTREXATE, METHOTREXATE SOD 
62701094036, METHOTREXATE, METHOTREXATE SOD 
00781107636, METHOTREXATE, METHOTREXATE SOD 
00182153995, METHOTREXATE, METHOTREXATE SOD 
00904174973, METHOTREXATE, METHOTREXATE SOD 
00364249936, METHOTREXATE, METHOTREXATE SOD 
00536399836, METHOTREXATE, METHOTREXATE SOD 
00054455015, METHOTREXATE, METHOTREXATE SOD 
54868382606, METHOTREXATE, METHOTREXATE SOD 
00378001450, METHOTREXATE, METHOTREXATE SOD 
54569181800, METHOTREXATE, METHOTREXATE SOD 
00555057245, METHOTREXATE, METHOTREXATE SOD 
00054855003, METHOTREXATE, METHOTREXATE SOD 
63323012250, METHOTREXATE, METHOTREXATE SOD 
66479013929, METHOTREXATE, METHOTREXATE SOD 
55390014301, METHOTREXATE, METHOTREXATE SOD 
58406067301, METHOTREXATE, METHOTREXATE SOD 
66479013721, METHOTREXATE, METHOTREXATE SOD 
00205532618, METHOTREXATE, METHOTREXATE SOD 
54569452500, METHOTREXATE, METHOTREXATE SOD 
61703040732, METHOTREXATE, METHOTREXATE SOD 
58406068117, METHOTREXATE, METHOTREXATE SOD 
66479013509, METHOTREXATE, METHOTREXATE SOD 
00469288030, METHOTREXATE, METHOTREXATE SOD 
10019094101, METHOTREXATE, METHOTREXATE SOD 
61703035038, METHOTREXATE, METHOTREXATE SOD 
61703040832, METHOTREXATE, METHOTREXATE SOD 
61703040813, METHOTREXATE, METHOTREXATE SOD 
63323012140, METHOTREXATE, METHOTREXATE SOD 
63323012104, METHOTREXATE, METHOTREXATE SOD 
63323012108, METHOTREXATE, METHOTREXATE SOD 
63323012110, METHOTREXATE, METHOTREXATE SOD 
63323012310, METHOTREXATE, METHOTREXATE SOD 
54868471600, METHOTREXATE, METHOTREXATE SOD 
10139006210, METHOTREXATE, METHOTREXATE SOD 
53905003410, METHOTREXATE, METHOTREXATE SOD 
55390003410, METHOTREXATE, METHOTREXATE SOD 
66758004008, METHOTREXATE, METHOTREXATE SOD 
66758004001, METHOTREXATE, METHOTREXATE SOD 
10139006202, METHOTREXATE, METHOTREXATE SOD 
66479013501, METHOTREXATE, METHOTREXATE SOD 
61703040707, METHOTREXATE, METHOTREXATE SOD 
00205455626, METHOTREXATE, METHOTREXATE SOD 
58406068114, METHOTREXATE, METHOTREXATE SOD 
10019094001, METHOTREXATE, METHOTREXATE SOD 




 Coding Definitions 
55390003110, METHOTREXATE, METHOTREXATE SOD 
66758004002, METHOTREXATE, METHOTREXATE SOD 
61703040822, METHOTREXATE, METHOTREXATE SOD 
66758004101, METHOTREXATE, METHOTREXATE SOD 
10139006240, METHOTREXATE, METHOTREXATE SOD 
61703040841, METHOTREXATE, METHOTREXATE SOD 
10019094002, METHOTREXATE, METHOTREXATE SOD 
55390003210, METHOTREXATE, METHOTREXATE SOD 
61703040858, METHOTREXATE, METHOTREXATE SOD 
55390003310, METHOTREXATE, METHOTREXATE SOD 
00205933792, METHOTREXATE, METHOTREXATE SOD 
63323012102, METHOTREXATE, METHOTREXATE SOD 
63323012302, METHOTREXATE, METHOTREXATE SOD 
54868479600, METHOTREXATE, METHOTREXATE SOD 
54868017301, METHOTREXATE, METHOTREXATE SOD 
00186142212, METHOTREXATE, METHOTREXATE SOD 
00186142013, METHOTREXATE, METHOTREXATE SOD 
00186142113, METHOTREXATE, METHOTREXATE SOD 
62991154503, MITOMYCIN, MITOMYCIN 
51927364200, MITOMYCIN, MITOMYCIN 
38779055307, MITOMYCIN, MITOMYCIN 
16729010811, MITOMYCIN, MITOMYCIN 
55390025201, MITOMYCIN, MITOMYCIN 
61703030650, MITOMYCIN, MITOMYCIN 
55390045201, MITOMYCIN, MITOMYCIN 
55390025301, MITOMYCIN, MITOMYCIN 
55390045301, MITOMYCIN, MITOMYCIN 
62701001001, MITOMYCIN, MITOMYCIN 
16729011505, MITOMYCIN, MITOMYCIN 
55390025101, MITOMYCIN, MITOMYCIN 
55390045101, MITOMYCIN, MITOMYCIN 
63323019140, MITOMYCIN, MITOMYCIN 
63323019120, MITOMYCIN, MITOMYCIN 
63323019020, MITOMYCIN, MITOMYCIN 
49452478502, Mitomycin, MITOMYCIN 
00015300222, MITOMYCIN, MUTAMYCIN 
00015300220, MITOMYCIN, MUTAMYCIN 
00015305920, MITOMYCIN, MUTAMYCIN 
00015300120, MITOMYCIN, MUTAMYCIN 
50419048858, SORAFENIB, NEXAVAR 
00026848858, SORAFENIB, NEXAVAR 
00172375675, PACLITAXEL, ONXOL 
00172375377, PACLITAXEL, ONXOL 
00172375473, PACLITAXEL, ONXOL 
63323017650, OXALIPLATIN, OXALIPLATIN 
41616017840, OXALIPLATIN, OXALIPLATIN 
41616017640, OXALIPLATIN, OXALIPLATIN 
66758005302, OXALIPLATIN, OXALIPLATIN 
61703036322, OXALIPLATIN, OXALIPLATIN 
63323065020, OXALIPLATIN, OXALIPLATIN 




 Coding Definitions 
66758005301, OXALIPLATIN, OXALIPLATIN 
61703036318, OXALIPLATIN, OXALIPLATIN 
00703398501, OXALIPLATIN, OXALIPLATIN 
55390011420, PACLITAXEL, PACLITAXEL 
61703034222, PACLITAXEL, PACLITAXEL 
00074433502, PACLITAXEL, PACLITAXEL 
51079096201, PACLITAXEL, PACLITAXEL 
00703476601, PACLITAXEL, PACLITAXEL 
00555198414, PACLITAXEL, PACLITAXEL 
55390030420, PACLITAXEL, PACLITAXEL 
55390031420, PACLITAXEL, PACLITAXEL 
55390051420, PACLITAXEL, PACLITAXEL 
66758004302, PACLITAXEL, PACLITAXEL 
10518010208, PACLITAXEL, PACLITAXEL 
63323076316, PACLITAXEL, PACLITAXEL 
00703476701, PACLITAXEL, PACLITAXEL 
66758004303, PACLITAXEL, PACLITAXEL 
55390011450, PACLITAXEL, PACLITAXEL 
61703034250, PACLITAXEL, PACLITAXEL 
00074433504, PACLITAXEL, PACLITAXEL 
10518010209, PACLITAXEL, PACLITAXEL 
63323076350, PACLITAXEL, PACLITAXEL 
51079096301, PACLITAXEL, PACLITAXEL 
00703476801, PACLITAXEL, PACLITAXEL 
00555198514, PACLITAXEL, PACLITAXEL 
55390030450, PACLITAXEL, PACLITAXEL 
55390031450, PACLITAXEL, PACLITAXEL 
55390051450, PACLITAXEL, PACLITAXEL 
00172375396, PACLITAXEL, PACLITAXEL 
66758004301, PACLITAXEL, PACLITAXEL 
55390011405, PACLITAXEL, PACLITAXEL 
00074433501, PACLITAXEL, PACLITAXEL 
61703034209, PACLITAXEL, PACLITAXEL 
10518010207, PACLITAXEL, PACLITAXEL 
63323076305, PACLITAXEL, PACLITAXEL 
51079096101, PACLITAXEL, PACLITAXEL 
00703476401, PACLITAXEL, PACLITAXEL 
55390030405, PACLITAXEL, PACLITAXEL 
55390031405, PACLITAXEL, PACLITAXEL 
55390051405, PACLITAXEL, PACLITAXEL 
00172375494, PACLITAXEL, PACLITAXEL 
00015321430, CARBOPLATIN, PARAPLATIN 
00015321530, CARBOPLATIN, PARAPLATIN 
00015321330, CARBOPLATIN, PARAPLATIN 
00015321630, CARBOPLATIN, PARAPLATIN 
00015321130, CARBOPLATIN, PARAPLATIN 
00015321230, CARBOPLATIN, PARAPLATIN 
00015321030, CARBOPLATIN, PARAPLATIN 
00015321076, CARBOPLATIN, PARAPLATIN 
00015322122, CISPLATIN, PLATINOL AQ 
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00015322022, CISPLATIN, PLATINOL AQ 
67253058042, METHOTREXATE, RHEUMATREX 
00005450704, METHOTREXATE, RHEUMATREX 
67253058043, METHOTREXATE, RHEUMATREX 
00005450705, METHOTREXATE, RHEUMATREX 
67253058044, METHOTREXATE, RHEUMATREX 
00005450707, METHOTREXATE, RHEUMATREX 
67253058045, METHOTREXATE, RHEUMATREX 
00005450709, METHOTREXATE, RHEUMATREX 
00005450791, METHOTREXATE, RHEUMATREX 
67253058046, METHOTREXATE, RHEUMATREX 
00015335222, DOXORUBICIN, RUBEX 
00069055038, SUNITINIB, SUTENT 
00069055030, SUNITINIB, SUTENT 
00069077038, SUNITINIB, SUTENT 
00069077030, SUNITINIB, SUTENT 
00069098038, SUNITINIB, SUTENT 
00069098030, SUNITINIB, SUTENT 
50242006301, ERLOTINIB, TARCEVA 
54868547400, ERLOTINIB, TARCEVA 
50242006401, ERLOTINIB, TARCEVA 
54868544700, ERLOTINIB, TARCEVA 
50242006201, ERLOTINIB, TARCEVA 
00015347630, PACLITAXEL, TAXOL SEMI-SYN 
00015347620, PACLITAXEL, TAXOL SEMI-SYN 
00015347911, PACLITAXEL, TAXOL SEMI-SYN 
00015347530, PACLITAXEL, TAXOL SEMI-SYN 
00015347520, PACLITAXEL, TAXOL SEMI-SYN 
00015347627, PACLITAXEL, TAXOL SEMI-SYN 
00015347527, PACLITAXEL, TAXOL SEMI-SYN 
00075800120, DOCETAXEL, TAXOTERE 
00075800301, DOCETAXEL, TAXOTERE 
00075800180, DOCETAXEL, TAXOTERE 
00075800404, DOCETAXEL, TAXOTERE 
00013733691, ETOPOSIDE, TOPOSAR 
51285036801, METHOTREXATE, TREXALL 
00555092901, METHOTREXATE, TREXALL 
51285036901, METHOTREXATE, TREXALL 
00555094501, METHOTREXATE, TREXALL 
51285036601, METHOTREXATE, TREXALL 
00555092701, METHOTREXATE, TREXALL 
51285036701, METHOTREXATE, TREXALL 
00555092801, METHOTREXATE, TREXALL 
00015309145, ETOPOSIDE, VEPESID 
00015309520, ETOPOSIDE, VEPESID 
00015309595, ETOPOSIDE, VEPESID 
00015308420, ETOPOSIDE, VEPESID 
00015306220, ETOPOSIDE, VEPESID 
00015306120, ETOPOSIDE, VEPESID 
00173080409, PAZOPANIB, VOTRIENT 
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00173063155, LEUCOVORIN, WELLCOVORIN 
00081063120, LEUCOVORIN, WELLCOVORIN 
00173063120, LEUCOVORIN, WELLCOVORIN 
54868414301, CAPECITABINE, XELODA 
00004110051, CAPECITABINE, XELODA 
00004110020, CAPECITABINE, XELODA 
54868414300, CAPECITABINE, XELODA 
68258903601, CAPECITABINE, XELODA 
00004110175, CAPECITABINE, XELODA 
00004110150, CAPECITABINE, XELODA 
54868526002, CAPECITABINE, XELODA 
54569571700, CAPECITABINE, XELODA 
54868526004, CAPECITABINE, XELODA 
54868526009, CAPECITABINE, XELODA 
00004110116, CAPECITABINE, XELODA 
54868526005, CAPECITABINE, XELODA 
54868526000, CAPECITABINE, XELODA 
54868526006, CAPECITABINE, XELODA 
54868526001, CAPECITABINE, XELODA 
54868526007, CAPECITABINE, XELODA 
54868526008, CAPECITABINE, XELODA 




ICD-9-CM diagnosis code V58.12; ICD-9-CM procedure codes 00.15, 99.28; 
HCPCS codes indicating immunotherapy J9015, J9214;  
NDC codes in the Durable Medical Equipment or prescription drug event data files 
indicating immunotherapy drugs : 
 
NDC Code, Generic Name, Brand Name 
00078049561, ALDESLEUKIN, PROLEUKIN 
00085012002, INTERFERON ALFA 2B, INTRON-A 
00085012003, INTERFERON ALFA 2B, INTRON-A 
00085012004, INTERFERON ALFA 2B, INTRON-A 
00085012005, INTERFERON ALFA 2B, INTRON-A 
00085028502, INTERFERON ALFA 2B, INTRON-A 
00085053901, INTERFERON ALFA 2B, INTRON-A 
00085057102, INTERFERON ALFA 2B, INTRON-A 
00085057106, INTERFERON ALFA 2B, INTRON-A 
00085064703, INTERFERON ALFA 2B, INTRON-A 
00085064704, INTERFERON ALFA 2B, INTRON-A 
00085064705, INTERFERON ALFA 2B, INTRON-A 
00085068901, INTERFERON ALFA 2B, INTRON-A 
00085076901, INTERFERON ALFA 2B, INTRON-A 
00085095301, INTERFERON ALFA 2B, INTRON-A 
00085111001, INTERFERON ALFA 2B, INTRON-A 
00085113301, INTERFERON ALFA 2B, INTRON-A 
00085116801, INTERFERON ALFA 2B, INTRON-A 
00085117901, INTERFERON ALFA 2B, INTRON-A 
00085117902, INTERFERON ALFA 2B, INTRON-A 




 Coding Definitions 
00085118402, INTERFERON ALFA 2B, INTRON-A 
00085119101, INTERFERON ALFA 2B, INTRON-A 
00085119102, INTERFERON ALFA 2B, INTRON-A 
00085123501, INTERFERON ALFA 2B, INTRON-A 
00085124201, INTERFERON ALFA 2B, INTRON-A 
00085125401, INTERFERON ALFA 2B, INTRON-A 
00339650099, INTERFERON ALFA 2B, INTRON-A 
00339650199, INTERFERON ALFA 2B, INTRON-A 
00339650299, INTERFERON ALFA 2B, INTRON-A 
00339650399, INTERFERON ALFA 2B, INTRON-A 
00339651199, INTERFERON ALFA 2B, INTRON-A 
00339651299, INTERFERON ALFA 2B, INTRON-A 
53905099101, ALDESLEUKIN, PROLEUKIN 
54868334100, INTERFERON ALFA 2B, INTRON-A 
65483011607, ALDESLEUKIN, PROLEUKIN 
Nephrectomy ICD-9-CM procedure codes (55.4, 55.5, 55.51, 55.52, 55.53, 55.54) and Current 
Procedural Terminology (CPT) procedure codes (50220, 50225, 50230, 50234, 
50236, 50240, 50320, 50545, 50543, 50546). 
Diabetes ICD-9-CM diagnosis codes 250.xx 
Atherosclerosis ICD-9-CM diagnosis codes 440.xx, 441.xx, 442.xx, 443.89, 444.xx, and 445.xx. 




ICD-9-CM procedure codes (35.x, 36.x, 37.1x, 37.24, 37.25, 37.3x, 37.4x, 37.6x, 
37.9x, 38.0x, 38.1x, 38.3x, 38.4x, 38.6x, 38.7x, 39.0x, 39.2x, 39.4x, 39.5x, 39.7x); 
CPT codes 32160, 32658 – 3266, 33015, 33020, 33025, 33030, 33031, 33050, 
33120, 33130, 33140, 33141, 33200 – 33203, 33206 – 33208, 33210 – 33218, 
33220, 33222 – 33226, 33233 – 33238, 33240 – 33247, 33249 – 33251, 33253 – 
33256, 33261, 33300, 33305, 33310, 33315, 33320 – 33322, 33330, 33332, 33335, 
33400, 33401, 33403- 33406, 33410 – 33417, 33420, 33422, 33425 – 33427, 
33430, 33460, 33463 – 33465, 33468, 33470 – 33472, 33474 – 33476, 33478, 
33496, 33500 – 33508, 33510 – 33514, 33516 – 33519, 33521 – 33523, 33530, 
33533 – 33536, 33542, 33545, 33548, 33572, 33600, 33602, 33606, 33608, 33610 - 
33612, 33615, 33617, 33619, 33641, 33645, 33647, 33660, 33665, 33670, 33675 - 
33677, 33681, 33684, 33688, 33690, 33692, 33694, 33697, 33702, 33710, 33720, 
33722, 33724, 33726, 33730, 33732, 33735 - 33737, 33750, 33755, 33762, 33764, 
33766 - 33768, 33770, 33771, 33774 - 33781, 33786, 33788, 33800, 33802, 33803, 
33813, 33814, 33820, 33822, 33824, 33840, 33845, 33851 - 33853, 33860, 33861, 
33863, 33870, 33875, 33877, 33880, 33881, 33883, 33884, 33886, 33889, 33891, 
33910, 33915 - 33920, 33922, 33924 - 33926, 33940, 33960, 33961, 33967, 33968, 
33970, 33971, 33973 - 33980, 33999, 34001, 34051, 34101, 34111, 34151, 34201, 
34203, 34401, 34421, 34451, 34471, 34490, 34501, 34502, 34510, 34520, 34530, 
34800, 34802 - 34805, 34808, 34812, 34813, 34820, 34825, 34826, 34830 - 34834, 
34900, 35001, 35002, 35005, 35011, 35013, 35021, 35022, 35045, 35081, 35082, 
35091, 35092, 35102, 35103, 35111, 35112, 35121, 35122, 35131, 35132, 35141, 
35142, 35151, 35152, 35161, 35162, 35180, 35182, 35184, 35188, 35189, 35190, 
35201, 35206, 35207, 35211, 35216, 35221, 35226, 35231, 35236, 35241, 35246, 
35251, 35256, 35261, 35266, 35271, 35276, 35281, 35286, 35301, 35311, 35321, 
35331, 35341, 35351, 35355, 35361, 35363, 35371, 35372, 35381, 35390, 35450, 
35452, 35454, 35456, 35458, 35459, 35460, 35470 - 35476, 35480 - 35485, 35490 - 
35495, 35500, 35501, 35506 - 35512, 35515, 35516, 35518, 35521, 35526, 35531, 
35533, 35536, 35541, 35546, 35548, 35549, 35551, 35556, 35558, 35560, 35563, 




 Coding Definitions 
35612, 35616, 35621, 35623, 35626, 35631, 35636, 35637, 35638, 35641, 35642, 
35645, 35646, 35647, 35650, 35651, 35654, 35656, 35661, 35663, 35665, 35666, 
35671, 35681 - 35683, 35685, 35686, 35691, 35693, 35694, 35695, 35700, 35701, 
35721, 35741, 35761, 35800, 35820, 35840, 35860, 35870, 35875, 35876, 35879, 
35881, 35883, 35884, 35900, 35901, 35903, 35905, 35907, 35910, 36260, 36261, 
36262, 36470, 36471, 36800, 36810, 36815, 36818 - 36822, 36825, 36830 - 36835, 
36860, 36861, 36870, 37140, 37145, 37160, 37180 - 37188, 37190, 37204 - 37208, 
37500, 37565, 37600, 37605 - 37607, 37609, 37615 - 37618, 37620, 37650, 37660, 
37788, 37790, 37799, 50100, 60600, 60605, 61609 - 61613, 61623, 61624, 61626, 
61630, 61635, 61640 - 61642, 61680, 61682, 61684, 61686, 61690, 61692, 61697, 
61698, 61700, 61702, 61703, 61705, 61708, 61710, 61711, 92961, 92970, 92971, 
92975, 92977, 92986, 92987, 92990, 92992, 92993, 93536, 93580, 93581; and 
HCPCS codes 0001T, 0002T, 0005T, 0033T, 0034T, 0035T, 0036T, 0037T, 
G0269, G0297, G0298, G0299, G0300, G0365, M0301, S2130, S2131, S2204, 
S2205, S2206, S2207, S2208, S2209. 
Placement of a 
CVC 
HCPCS or CPT codes C1751, S5520, S5522, 36488, 36489, 36490, 36491, 36493, 
36530, 36531, 36532, 36536, 36537, 36555, 36556, 36557, 36558, 36560, 36561, 
36563, 36565, 36566, 36568, 36569, 36570, 36571, 36575, 36576, 36578, 36580, 
36581, 36582, 36583, 36584, 36585, 36589, 36590, 36595, 36596, 36597, 75998 
Kidney disease ICD-9-CM diagnosis codes 403, 403.0, 403.00, 403.01, 403.1, 403.10, 403.11, 
403.9, 403.90, 403.91, 404, 404.0, 404.00, 404.01, 404.02, 404.03, 404.1, 404.10, 
404.11, 404.12, 404.13, 404.9, 404.90 , 404.91 , 404.92, 404.93, 582 , 582.0, 582.1, 
582.2, 582.4, 582.8, 582.81, 582.89, 582.9, 584, 584.5, 584.6, 584.7, 584.8, 584.9, 






Appendix C. Adapted Charlson Comorbidity Index 
Note. Based on publically-available code retrieved from 
http://www.appliedresearch.cancer.gov/seermedicare/program/charlson.comorbidity.macr
o.txt 
 Condition Weight Codes  
Diagnoses   ICD-9-CM Diagnosis Codes 
 Myocardial Infarction 1 410 – 410.9 
 Old Myocardial Infarction 1 412 
 Congestive Heart Failure 1 428 – 428.9 
 Peripheral Vascular Disease 1 441-441.9, 443.9, 785.4, V43.4 
 Cerebrovascular Disease 1 430 – 437.9, 438 
 Chronic Obstructive 
Pulmonary Disease 
1 490 – 496.9, 500 – 505.9, 506.4 
 Dementia 1 290-290.9 
 Paralysis 2 342-342.9, 344.1 
 Diabetes 1 250, 250.0-250.3, 250.7 
 Diabetes with Sequelae 2 250.4-250.6, 250.8-250.9 
 Chronic Renal Failure 2 582-582.9, 583-583.9, 585, 586, 588-
588.9 
 Various Cirrhodites 1 571.2, 571.4, 571.5, 571.6 
 Moderate to Severe Liver 
Disease 
3 572.2-572.8, 456.0-456.1, 456.2, 456.20, 
456.21 
 Ulcers 1 531-531.9, 532-532.9, 533-533.9, 534-
534.9 
 Rheumatoid Arthritis 1 710.0, 710.1, 710.4 , 714.0-714.2, 714.81, 
725 
 AIDS 6 042.0 – 044.9 
Procedures    
 Peripheral Vascular Disease  1 ICD-9-CM Procedure codes:  
381.3 , 381.4, 381.6, 381.8, 383.3, 383.4, 
383.6, 383.8, 384.3, 384.4, 384.6, 384.8, 
392.2-392.6, 392.8, 392.9 
HCPCS: 
 '35011', '35013', '35045', '35081', '35082', 
'35091', '35092', '35102', '35103', '35111', 
'35112', '35121', '35122', '35131', '35132', 
'35141', '35142', '35151', '35152', '35153', 
'35311', '35321', '35331', '35341', '35351', 
'35506', '35507', '35511', '35516', '35518', 
'35521', '35526', '35531', '35533', '35536', 
'35541', '35546', '35548', '35549', 
'35551','35556', '35558', '35560', '35563', 
'35565', '35566', '35571','35582', '35583', 
'35585', '35587', '35601', '35606', 
'35612','35616', '35621', '35623', '35626', 
'35631', '35636', '35641','35646', '35650', 
'35651', '35654', '35656', '35661', 




'35695', and '35355' to '35381' 




'35301', '35001', '35002', '35005', '35501', 
'35508', '35509', '35515', '35642', '35645', 
'35691', '35693' 
 Moderate to Severe Liver 
Disease 




 '37140', '37145', '37160', '37180', '37181', 





Appendix D. Code to Calculate the Charlson Comorbidity Score Weights 
Note. Publically available code retrieved from 
http://healthcaredelivery.cancer.gov/seermedicare/program/comorbidity.html 
 
   /********************************************************************** 
    Changes have been made to the remove.ruleout.dxcodes.macro.txt on  
    July 22, 2010 to remove code (below) that made a selection 
    on HCPCS. Now all the claims are looked at for conditions. 
     
    if (&FILETYPE='M') or 
      ('00100' <= &HCPCS <= '01999' or '10021' <= &HCPCS <= '69979' or 
       '77261' <= &HCPCS <= '79999' or 
       '90918' <= &HCPCS <= '91299' or '92950' <= &HCPCS <= '99199'); 
     
    Please make sure you use the current remove.ruleout.dxcodes.macro.txt 
    before running this macro. 
     
    ***************************************************************** 
    This SAS macro uses a dataset of claim records to calculate a  
    comorbidity index for a patient with respect to cancer. This code 
    reflects the Deyo adaptation of the Charlson comorbidity index, with 
    several procedure codes that reflect the Romano adaptation. 
    (NOTE: since cancer is the disease of interest, it is not included 
    in the comorbidity index given below.)  The dataset must contain  
    lists of diagnosis and surgery codes. There are other specific  
    variables needed to complete this task. 
   
    In order to use this program: 
      1. Include this file in your SAS program   
         %include '/directory path/charlson.comorbidity.macro.sas'; 
      2. Create a clean file of claim records to send to the macro. 
       If you wish to remove diagnoses for procedures done for  
       'rule out' purposes, you must do so externally to this macro. 
   (SEE remove.ruleout.dxcodes.macro.sas from SEER-Medicare web site) 
       You may include claim information from any file, including 
       MEDPAR, Outpatient SAF and Physicial/Supplier (NCH). All claim 
   records of interest should be included into the same file. 
       You must sort the claim records by your person identifier. 
      3. After setting up your data file, call the macro COMORB: 
          COMORB(ClmData, RegCase, Ind_Pri, LOS, dx01-dx10, 10, surg01-surg10, 10, HCPCS, Source) 
       would send the data set 'ClmData', sorted by the person  
       identifier 'RegCase' to the macro. The variable 'Ind_Pri' 
       must be set on each record as either index (I) or Prior event (P) 
       with respect to the cancer of interest. The number of 
       days for a hospital stay is found in the variable 'LOS'. 
       There are 10 diagnosis codes in the array variables 'dx01-dx10'. 
       Similarly, there are 10 surgery codes in the array variables  
       'surg01-surg10'. Diagnosis and surgery codes are in ICD-9 format. 
          HCPCS are the procedure codes from the SAF and NCH files. Only CPT-4 




   record is found in the variable 'Source' (M=Medpar, O=Outpatient, 
   N=NCH). 
     
    This returns the data set COMORB which contains 1 record for each person 
    that had at least one claim record. The variables included in this data set are 
    the person identifier (in the example, RegCase), Charlson scores for  
    prior conditions, index conditions and prior+index conditions, and the 
    condition indicator flags for prior and for index time frames.  
     
    NCI usually uses PCHRLSON calculated using claims from 
     (Date of Diagnosis - 12 months) through (Date of DX - 1 month) 
   **********************************************************************/ 
  
   /* internal macro to set indicators */ 
%MACRO FLAGSET(VAR,FLAG,NFLAGS,POSISHN); 
   &FLAG = &POSISHN; 
   &NFLAGS = &NFLAGS + 1; 
   &VAR = 1; 
%MEND; 
  




   /********************************************************************** 
    SETIN:    Dataset name: a dataset that contains the following: 
    PATID:    Variable name: Unique ID for each patient. &SETIN must be 
              sorted by &PATID. There may be more than 1 record per patient. 
    IDXPRI:   Variable name: indicates for each record if the Dx and Surg  
           codes are Index 'I' or Prior 'P' to the event of interest. 
           If the variable does not equal I or P, the record will not be 
           used. This variable should be set by the calling program. 
    DAYS:     Variable name: contains the length of stay for hospital visits. 
    DXVARSTR: Variable names: the diagnosis codes in ICD-9, ie 'DX01-DX10' 
    NDXVAR:   Number: the actual number of diagnosis codes in DXVARSTR 
    SXVARSTR: Variable names: the surgery codes in ICD-9, ie 'SURG01-SURG10' 
    NSXVAR:   Number: the actual number of surgery codes in SXVARSTR 
    HCPCS:    Variable name: the SAF and NCH file procedure codes in CPT-4. 
    FILETYPE: Variable name: the source of the claim record. Only important 
           value is 'M' for MEDPAR (inpatient hospital records). If this 
           is 'M', the check for Acute MI will include &DAYS > 2. 
   **********************************************************************/ 
  
 DATA COMORB; 
   RETAIN CVPRIO01-CVPRIO18 
          CVINDX01-CVINDX18;  
   LENGTH DEFAULT=3; 
   SET &SETIN; 
   BY &PATID; 
     
   /* Flag arrays, diagnosis and surgery code arrays */ 




   ARRAY CLINDX (18) CVINDX01-CVINDX18; 
   ARRAY COVAR  (18) ACUTEMI OLDMI CHF VASCUL1 VASCUL2 CVD 
                     PULMON1 DEMENTIA PARALYS DIABET1 DIABET3 RENAL1 
                     LIVER1 LIVER2 ULCER1 ULCER2 RHEUM AIDS; 
   ARRAY FLAGS (*) FLAG01-FLAG18; 
   ARRAY DX (&NDXVAR) $ &DXVARSTR; 
   ARRAY SX (&NSXVAR) $ &SXVARSTR; 
          
   /* Initialization */ 
   IF FIRST.&PATID THEN DO; 
     DO M=1 TO 18; 
       CLPRIO(M)=0; 
       CLINDX(M)=0; 
       END; 
     END; 
 
   DO M=1 TO 18; 
     COVAR(M)=0; 
     FLAGS(M)=0; 
     END; 
     
   NFLAGS=0; 
     
   /* Diagnosis code loop */   
   DO K=1 TO &NDXVAR; 
     dx_4 = substr(dx(k),1,4); 
     dx_3 = substr(dx(k),1,3); 
 
     /********** MYOCARDIAL INFARCTION WEIGHT = 1 ****************/ 
     IF ACUTEMI=0 THEN DO;   
       IF dx_3 = '410' then do;                     /* 410 thru 4109 */ 
          IF ((&FILETYPE='M') & (&DAYS > 2)) | NOT (&FILETYPE='M') THEN DO;  
            %FLAGSET(ACUTEMI,FLAGS(NFLAGS+1),NFLAGS,1); 
            END; 
          END; 
       END; 
  
     IF OLDMI=0 THEN DO; 
       IF DX(K) = '412  ' then do; 
          %FLAGSET(OLDMI,FLAGS(NFLAGS+1),NFLAGS,2); 
          END; 
       END; 
  
     /********** CHF ***** WEIGHT = 1 ****************************/ 
     IF CHF=0 THEN DO; 
       IF dx_3 = '428' then do;                    /* 428 thru 4289 */  
          %FLAGSET(CHF,FLAGS(NFLAGS+1),NFLAGS,3); 
          END; 
       END; 
  
     /*********** PERIPHERAL VASCULAR DISEASE ******* WEIGHT = 1**/ 




       IF dx_3 = '441' | dx_4 in ('4439', '7854', 'V434', 'v434') then do; 
          %FLAGSET(VASCUL1,FLAGS(NFLAGS+1),NFLAGS,4); 
          END; 
       END; 
  
     /********* CEREBROVASCULAR DISEASE ******* WEIGHT = 1 *******/ 
     IF CVD=0 THEN DO;       /* 430 thru 4379 */ 
       IF '430' <= dx_3 <= '437' | DX(K)= '438  ' then do;  
          %FLAGSET(CVD,FLAGS(NFLAGS+1),NFLAGS,6); 
          END; 
       END; 
  
     /*********** COPD *********************** WEIGHT = 1 ********/ 
     IF PULMON1=0 THEN DO; 
       IF '490' <= dx_3 <= '496' | '500' <= dx_3 <= '505' |  
          dx_4 = '5064' THEN DO; 
          %FLAGSET(PULMON1,FLAGS(NFLAGS+1),NFLAGS,7); 
          END; 
       END; 
   
     /********  DEMENTIA ****** WEIGHT = 1 ***********************/ 
     IF DEMENTIA=0 THEN DO; 
       IF dx_3 = '290' then do;                    /* 290 thru 2909 */  
          %FLAGSET(DEMENTIA,FLAGS(NFLAGS+1),NFLAGS,8); 
          END; 
       END; 
  
     /********* PARALYSIS **************** WEIGHT = 2 ************/ 
     IF PARALYS=0 THEN DO;      
       IF dx_3 = '342' | dx_4 = '3441' then do;           /* 342 thru 3429 */  
          %FLAGSET(PARALYS,FLAGS(NFLAGS+1),NFLAGS,9); 
          END; 
       END; 
  
     /******** DIABETES ************* WEIGHT = 1 *****************/ 
     IF DIABET1=0 THEN DO; 
       IF DX(K)= '250  ' | dx_4 = '2507' | '2500' <= dx_4 <= '2503' then do; 
          %FLAGSET(DIABET1,FLAGS(NFLAGS+1),NFLAGS,10); 
          END; 
       END; 
  
     /********* DIABETES WITH SEQUELAE ****** WEIGHT = 2 *********/ 
     IF DIABET3=0 THEN DO; 
       IF ('2504' <= dx_4 <= '2506') | ('2508' <= dx_4 <= '2509') THEN DO; 
          %FLAGSET(DIABET3,FLAGS(NFLAGS+1),NFLAGS,11); 
          END; 
       END; 
  
     /********* CHRONIC RENAL FAILURE ******* WEIGHT = 2 *********/ 
     IF RENAL1=0 THEN DO;      /* 582 - 5829; 583 - 5839, 588 - 5889 */ 
       IF dx_3 in ('582', '583', '585', '586', '588') then do; 




          END; 
       END; 
  
     /************** VARIOUS CIRRHODITES ******** WEIGHT = 1 *****/ 
     IF LIVER1=0 THEN DO;         /* includes 5714x ICD-9-CM codes */ 
       IF dx_4 in ('5712', '5714', '5715', '5716') then do; 
          %FLAGSET(LIVER1,FLAGS(NFLAGS+1),NFLAGS,13); 
          END; 
       END; 
  
     /************** MODERATE-SEVERE LIVER DISEASE *** WEIGHT = 3*/ 
     IF LIVER2=0 THEN DO; 
       IF ('5722' <= dx_4 <= '5728') | ('4560' <= dx_4 <= '4561') | 
          DX(K) in ('4562 ', '45620',  '45621') THEN DO; 
          %FLAGSET(LIVER2,FLAGS(NFLAGS+1),NFLAGS,14); 
          END; 
       END; 
  
     /*************** ULCERS ********** WEIGHT = 1 ***************/ 
     IF ULCER1=0 THEN DO; 
       IF '5310' <= dx_4 <= '5313' | '5320' <= dx_4 <= '5323' | 
          '5330' <= dx_4 <= '5333' | '5340' <= dx_4 <= '5343' | 
          dx_4 in ('531 ', '5319', '532 ', '5329', '533 ', '5339',  
            '534 ', '5349') THEN DO; 
          %FLAGSET(ULCER1,FLAGS(NFLAGS+1),NFLAGS,15); 
          END; 
       END; 
     IF ULCER2=0 THEN DO; 
       IF '5314' <= dx_4 <= '5317' | '5324' <= dx_4 <= '5327' |  
          '5334' <= dx_4 <= '5337' | '5344' <= dx_4 <= '5347' THEN DO; 
          %FLAGSET(ULCER2,FLAGS(NFLAGS+1),NFLAGS,16); 
          END; 
       END; 
  
     /*************** RHEUM  ********** WEIGHT = 1 ***************/ 
     IF RHEUM=0  THEN DO; 
       IF DX(K) in ('71481', '725  ', '7100 ', '7101 ', '7104 ') | 
          '7140' <= dx_4 <= '7142' THEN DO; 
          %FLAGSET(RHEUM,FLAGS(NFLAGS+1),NFLAGS,17); 
          END; 
       END; 
  
     /*************** AIDS   ********** WEIGHT = 6 ***************/ 
     IF AIDS=0   THEN DO; 
       IF '042' <= dx_3 <= '044' then do;          /* 042 thru 0449 */ 
          %FLAGSET(AIDS,FLAGS(NFLAGS+1),NFLAGS,18); 
          END; 
       END; 
  
   END; /* end of Diagnosis code loop */ 
 




   DO J=1 TO &NSXVAR; 
     /*********** PERIPHERAL VASCULAR DISEASE ******* WEIGHT = 1**/ 
     IF VASCUL2=0 THEN DO; 
       IF SX(J) = '3813' | SX(J) = '3814' | SX(J) = '3816' | 
          SX(J) = '3818' | SX(J) = '3843' | SX(J) = '3844' | 
          SX(J) = '3846' | SX(J) = '3848' | SX(J) = '3833' | 
          SX(J) = '3834' | SX(J) = '3836' | SX(J) = '3838' | 
          '3922' <=SX(J)<= '3929' & SX(J) ^= '3927' THEN DO; 
          %FLAGSET(VASCUL2,FLAGS(NFLAGS+1),NFLAGS,5); 
          END; 
       END; 
  
     /********* CEREBROVASCULAR DISEASE ******* WEIGHT = 1 *******/ 
     IF CVD=0 THEN DO; 
       IF SX(J) = '3812' | SX(J) = '3842' THEN DO; 
          %FLAGSET(CVD,FLAGS(NFLAGS+1),NFLAGS,6); 
   END; 
       END; 
  
     /************** MODERATE-SEVERE LIVER DISEASE *** WEIGHT = 3*/ 
     IF LIVER2=0 THEN DO; 
       IF SX(J) = '391 ' | SX(J) = '4291' THEN DO; 
          %FLAGSET(LIVER2,FLAGS(NFLAGS+1),NFLAGS,14); 
   END; 
       END; 
        
   END; /* end of Surgery code loop */ 
  
   /* HCPCS procedure code */  
   /*********** PERIPHERAL VASCULAR DISEASE ******* WEIGHT = 1**/ 
   IF VASCUL2=0 THEN DO; 
     IF &HCPCS IN ('35011', '35013',  '35045', '35081', '35082',  
 '35091', '35092', '35102', '35103', '35111', '35112', '35121',  
 '35122', '35131', '35132', '35141', '35142', '35151', '35152',  
 '35153', '35311', '35321', '35331', '35341', '35351', '35506',  
 '35507', '35511', '35516', '35518', '35521', '35526', '35531',  
 '35533', '35536', '35541', '35546', '35548', '35549', '35551', 
 '35556', '35558', '35560', '35563', '35565', '35566', '35571', 
 '35582', '35583', '35585', '35587', '35601', '35606', '35612', 
 '35616', '35621', '35623', '35626', '35631', '35636', '35641', 
 '35646', '35650', '35651', '35654', '35656', '35661', '35663', 
 '35665', '35666', '35671', '35694', '35695') OR 
        '35355' <= &HCPCS <= '35381'  
        THEN DO; 
        %FLAGSET(VASCUL2,FLAGS(NFLAGS+1),NFLAGS,5); 
        END; 
     END; 
 
   /********* CEREBROVASCULAR DISEASE ******* WEIGHT = 1 *******/ 
   IF CVD=0 THEN DO; 
     IF &HCPCS IN ('35301', '35001', '35002', '35005', '35501', '35508', 




        %FLAGSET(CVD,FLAGS(NFLAGS+1),NFLAGS,6); 
        END; 
     END; 
 
   /************** MODERATE-SEVERE LIVER DISEASE *** WEIGHT = 3*/ 
   IF LIVER2=0 THEN DO; 
     IF &HCPCS IN ('37140', '37145', '37160', '37180', '37181', '75885',  
        '75887', '43204', '43205') THEN DO; 
        %FLAGSET(LIVER2,FLAGS(NFLAGS+1),NFLAGS,14); 
        END; 
     END; 
 
   /* end HCPCS procedure code */  
 
 
   /* Use general indicators to turn on Prior and Index indicators */ 
   IF NFLAGS > 0 THEN DO; 
     DO M=1 TO NFLAGS; 
       I=FLAGS(M); 
       IF COVAR(I) THEN DO; 
         IF &IDXPRI = 'P'   THEN  CLPRIO(I)=1; 
         ELSE IF &IDXPRI = 'I'   THEN  CLINDX(I)=1; 
         END; 
       END; 
     END; 
 
   IF LAST.&PATID THEN DO; 
     /* CALCULATE THE COEFFICIENT FOR PRIOR CONDITIONS ONLY */ 
     PCHRLSON = (CVPRIO01 | CVPRIO02) + 
                (CVPRIO03) + 
                (CVPRIO04 | CVPRIO05) + 
                (CVPRIO06) + 
                (CVPRIO07) + 
                (CVPRIO08) + 
                ((CVPRIO10) & ^(CVPRIO11)) + 
                ((CVPRIO13) & ^(CVPRIO14)) + 
                (CVPRIO15 | CVPRIO16) + 
                (CVPRIO17) + 
                ((CVPRIO09) * 2) + 
                ((CVPRIO12) * 2) + 
                ((CVPRIO11) * 2) + 
                ((CVPRIO14) * 3) + 
                ((CVPRIO18) * 6); 
  
     /* CALCULATE THE COEFFICIENT FOR PRIOR AND INDEX COND */ 
     CHRLSON = (CVPRIO01 | CVPRIO02 | CVINDX02) + 
               (CVPRIO03) + 
               (CVPRIO04 | CVINDX04 | CVPRIO05 | CVINDX05) + 
               (CVPRIO06) + 
               (CVPRIO07 | CVINDX07) + 
               (CVPRIO08 | CVINDX08) + 




               ((CVPRIO13 | CVINDX13) & ^(CVPRIO14 | CVINDX14)) + 
               (CVPRIO15) + 
               ((CVPRIO09) * 2) + 
               ((CVPRIO12 | CVINDX12) * 2) + 
               ((CVPRIO11 | CVINDX11) * 2) + 
               ((CVPRIO14 | CVINDX14) * 3);  
  
     /* CALCULATE THE COEFFICIENT FOR INDEX CONDITIONS ONLY */ 
     XCHRLSON = (CVINDX02) + 
                (CVINDX04 | CVINDX05) + 
                (CVINDX07) + 
                (CVINDX08) + 
                ((CVINDX10) &^ (CVINDX11)) + 
                ((CVINDX13) &^ (CVINDX14)) + 
                ((CVINDX12) * 2) + 
                ((CVINDX11) * 2) + 
                ((CVINDX14) * 3);  
 
     OUTPUT; 
     END; 
    
   KEEP &PATID PCHRLSON CHRLSON XCHRLSON CVPRIO01-CVPRIO18 CVINDX01-
CVINDX18; 
   Label PCHRLSON = 'Prior Charlson comorbidity score' 
         CHRLSON  = 'Prior+Index Charlson comorbidity score' 
         XCHRLSON = 'Index Charlson comorbidity score' 
          
         CVPRIO01 = 'Prior: MYOCARDIAL INFARCTION (1)'             
         CVPRIO02 = 'Prior: OLD MYOCARDIAL INFARCTION (1)'         
         CVPRIO03 = 'Prior: CHF (1)'                               
         CVPRIO04 = 'Prior: PERIPHERAL VASCULAR DISEASE (DX, 1)'   
         CVPRIO05 = 'Prior: PERIPHERAL VASCULAR DISEASE (SURG, 1)' 
         CVPRIO06 = 'Prior: CEREBROVASCULAR DISEASE (1)'           
         CVPRIO07 = 'Prior: COPD (1)'                              
         CVPRIO08 = 'Prior: DEMENTIA (1)'                          
         CVPRIO09 = 'Prior: PARALYSIS (2)'                         
         CVPRIO10 = 'Prior: DIABETES (1)'                          
         CVPRIO11 = 'Prior: DIABETES WITH SEQUELAE (2)'            
         CVPRIO12 = 'Prior: CHRONIC RENAL FAILURE (2)'             
         CVPRIO13 = 'Prior: VARIOUS CIRRHODITES (1)'               
         CVPRIO14 = 'Prior: MODERATE-SEVERE LIVER DISEASE (3)'     
         CVPRIO15 = 'Prior: ULCERS1 (1)'                           
         CVPRIO16 = 'Prior: ULCERS2 (1)'                           
         CVPRIO17 = 'Prior: RHEUM (1)'                             
         CVPRIO18 = 'Prior: AIDS (6)'                              
          
         CVINDX01 = 'Index: MYOCARDIAL INFARCTION (1)'             
         CVINDX02 = 'Index: OLD MYOCARDIAL INFARCTION (1)'         
         CVINDX03 = 'Index: CHF (1)'                               
         CVINDX04 = 'Index: PERIPHERAL VASCULAR DISEASE (DX, 1)'   
         CVINDX05 = 'Index: PERIPHERAL VASCULAR DISEASE (SURG, 1)' 




         CVINDX07 = 'Index: COPD (1)'                              
         CVINDX08 = 'Index: DEMENTIA (1)'                          
         CVINDX09 = 'Index: PARALYSIS (2)'                                  
         CVINDX10 = 'Index: DIABETES (1)'                          
         CVINDX11 = 'Index: DIABETES WITH SEQUELAE (2)'            
         CVINDX12 = 'Index: CHRONIC RENAL FAILURE (2)'             
         CVINDX13 = 'Index: VARIOUS CIRRHODITES (1)'               
         CVINDX14 = 'Index: MODERATE-SEVERE LIVER DISEASE (3)'     
         CVINDX15 = 'Index: ULCERS1 (1)'                           
         CVINDX16 = 'Index: ULCERS2 (1)'                           
         CVINDX17 = 'Index: RHEUM (1)'                             
         CVINDX18 = 'Index: AIDS (6)'                              









Appendix E: Unadjusted Kaplan-Meier Survival Curves 
Figure E1. Time to Any VTE in the year prior to index date by exposure status. Any ATE 
= any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI = 
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE 






Figure E2. Time to DVT in the year prior to index date by exposure status. Any ATE = any arterial 
thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI = myocardial 







Figure E3. Time to PE in the year prior to index date by exposure status. Any ATE = any 
arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI = 
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE 






Figure E4. Time to Other VTE in the year prior to index date by exposure status. Any ATE 
= any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI = 
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE 






Figure E5. Time to Any ATE in the year prior to index date by exposure status. Any ATE 
= any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI = 
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE 






Figure E6. Time to MI in the year prior to index date by exposure status. Any ATE = any 
arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI = 
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE 






Figure E7. Time to IS in the year prior to index date by exposure status. Any ATE = any 
arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI = 
myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; VTE 






Figure E8. Time to Any VTE in the follow-up period after index date by exposure status. 
Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic 
stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary 






Figure E9. Time to DVT in the follow-up period after index date by exposure status. Any 
ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; 
MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; 






Figure E10. Time to PE in the follow-up period after index date by exposure status. Any 
ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; 
MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; 






Figure E11. Time to Other VTE in the follow-up period after index date by exposure 
status. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = 
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = 






Figure E12. Time to Any ATE in the follow-up period after index date by exposure 
status. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = 
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = 






Figure E13. Time to MI in the follow-up period after index date by exposure status. Any ATE = any arterial 
thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; MI = myocardial 







Figure E14. Time to IS in the follow-up period after index date by exposure status. Any 
ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = ischemic stroke; 
MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = pulmonary embolism; 






Figure E15. Time to Any VTE in kidney cancer patients in the follow-up period after index date by 
histology group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; 
IS = ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = 






Figure E16. Time to DVT in kidney cancer patients in the follow-up period after index date by histology 
group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = 
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = 






Figure E17. Time to PE in kidney cancer patients in the follow-up period after index date by histology 
group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = 
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = 






Figure E18. Time to Other VTE in kidney cancer patients in the follow-up period after index date by 
histology group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; 
IS = ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = 






Figure E19. Time to Any ATE in kidney cancer patients in the follow-up period after index date by 
histology group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; 
IS = ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = 






Figure E20. Time to MI in kidney cancer patients in the follow-up period after index date by histology 
group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = 
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = 






Figure E21. Time to IS in kidney cancer patients in the follow-up period after index date by histology 
group. Any ATE = any arterial thromboembolic event (MI or IS); DVT = deep vein thrombosis; IS = 
ischemic stroke; MI = myocardial infarction; Other VTE = other venous thromboembolic event; PE = 
pulmonary embolism; VTE = venous thromboembolic event. 
 
